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ABSTRACT

Jang, Yumi. Ph.D., Purdue University, December 2015. Anticancer Effects of Vitamin E
Forms and Their Long-chain Metabolites via Modulation of Sphingolipid Metabolism.
Major Professor: Qing Jiang.

Cancer is one of the leading causes of death. Studies have shown that vitamin E
forms including gamma-tocopherol (γT), delta-tocopherol (δT), and gamma-tocotrienol
(γTE) exhibited potent anticancer activities in various types of cancer cells. But
molecular mechanisms underlying anticancer actions of γTE are not completely
understood. 13’-carboxychromanols (13’-COOHs), major fecal excreted long-chain
metabolites of vitamin E, have recently been shown to induce apoptosis in liver cancer
cells. However, it is not clear whether 13’-COOHs have anticancer effects on other types
of cancer. In the current study, we investigated the anticancer effects and mechanisms of
γTE and 13’-COOHs; δT-13’-COOH and δTE-13’-COOH, which are metabolites of δT
or delta-tocotrienol (δTE), respectively. Like γTE, 13’-COOHs inhibited the growth and
induced apoptosis and autophagy in human colon, breast, and pancreatic cancer cells in a
time- and dose-dependent manner. In these activities, 13’-COOHs were similar or more
potent than γTE, both of which were much stronger than γT and δT. Since we have
previously shown that γTE and γT induce prostate cancer cell death by modulation of
sphingolipid metabolism, we investigated whether γTE and 13’-COOHs have effects on
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the levels of sphingolipids in cancer cells using liquid chromatography tandem mass
spectrometry. Treatment of human colon cancer HCT-116 cells with γTE or δT-13’COOH significantly increased in intracellular dihydroceramides (dhCers) and
dihydrosphingosine (dhSph), sphingoid bases in de novo synthesis pathway of
sphingolipids, but decreased in C16:0-ceramide (Cer) during shorter treatment. During
longer treatment, γTE or δT-13’-COOH increased in C16:0- and C18:0-Cers while
decreased in SMs. To investigate potential effects on de novo synthesis of sphingolipids,
we used 13C3, 15N-labeled L-serine, which condensed with palmitoyl-CoA to form the
first sphingolipid intermediate in the de novo synthesis pathway. We found that compared
with controls, γTE or δT-13’-COOH treatment increased labeled dhCers and dhSph, but
led to decrease in labeled Cers. These results strongly suggest that γTE or δT-13’-COOH
inhibit dihydroceramide desaturase (DEGS)-catalyzed reactions and may activate
sphingomyelin hydrolysis to enhance Cer levels. Consistently, we found that γTE or δT13’-COOH inhibited the DEGS activity, while they did not affect DEGS expression. The
importance of sphingolipid modulation was further supported by blocking the increase of
these sphingolipids, which resulted in a partial counteraction of γTE or 13’-COOHsinduced cell death. In agreement with these cell-based studies, δTE-13’-COOH showed
anticancer activities in a preclinical model in mice. In addition, we found that various
phytochemicals including curcumin, resveratrol, and epigallocatechin gallate, etc. also
modulated sphingolipid metabolism in cancer cells. Overall, our studies demonstrate that
γTE and 13’-COOHs have potent anticancer effects by modulating enzyme activities in
sphingolipid metabolism.
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CHAPTER 1. LITERATURE REVIEW

1.1

1.1.1

Vitamin E

Vitamin E Forms and Food Sources

Vitamin E is an important nutrient and is a well-known lipophilic chain-breaking
antioxidant. In 1922, Evans and Bishop first discovered vitamin E as an essential dietary
factor for reproduction in rats (Evans and Bishop, 1922). Since the discovery, many
researchers have focused on the potential health benefits of vitamin E for various
diseases. Natural forms of vitamin E consist of eight structurally related molecules that
can be further divided into two major groups, which are tocopherols and tocotrienols.
Tocopherols and tocotrienols are composed of the same basic chemical structure
characterized by a 16-carbon phytyl chain which is attached at the 2-position of a
chromane ring. However, the difference between tocopherols and tocotrienols is that
tocopherols have a saturated phytyl chain whereas tocotrienols have an unsaturated
phytyl chain with three double bonds. Individual tocopherols and tocotrienols, which are
α-, β-, γ- and δ-tocopherol (αT, βT, γT and δT) and α-, β-, γ- and δ-tocotrienol (αTE,
βTE, γTE and δTE), are differ from each other based on the number and position of

2

methyl groups in the chromane ring. The structures of tocopherols and tocotrienols are
illustrated in Figure 1.1.

Figure 1.1 Structures of natural forms of vitamin E. (A) Tocopherols and (B) tocotrienols.
All vitamin E forms contain a 16-carbon phytyl chain which is attached at the 2-position
of a chromane ring. The difference between tocopherol and tocotrienol is that tocotrienol
has an unsaturated phytyl chain with three double bonds.

3
Furthermore, vitamin E is found in both natural and synthetic forms. Natural
forms of tocopherol have the RRR configuration at the 2, 4’, and 8’-positions of the
phytyl tail, and natural forms of tocotrienol have the R configuration at the 2-position of
the phytyl tail. Both natural single stereoisomeric form of α-tocopherol (RRR, formerly
d-α-tocopherol) and synthetic form of α-tocopherol are available commercially for the
use as a dietary supplement. When α-tocopherol is synthesized chemically, this synthetic
form consists of an approximately equimolar mixture of all eight possible stereoisomers
(all-racemic α-tocopherol, formerly dl-α-tocopherol): RRR, RRS, RSS, RSR, SRR, SSR,
SRS, and SSS (Brigelius-Flohe and Traber, 1999; Burton et al., 1998). Although they
have similar structures, the different stereoisomers of vitamin E have different
bioavailability and bioacitivity, which will be discussed in the next section. In addition,
as the free forms of vitamin E are easy to be oxidized, more stable forms of vitamin E as
a dietary supplement have been produced. Since ester forms are very stable, α-tocopherol
is usually sold either as acetate esters (RRR α-tocopheryl acetate or all-rac α-tocopheryl
acetate) or as succinate esters (RRR α-tocopheryl succinate or all-rac α-tocopheryl
succinate). Among them, the acetate ester of all-rac α-tocopherol is the most common
form of vitamin E supplementation due to the cost and the stability (Vagni et al., 2011).
Since humans and animals do not make vitamin E, they acquire natural forms of
vitamin E from plants. Vitamin E is found in various types of foods such as some fruits,
vegetable oils, green leafy vegetables, plant seeds, corn, barley, oats, and wheat germ.
Natural sources of tocopherols include vegetable oils, plant seeds and nuts. For instance,
peanuts, almonds, and sunflower seeds are major sources of αT, whereas γT is rich in
walnuts, pecans, corn oil, soybean oil and sesame oil. δT is found in soybean oil and rice
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germ. As the corn and soybean oils are widely used, γT accounts for about 70% of the
vitamin E in the US diet. On the other hand, tocotrienols are mainly found in palm oil,
barley, oats and some cereal grains, but in much smaller amounts than tocopherols (Jiang
et al., 2001; McLaughlin and Weihrauch, 1979; Slover, 1971).

1.1.2

Bioavailability and Metabolites

Vitamin E is a lipophilic (fat-soluble) vitamin, and similar to other lipids, all
vitamin E forms are absorbed equally into the intestine along with dietary fat, and
incorporated into chylomicrons. The chylomicron-bound vitamin E is transported through
lymphatic system to peripheral tissues such as skin, adipose, muscle or brain with the
help of lipoprotein lipase. The chylomicron remnants are taken up by the liver for
metabolism or further distribution. In the liver, αT is preferentially incorporated into
very-low-density lipoproteins due to the high affinity of α-tocopherol transfer protein (αTTP) together with ATP-binding cassette transporter A1 (ABCA1), and re-distributed
throughout the body. Therefore, αT is the predominant form in most human and animal
tissues and plasma as it is protected by α-TTP from being metabolized (Brigelius-Flohe
and Traber, 1999; Jiang, 2014; Jiang et al., 2001; Manor and Morley, 2007; Traber,
2007).
In contrast, α-TTP has much lower affinity toward other forms of vitamin E.
Thus, non-αT forms of vitamin E such as β-, γ-, δ-T and α-, β-, γ-, δ-TE are relatively low
in tissues as they are preferentially catabolized in the liver via cytochrome P450
(CYP4F2)-mediated ω-hydroxylation to 13’-hydroxychromanol (13’-OH). 13’-OH is
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then further oxidized to 13’-carboxychromanol (13’-COOH), followed by β-oxidation of
the phytyl chain to generate various shorter chain length of carboxychromanols including
11’- and 9’-COOHs, and the terminal product 3’-COOH or (2’-carboxyethyl)-6hydroxychromans (CEHCs), which is the water-soluble metabolite of vitamin E, and then
primarily excreted out of the body by the urine (Fig. 1.2) (Jiang, 2014; Sontag and
Parker, 2002; Swanson et al., 1999). In parallel with β-oxidation, conjugation such as
sulfation and glucuronidation of the phenolic on the chromane ring in the intermediate
metabolites takes place when the intake of vitamin E forms is high (Jiang et al., 2007).
Therefore, despite γT is the major form of vitamin E in the US diet, αT is the
predominant form of vitamin E in the body. The plasma concentrations of αT are about
20~30 μM, but γT is 5-10 times lower than αT in the plasma (Behrens and Madere, 1986;
Jiang et al., 2001). Also, the bioavailability of γT is suppressed by increased intake of αT
(Handelman et al., 1985), but γT supplementation increased the levels of both
tocopherols (Clement and Bourre, 1997).
In addition to the different bioavailability of each natural vitamin E form, the
different stereoisomers of vitamin E have different bioavailability as well as biopotencies.
Both natural form of vitamin E and synthetic vitamin E are absorbed in the body.
However, after absorption, RRR-αT, a natural form of vitamin E has a greater
bioavailability and activities than the all-rac forms due to the higher affinity of RRR-αT
toward the liver protein named α-TTP over the synthetic forms. Thus, synthetic forms of
vitamin E are preferentially excreted. The bioavailability of natural vitamin E is about
twice as high compared with synthetic forms, thus intake of twice more amount of
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synthetic forms of vitamin E are required to match the bioavailability of the natural forms
(Brigelius-Flohe and Traber, 1999; Burton et al., 1998; Vagni et al., 2011).

Figure 1.2 Metabolism of vitamin E forms and their metabolites. Vitamin E forms are
metabolized via ω-hydroxylation and β-oxidation
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1.1.3

Bioactivities of Vitamin E

The biological activity of vitamin E compounds has historically been assessed by
the rat fetal resorption assay. In this assay, the biological activity of vitamin E is
measured based on its ability to prevent or reverse the symptoms of vitamin E deficiency
such as fetal resorption, encephalomalacia and muscular dystrophy, followed by embryo
death. Among natural forms of vitamin E, αT has been shown to have the highest
biological acitivity measured by this assay. Studies have also demonstrated that α-TTP is
present in pregnant rodent uterus, and αT is important during pregnancy (Bieri and
Evarts, 1974). However, this difference in activity between vitamin E forms appears to be
caused by the lower concentrations of non-αT forms of vitamin E in tissues and plasma
due to its shorter retention time, not because of their actual differences in biological
activity.

Antioxidant function
Free radicals generated by oxidative stress exert an important role in the
development of numerous diseases including cancer, atherosclerosis, and
neurodegenerative diseases. All vitamin E forms have been well recognized as one of the
most important antioxidants. It has been known to be a potent, lipophilic peroxyl radical
scavenger that protects biological molecules from oxygen toxicity. In vitamin E studies,
most researches have primarily focused on αT until recently, because αT is the
predominant form of vitamin E in tissues and plasma, and due to its highest biological
activities as well as the relationship between its low intake and the higher incidence of
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vitamin E deficiency-associated ataxia. Moreover, among tocopherols, αT has been
shown to have the highest antioxidant activities against peroxyl radical (LOO⋅) and deltatocopherol is the least active (alpha > beta = gamma > delta). αT terminates the chain
reaction of free radical mediated lipid peroxidation by donating hydrogens from the
phenolic group on the chromane ring to lipid radicals. Therefore, αT protects lipid
membrane from lipid radical damage (Kamal-Eldin and Appelqvist, 1996). After αT
becomes a free radical itself, it can be recycled back to antioxidant form by vitamin C
(ascorbic acid) (Traber and Stevens, 2011). In contrast, γT has its unique ability to
change highly reactive nitrogen back into safe NO, thereby protection against oxidation
damage by reactive nitrogen species. αT lacks this ability (Cooney et al., 1993; Jiang et
al., 2001).
On the other hand, tocotrienols also show antioxidant effects by scavenging the
chain-propagating peroxyl radical. It has been demonstrated that αTE has a more potent
antioxidant activity than αT for the scavenging peroxyl radicals in liposomes as it is
distributed more evenly in the phospholipid bilayer of the plasma membrane, and it
shows more efficient collision with radicals (Packer et al., 2001; Wong and
Radhakrishnan, 2012).
In addition to tocopherols and tocotrienols, 13’-carboxychromanols from δT and
δTE, which are long-chain metabolites of vitamin E, have been shown to exert stronger
antioxidative activities compared with dl-αT (Jiang, 2014; Terashima et al., 2002).
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Non-antioxidant functions
Besides antioxidant activities of vitamin E, vitamin E isoforms have other
biological functions independent of their antioxidant properties such as antiinflammatory, anticancer, cardioprotective, and antidiabetic effects. Chronic
inflammation has been recognized to contribute to the development of other chronic
diseases including cardiovascular diseases and cancer (Balkwill and Mantovani, 2001;
Libby et al., 2002). Eicosanoids derived from arachidonic acid via cyclooxygenases
(COX) and 5-lipoxygenase (LOX)-catalyzed reaction play important roles in regulation
of inflammation and cancer (Vane, 1976; Wang and Dubois, 2010). Mechanistic studies
have shown that vitamin E forms such as γT, δT, and γTE exert anti-inflammatory
activities by inhibiting COXs and 5-LOX activities and suppressing nuclear factor κB
(NF-κB) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT)
6 or JAK-STAT3 signaling pathways in various types of cells (Jiang, 2014; Jiang et al.,
2000; Wang and Jiang, 2013; Wong and Radhakrishnan, 2012). In particular, recent
studies in our group found novel mechanisms of anti-inflammatory effects of γTE in
which γTE inhibited TNFα-stimulated NF-κB, TAK1 and JNK activation by modulation
of sphingolipids, induction of ER stress followed by up-regulation of A20 (Wang et al.,
2015). In addition, our group have also demonstrated that δT-13’-COOH, a long-chain
carboxychromanol from δT, competitively inhibited COX-1 and -2 activities, and it was
much stronger than short-chain carboxychromanols and unmetabolized vitamin E forms
in these effects (Jiang et al., 2008). δT-13’-COOH also inhibited 5-LOX activity (Jiang et
al., 2011), indicating that δT-13’-COOH is a unique dual inhibitor of COX-1/COX-2 and
5-LOX.
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In addition to the anti-inflammatory activities of vitamin E forms, αT, γT, and δT
have been demonstrated to prevent the development of atherosclerosis by inhibiting
protein kinase C activity and proliferation of smooth muscle cell (Chatelain et al., 1993;
Tasinato et al., 1995). Several studies have been shown that the plasma concentrations
and the intake of γT are inversely associated with increased risk of cardiovascular disease
(CVD), suggesting that γT is important in the defense against CVD (Ohrvall et al., 1996).
Moreover, tocotrienols have been shown to have cardioprotective effects, which may be
stem from their blood-pressure-lowering, cholesterol-lowering, and antiatherogenic
effects of tocotrienols (Wong and Radhakrishnan, 2012). In the cholesterol-lowering
activities of tocotrienols, tocotrienols affected on the mevalonate pathway by posttranscriptionally suppressing the 3-hydroxyl-3-methyl-glutaryl CoA reductase (Parker et
al., 1993).
Vitamin E forms also showed antidiabetic effects. For example, γT, but not αT,
partially protected insulin-secreting cells from the nitric oxide-induced functional
inhibition (Sjoholm et al., 2000) and palm vitamin E (tocotrienol-rich diet; TRF)
decreased advanced glycosylation end-points in non-diabetic rats and improved glycemic
control in streptozotocin-induced diabetic rats (Wan Nazaimoon and Khalid, 2002).
Independent of its antioxidant activity, vitamin E forms also have shown to
prevent cancer by inhibition of cell-cycle, suppression of DNA synthesis and by inducing
apoptosis (Wong and Radhakrishnan, 2012). The anticancer activities of each vitamin E
form will be more discussed in the following section.
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1.2

Vitamin E Forms in Cancer Prevention

1.2.1

Cancer

Cancer, also known as a malignant tumor and a complex disease caused by
abnormal and uncontrolled cell proliferation, is one of the leading causes of death
worldwide. Over the past 60 years, death rates from heart diseases and stroke have
dropped significantly, but the death from cancer has changed little since the 1950s.
According to World Health Organization (WHO), cancer now accounts for more than 14
million new cases and 8.2 million deaths per year worldwide (World Cancer Report
2014). Cumulative cancer risk is estimated to be 30% and 22% in men and women,
respectively, by age 75 in developed area worldwide (Jemal et al., 2011). Therefore,
cancer is a growing health problem around the world. Among various cancer types, lung,
colon, breast, and pancreatic cancers are the major leading causes of cancer-related death
in the United States (Siegel et al., 2015). However, there is still no effective therapy for
late-stage cancer as many cancer therapeutic agents have side effects or due to high rates
of cancer recurrence. Since cancer is a result of a multistep process, which takes years or
decades to develop, chemoprevention that prevents or delays the onset of late-stage
cancer can be an attractive strategy for reducing cancer-related death.
In this regard, natural forms of vitamin E are potentially good chemoprevention
agents as they are known to be safe and specific forms of vitamin E have been shown to
have cancer prevention effects. Among them, αT, which is the predominant vitamin E
form in tissues and the primary form in vitamin E supplements, and shows ataxia, muscle
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degeneration, and infertility when it has deficiency, is the most extensively studied
vitamin E form in relation to prevention of chronic diseases such as cardiovascular
diseases and cancer. However, the human clinical studies as well as numerous animal
studies of αT in cancer prevention resulted in inconsistent and disappointing outcomes
(Moya-Camarena and Jiang, 2012). In this section, we review the several studies of
vitamin E forms including αT and non-αT forms of vitamin E in cancer prevention so far.
In addition, potential mechanisms of the actions by vitamin E metabolites are briefly
discussed.

1.2.2

α-Tocopherol

Despite eight different forms of vitamin E, most studies have focused on αT for
the last couple of decades due to its abundance in the body and antioxidant properties.
Especially, all the human intervention studies for the vitamin E in cancer prevention have
exclusively focused on αT. Since 1993, eight large randomized clinical trials (RCTs) to
examine the effect of αT or combinations of αT with other nutrients on cancer incidence
and cancer mortality have been reported; Linxian study (Blot et al., 1993), the αTocopherol, β-Carotene Cancer Prevention Study (ATBC) (Heinonen et al., 1998), Heart
Protection Study (HPS) (Heart, 2002), Supple’ mentation en Vitamines et Miéraux
Antioxydants (SUVIMAX) (Hercberg et al., 2004), Women’s Health Study (WHS) (Lee
et al., 2005), The Heart Outcomes Prevention Evaluation and The HOPE-The Ongoing
Outcomes (HOPE and HOPE-TOO) (Lonn et al., 2005), Selenium and vitamin E Cancer
Prevention Tiral (SELECT) (Lippman et al., 2009), Physician’s Health Study II (PHSII)
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(Gaziano et al., 2009). However, results from eight large intervention studies that tested
the anticancer effects of αT have been inconsistent and disappointing. Only three studies
including the Linxian study, the ATBC study, and the SUVIMAX study have found that
αT or its combination with other antioxidants reduced total cancer incidence and
mortality or a risk of prostate cancer. Importantly, these three studies have something in
common with their population characteristics that they were not general healthy
populations. Specifically, the Linxian study in China had population with moderate
micronutrients deficiency, and the ATBC study was conducted in male heavy smokers,
and the subjects of the SUVIMAX study included men who have low plasma levels of
antioxidant levels.
Beside these human clinical studies, several animal studies to test the beneficial
effects of αT on cancer have also yielded inconsistent and disappointing outcomes. On
the other hand, recent mechanistic studies and studies using preclinical animal models
have demonstrated that other forms of vitamin E appear to have different and stronger
biological properties compared with αT for the prevention and therapy against cancer.

1.2.3

Non-αT Forms of Vitamin E

Despite most studies in the cancer prevention focused exclusively on the αT form
of vitamin E in the past, recent studies by others and us have shown that other forms of
vitamin E appear to have unique and stronger anticancer activities.
γT, the major form of vitamin E in many plant seeds and in the US diet, and the
second most common tocopherol in human serum, has unique and important properties
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for cancer prevention and therapy that are not shared by αT. First of all, as we already
mentioned in section 1.1.3, γT exerts anti-inflammatory activities, which are known to
play important roles in cancer prevention. Specifically, our previous studies have shown
that γT and γ-CEHC, but not αT, exert anti-inflammatory activities by inhibition of
prostaglandin E2 (PGE2) synthesis, which occurred through COX-catalyzed reaction, in
activated macrophages and epithelial cells and by inhibition of 5-LOX-catalyzed
synthesis of leukotriene B4 (LTB4) in carrageenan-induced inflammation in rats (Jiang
and Ames, 2003; Jiang et al., 2000). We also showed that γT, but not αT, inhibited
proliferation and induced apoptosis in human prostate cancer cells, but not in normal
prostate epithelial cells by interrupting sphingolipid metabolism, specifically by
accumulating dihydrosphingosine and dihydroceramides (Jiang et al., 2004). Follow-up
studies also reported that γT induced apoptosis in human breast cancer cells by the
induction of increases in cellular ceramides and dihydroceramides levels and activating cJun N-terminal kinase (JNK)/CCAAT/enhancer-binding protein homologous protein
(CHOP)/death receptor-5 (DR5) proapoptotic signaling (Gopalan et al., 2012; Yu et al.,
2008b). Moreover, RRR-γT, but not RRR-αT induced apoptosis in multiple colon cancer
cell lines, but not in normal colon cells (Campbell et al., 2006). In addition to a number
of cancer cell studies, several animal studies were conducted to investigate whether these
anticancer effects of γT are also translated into in vivo animal models. Yu et al. reported
that γT supplementation, but not αT, significantly reduced breast tumor growth compared
with control diet group in xenograft mouse models (Yu et al., 2009; Yu et al., 2008a). γT,
but not αT, also suppressed tumor progression, along with activation of caspase-3 and -7
in the ventral lobe in a transgenic prostate cancer rat model (Takahashi et al., 2009). Our
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group recently demonstrated that γT significantly attenuated moderate colitis and
suppressed inflammation-promoted colon tumorigenesis (Jiang et al., 2013). Furthermore,
several studies investigated the anticancer effects of γT in vivo using γT-rich mixed
tocopherols (γ-TmT). γ-TmT supplementation as well as γT or δT produced a significant
inhibition of azoxymethane (AOM)-induced aberrant crypt foci (ACF; a precancer lesion)
in the colon of rats (Guan et al., 2012; Newmark et al., 2006). Another study was
conducted to test the effects of γ-TmT against colon cancer, and in this study, γ-TmT
suppressed AOM/DSS-induced tumorigenesis in CF-1 mice (Ju et al., 2009). Besides
colon cancer, γ-TmT was also effective in suppression of breast tumorigenesis in
preclinical rat models (Lee et al., 2009; Smolarek et al., 2012; Suh et al., 2007).
Moreover, in a human study, Helzlsouer et al. conducted a nested case-control study to
investigate the associations of αT, γT, and selenium with incidence of prostate cancer.
They observed that higher plasma γT concentrations were associated with a statistically
significant lower risk of developing prostate cancer. Interestingly, this protective
association against prostate cancer was found with only γT, not with αT or selenium
(Helzlsouer et al., 2000).
Besides tocopherols, recent studies suggested that tocotrienols, especially γTE
and δTE, appear to have potent anticancer effects in various cancer cells. γTE, which is
an abundant vitamin E form in palm oil, has been shown to have strong antiinflammatory activities by inhibition of TNFα-stimulated NF-κB, TAK1 and JNK
activation via sphingolipid modulation, ER stress induction, and A20 upregulation (Wang
et al., 2015). γTE inhibited cell proliferation and induced apoptosis in human colon
cancer cells, by the mechanisms of cell cycle arrest, an increase of Bax/Bcl-2 ratio, and
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activation of caspase-3 (Xu et al., 2009). Our group also showed that γTE induced
apoptosis and autophagy by interrupting sphingolipid modulation in prostate and breast
cancer cells (Gopalan et al., 2012; Jiang et al., 2012). Several studies have shown that
γTE and δTE significantly inhibited cell proliferation and induced apoptosis in both
estrogen receptor-negative MDA-MB-435 and estrogen receptor-positive MCF-7 human
breast cancer cells (Guthrie et al., 1997; Loganathan et al., 2013; Park et al., 2010; Yu et
al., 1999b). Consistent with the results in cancer cell culture studies, γTE and δTE
showed effective anticancer properties in several in vivo animal studies. For instance,
several studies have shown that γTE supplementation significantly inhibited prostate
tumor growth in xenograft models (Jiang et al., 2012; Kumar et al., 2006; Yap et al.,
2010). γTE also showed these anticancer properties against pancreatic cancer, which
generally shows resistance to chemotherapy, by inhibition of tumor growth and
sensitization it to gemcitabine (Kunnumakkara et al., 2010). Interestingly, Hiura et al.
reported that both γTE and δTE supplementation significantly delayed liver tumor
growth, by particularly being accumulated in tumors, not in normal tissues (Hiura et al.,
2009). In addition, δTE was observed to show potent tumor antiangiogenic potential
compared with αT (Shibata et al., 2009).

1.2.4

13’-Carboxychromanol, a Long-chain Vitamin E Metabolite

13’-carboxychromanol (13’-COOH) is a long-chain metabolite of vitamin E (Fig.
1.2). Sontag and Parker first discovered cytochrome P450 ω-hydroxylase pathway of
tocopherol catabolism and identified all key intermediates including long- and short-
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chain carboxychromanols and final metabolite, 3’-carboxychromanol in human
hepatocyte (Sontag and Parker, 2002). Consistently, our group identified these
intermediates after treatment with γT and δT in human A549 cells, and first discovered
that in parallel with β-oxidation, sulfation of intermediate metabolites takes place.
Importantly, these sulfated or non-sulfated long-chain carboxychromanols were found in
rat plasma and liver upon vitamin E supplementation (Jiang et al., 2007). We also
observed the similar metabolism of γTE in human A549 cells and in rats (Freiser and
Jiang, 2009). Bardowell et al. revealed the presence of all six carboxychromanol
metabolites and 13’-OH in fecal samples from mice fed with 800 mg/kg body weight γT
and δT for 12 weeks. They also found similar findings in fecal material from an adult
male supplemented with 400 mg/kg/day γT for 14 days (Bardowell et al., 2012a).
Recently, our group began to investigate the biological activities of these vitamin
E metabolites and demonstrated that long-chain carboxychromanols have stronger antiinflammatory activities than their unmetabolized vitamin E forms. Particularly, δT-13’COOH, a long-chain carboxychromanol from δT, has been shown to exert antiinflammatory effects by showing much more potent inhibiting actions on COX-1/COX-2
and 5-LOX activities than short-chain carboxychromanols and unmetabolized vitamin E
precursors (Jiang et al., 2008; Jiang et al., 2011). Moreover, Birringer et al. investigated
the biological activities of long-chain carboxychromanols synthesized from garcinoid
acid, a δTE derivative extracted from the African bitter nut Garcinia kola, in human
HepG2 hepatocellular liver carcinoma cells. 13’-COOHs from αT and δT have shown to
induce mitochondria-mediated apoptosis with increased mitochondrial ROS formation
and reduced mitochondrial membrane potential (Birringer et al., 2010). Although, the
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results of these studies show that vitamin E metabolites, especially 13’-COOHs exert
potential anticancer properties, thus may contribute to beneficial effects of vitamin E
forms in vivo, the effects and the underlying mechanisms by which 13’-COOHs exert
these beneficial effects are not completely understood yet, thus warranting further
investigation.

1.3

Phytochemicals in Cancer Prevention

1.3.1

Overview of Phytochemicals

Cancer is the second leading cause of death worldwide, and now many
researchers have been focusing on the prevention as well as the treatment to overcome
cancer. The World Health Organization (WHO) indicates that at least one-third of all
cancer deaths are preventable and that the diet is closely associated with this cancer
prevention (Bode and Dong, 2009). Epidemiological studies have consistently shown that
populations consuming high levels of fruits and vegetables have low incidence rates of
various cancers (Block et al., 1992; Steinmetz and Potter, 1996). Therefore, numerous
cell culture and animal model studies have been conducted to find biologically active
compounds from edible plants and evaluate their protective effects against various
diseases including cancer. This group of plant bioactive compounds now called as
phytochemicals. Phytochemicals are non-nutritive plant chemicals expressed as
secondary metabolites (‘phyto’ means ‘plant’ in the Greek word), which have protective
or disease-preventing properties in humans and animals. The National Cancer Institute
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(NCI) has identified that to date, greater than 1,000 different phytochemicals from plant
sources have cancer preventive activities. Since phytochemicals are natural products, they
have been used for the prevention and treatment of cancer for a long time due to their
safety and general availability, and became important research targets for cancer research
(Surh, 2003). Phytochemicals are generally classified as phenolics, carotenoids, alkaloids,
nitrogen-containing compounds, and organosulfur compounds (Liu, 2004). They are
typically divided into two distinct classes depending on their chemical structure,
solubility, and physiological absorption properties; water-soluble dietary phytochemicals:
phenolics and polyphenols, lipid-soluble dietary phytochemicals: carotenoids,
tocochromanols (vitamin E derivatives), and curcuminoids. Among them, the most
studied phytochemicals are the phenolics and carotenoids. This review will briefly
introduce a general classification of phytochemicals and their key phytochemicals from
each group with their dietary sources and health beneficial properties. Figure 1.3
illustrates the chemical structures of representative dietary phytochemicals that have been
known to possess chemopreventive potential.
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Figure 1.3 Chemical structures of representative dietary phytochemicals. Structures of
curcumin, quercetin, epigallocatechin gallate (EGCG), resveratrol, and sulforaphane.

Phenolics
Phenolics (also known as polyphenols) are compounds that contain one or more
hydroxyl groups attached to one or more aromatic rings in their chemical structure. They
are generally categorized as flavonoids, phenolic acids, stilbenes, curcuminoids,
coumarins, and tannins, and numerous epidemiological studies have been demonstrated
that phenolics showed beneficial properties against cancer, CVD, neurodegenerative
diseases, diabetes, and osteoporosis (Gonzalez-Vallinas et al., 2013).
Flavonoids represent the 60% of dietary phenolics with more than 4,000 varieties.
Their chemical structure consists of two benzene rings linked by three carbons that are
usually in an oxygenated heterocycle ring. Based on the differences in the heterocycle
ring, they are classified into six groups: flavonols (quercetin and kaempferol), flavanols
(catechin, epicatechin, epigallocatechin, and epigallocatechin gallate), flavones (luteolin
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and apigenin), flavanones (naringenin), anthocyanidins, and isoflavonoids (genistain)
(Liu, 2004).
Quercetin. Quercetin is the most abundant flavonoids in fruits and vegetables. It is a
flavonol and the major sources are onion, apple, and broccoli. Quercetin has shown a free
radical-scavenging activity and health benefits against many diseases including CVD,
cancer, and neurodegenerative diseases. Quercetin exerts its anticancer effects by its
antioxidant and antiproliferative activities and by regulating various cell-signaling
pathways, cell cycle, and apoptosis (Murakami et al., 2008; Okamoto, 2005).
(-)-Epigallocatechin-3-gallate (EGCG). EGCG is the major catechin and an antioxidant
polyphenol flavonoid found mostly in green tea. It has been shown to exert health
beneficial properties for cancer, atherosclerosis, and neurodegenerative diseases (Khan et
al., 2006).
Stilbenes are a family of plant secondary metabolites produced in a small number
of plant species including grapevine in response to environmental stresses which are
biotic and abiotic stresses. The bioactive stilbenes such as resveratrol and pterostilbene
possess several health benefits such as antioxidant, cardioprotective, and cancer
preventive properties (Rimando and Suh, 2008).
Resveratrol. Among stilbenes, in particular, resveratrol, which is mainly present in grapes
and red wine, has received much attention because of its anticancer, antioxidant,
cardioprotective, and lifespan extending properties (Agarwal and Baur, 2011; Bishayee,
2009).
Curcuminoids are components of the cherished Indian spice known as rhizome of
turmeric, and produce a pronounced yellow color and flavor, which allow it to be used as

22
spice blends, such as curry. Curcumin is the primary curcuminoid and several studies in
recent years have shown that it has several biological activities, including antioxidant,
anti-inflammatory, anti-microbial, anti-mutagen and anticancer properties (Shehzad et al.,
2010).

Carotenoids
Carotenoids are naturally occurring fat-soluble pigments, and about 600 different
carotenoids have been identified and they are particularly plentiful in the red, orange, and
yellow colored fruits and vegetables, and dark leafy green vegetables. There are two
categories of carotenoids, which are provitamin A carotenoids that the body can turn into
vitamin A such as β-carotene and β-cryptoxanthin, and non-provitamin A carotenoids
such as lutein, lycopene, and zeaxanthin. Carotenoids are powerful antioxidant and have
been implicated in many beneficial effects on human health with anticancer,
cardioprotective, and immune system enhancing properties (Britton, 1995; Maiani et al.,
2009; Tan et al., 2010)

Organosulfur compounds
Organosulfur compounds are naturally occrurring organic compounds that contain
sulfur in their structure. Dietary organosulfur compounds are commonly found in garlic
and cruciferous vegetables such as broccoli, cabbage, and cauliflower. These compounds
have been demonstrated that they possess a number of biological activities such as
antioxidant, antimicrobial, and anticancer effects. Moreover, several epidemiological
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studies have suggested that comsumption of organosulfur compounds can decrease the
incidence of different types of cancer (Moriarty et al., 2007).
Sulforaphane. Sulforaphane is a compound in the isothiocyanate group of organosulfur
compounds. It is obtained from cruciferous vegetables such as broccoli and cabbage.
For example, when fresh broccoli is chopped or chewed, it releases enzyme myrosinase,
and myrosinase-catalyzed hydrolysis of glucosinolate glucoraphanin occurs to produce
sulforaphane. It has shown antioxidant and anticancer activities against various types of
cancer (Clarke et al., 2008).

1.3.2

Molecular and Cellular Targets of Phytochemicals for Cancer Prevention

Carcinogenesis is a multistep process and it consists of three closely linked stages
that are tumor initiation, promotion and progression. Moreover, as cancer is a multifactor
disease, it may require treatment with compounds that can alter this multiple process and
target multiple intracellular components with greater effectiveness and less toxicity. In
this regard, a large variety of phytochemicals are potential chemopreventive reagents due
to its safety and numerous recent studies have demonstrated that several phytochemicals
have anticancer properties by targeting various cellular signaling molecules. These
chemopreventive phytochemicals can block, reverse or retard the development and
progression of the cells in premalignant stage into malignant ones. The cellular
mechanisms that phytochemicals elicit anticancer effects are multi-faceted, thus various
cellular molecules and signalings could be potential targets of chemopreventive
phytochemicals including regulation of cell signaling cascades by affecting several
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kinases and transcription factors that decide the expression of genes involved in cell
survival or death (Surh, 2003). During the past decades, there has been remarkable
advances in identifying the molecular and cellular targets that mediate chemopreventive
effects of specific phytochemicals, but despite this progress, the identification of clear
mechanisms and targets of these phytochemicals are still incomplete. This section will
review several identified key cellular signaling pathways and molecular targets by which
representative phytochemicals exert their chemopreventive effects. Representative
cellular signaling molecules and pathways targeted by various phytochemicals include
the NRF/KEAP1 complex, NF-κB and AP1 with MAPK pathways, oncogenic
AKT/protein kinase B (PKB) signaling pathway, β-catenin, and proteins involved in
apoptosis induction.

1.3.2.1 NRF-KEAP1 Complex and Activation of NRF

One of the important ways to prevent cancer development is to block the initiation
stage of carcinogenesis. The exposure to toxic environmental insults which cause DNA
damage can be blocked and detoxified by phase II enzymes such as glutathione Stransferase (GST), NAD(P)H:quinone oxidoreductase (NQO) and heme oxygenase-1
(HO-1), resulting in the removal of toxicants from the cells before they are able to
damage the DNA (Hayes and McMahon, 2001). The nuclear factor-erythroid 2p45 (NFE2)-related factor 2 (NRF2) is a transcription factor that regulates expression of phase II
enzymes. A cytosolic actin-binding protein called Kelch-like ECH-associated protein 1
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(KEAP1) is a negative regulator of NRF2 which inhibits its translocation to the nucleus
(Itoh et al., 1999). These two proteins interact with each other, but phase II enzyme
inducers or prooxidants break the link, resulting in the releasement of NRF2 from
KEAP1. In addition, phosphorylation of NRF2 by several kinases such as
phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), c-Jun NH2-terminal
kinase (JNK) and extracellular-signal-regulated kinase (ERK) are known to facilitate the
dissociation of NRF2 and KEAP1 (Huang et al., 2002). The released and translocated
NRF2 in nucleus binds to the antioxidant-responsive element (ARE) to express genes that
encode phase II detoxification or antioxidant enzymes.
Several phytochemicals have been demonstrated to activate NRF. For instance,
Chen et al. found that EGCG, a major green tea polyphenol, showed potent activation of
ARE, MAPKs including ERK, JNK and p38, and caspase-3-mediated cell death (Chen et
al., 2000). Sulforaphane from cruciferous vegetables also activated MAPKs and
upregulated ARE-dependent phase II detoxifying enzymes (Yu et al., 1999a).

1.3.2.2 Suppressing NF-κB and AP1 Activation

Several chemopreventive agents elicit anticancer effects by modulating cellsignaling pathways that regulate cell proliferation and differentiation. One of the
components that play important roles in these pathways is the mitogen-activated protein
kinases (MAPKs). Abnormal regulation of this MAPK pathway and its downstream
transcription factor can cause uncontrolled cell proliferation and growth, leading to
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conversion to malignancy (Zhang and Liu, 2002). These MAPKs and other kinases such
as PKC and PI3K activate several transcription factors, including nuclear factor κB (NFκB) and activator protein 1 (AP1) (Li and Verma, 2002). NF-κB and AP1 are ubiquitous
eukaryotic transcription factors that regulate various target gene expression and mediate
pleiotropic effects, thus they are targets of several chemopreventive phytochemicals.
Overexpression or aberrant activation of NF-κB has been associated with overproliferation and malignant transformation. Inactive NF-κB resides in the cytoplasm as a
complex with the regulatory protein IκB. The activation of NF-κB pathway starts from
the phosphorylation of IκB by IκB kinase (IKK), leading to IκB phosphorylation,
ubiquitination and degradation by the 26S proteasome. The released NF-κB from IκB is
then translocated to the nucleus, and it binds to specific promoter regions of genes, which
are involved in the regulation of cell proliferation, differentiation, apoptosis and
inflammation (Li and Verma, 2002). Recent studies have shown that activation of NF-κB
is also regulated by AKT signaling pathway. PI3K activates AKT via phosphorylation,
and this leads to NF-κB activation by stimulating IKK activity (Das et al., 2003; Li and
Sarkar, 2002). AP1 is another transcription factor that is also regulated by the MAPK
signaling cascade and regulates gene expressions that are involved in cell proliferation
and differentiation, leading to tumor promotion and malignant transformation (Li and
Verma, 2002).
A number of chemopreventive phytochemicals have been shown to suppress NFκB and AP1 activation, leading to prevent abnormal cell proliferation and growth.
Curcumin inhibits TNF-α-induced COX-2 gene transcription and NF-κB activation
(Plummer et al., 1999). Genistein inhibits AKT activation and NF-κB activation (Gong et
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al., 2003; Li and Sarkar, 2002). EGCG inhibits the activities of PI3K and AKT (Pianetti
et al., 2002). In addition, IKK has shown to be inhibited by several chemopreventive
phytochemicals, including curcumin (Bharti et al., 2003; Plummer et al., 1999),
resveratrol (Holmes-McNary and Baldwin, 2000) and EGCG (Yang et al., 2001).

1.3.2.3 Downregulation of β-Catenin-mediated Signaling Pathway

β-Catenin is one of the important targets of numerous chemopreventive
phytochemicals. It functions as a transcription factor and involves in the regulation of cell
proliferation and tumorigenesis. Growth factors and WNT proteins stimulate β-cateninmediated signaling pathway. The interaction of a WNT protein with its transmembrane
receptor inactivates glycogen synthase kinase-3β (GSK-3β) by phosphorylation. The
interaction of a growth factor with receptor kinase (RTK) activates PI3K, leading to AKT
phosphorylation. Phosphorylated AKT also inactivates GSK-3β by phosphorylation.
GSK-3β forms a multiprotein complex with adenomatous polyposis coli (APC), axin and
conductin, and this complex regulates the fate of β-catenein. In the presence of a growth
factor or WNT signal, the phosphorylated and inactivated GSK-3β stabilizes β-catenin in
the cytoplasm. The β-catenin translocates to the nucleus and acts as a transcription factor,
resulting in the activation of gene transcription involved in the cellular proliferation and
growth. On the other hand, in the absence of stimuli, GSK-3β phosphorylates cytosolic βcatenin, which is in turn targeted for ubiquitylation followed by proteasomal degradation
(MacDonald et al., 2009).
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Some chemopreventive phytochemicals have been shown to target and
downregulate the β-catenin-mediated signaling pathway and exert subsequent anticancer
activities. For instance, curcumin reduced the cellular levels of β-catenin through
caspase-mediated degradation of the protein (Mahmoud et al., 2000). Resveratrol has also
shown to attenuate the expression of β-catenin in human colon cancer cells (Joe et al.,
2002). Inhibition of β-catenin activity and reduction of its protein expression has been
shown by EGCG treatment (Dashwood et al., 2002).

1.3.2.4 Induction of Apoptosis

Despite the regulation of abnormal cell proliferation and growth may retard or
block tumor development, the induction of programmed cell death via apoptosis can
completely remove abnormal cells from a tissue. In contrast to necrosis, apoptosis is a
tightly regulated mechanism of cell death that can be induced by a variety of signals and
stimuli.
Several dietary phytochemicals have been shown to induce apoptosis in cancer
cells. Sulforaphane, a molecule in the isothiocyanate group of organosulfur compounds,
induces apoptosis and inhibition of proliferation of human bladder cancer cells (Tang et
al., 2006). EGCG treatment also inhibits cell growth and induces apoptosis in human
epidermoid carcinoma cells, but not in normal human epidermal keratinocytes (Ahmad et
al., 1997). Curcumin was also reported to induce apoptosis by up-regulating pro-
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apoptotic proteins such as Bim, Bax, and Bak, and down-regulating the anti-apoptotic
proteins such as Bcl-2 and Bcl-xL (Shankar and Srivastava, 2007).

1.4

Sphingolipids Metabolism and Their Biological Activities

1.4.1

Overview of Sphingolipids

Over the past twenty years, several groups of lipids and their metabolites have
started to receive more attention, as they serve as biologically active molecules exerting a
wide range of biological functions and providing health benefits through modification of
tissue composition or induction of several cell-signaling pathways. Among a broad
variety of bioactive lipids, evidences suggested that the polyunsaturated fatty acids
(PUFAs) and eicosanoids are the most important bioactive lipids. Another well-known
group of bioactive lipids is the sphingolipids. Sphingolipids were first identified in brain
extracts at the end of the 19th century and were named after the Greek mythological
creature, the Sphinx, on the basis of the nature of their enigmatic molecular structure
(Thudichum, 1884).
Sphingolipids are a class of natural lipids that primarily have sphingosine as their
structural backbone, amide-linked long-chain fatty acids, and one of various polar head
groups. Thus, they are the most structurally diverse class of membrane lipids depending
on their head groups. Among them, since sphingomyelin (SM) is an essential component
in the outer leaflet of the plasma membrane and provides a barrier to the extracellular
environment, sphingolipids were thought to act only as structural roles. However, current
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evidence also suggests that they are pleiotropic molecules playing important roles in the
regulation of numerous functions including cell survival, apoptosis, senescence, and
differentiation. Indeed, sphingolipid metabolism has proved to be a dynamic process, and
several sphingolipid metabolites are now recognized as second messengers playing
essential roles in various cell functions (Hannun et al., 1986; Hannun and Obeid, 2008;
Spiegel and Merrill, 1996).
The levels of endogenous sphingolipid metabolites are controlled by de novo
synthesis and dynamic metabolisms involving synthesis of complex sphingolipids and
catabolic pathways of complex sphingolipids or ceramides (Fig. 1.4) (Gault et al., 2010;
Hannun and Obeid, 2008). Therefore, this review section will focus on the dynamic
sphingolipid metabolism and enzymes involved in this pathway.

1.4.1.1 De novo Sphingolipids Biosynthesis

The de novo sphingolipid biosynthesis starts in the endoplasmic reticulum from
condensation of palmitoyl-CoA and serine into 3-keto-dihydrosphingosine by serine
palmitoyltransferase (SPT). The intermediate 3-ketosphinganine is rapidly reduced to
dihydrosphingosine (dhSph) by a NADPH dependent 3-ketosphinganine reductase. An
acylation by a family of (dihydro)ceramide synthases (CerSs) using fatty acyl-CoAs
generates dihydroceramide (dhCer) subspecies. Dihydroceramide desaturase (DEGS)
introduces a 4,5-trans double bond in dhCers to make the final product, Ceramide (Cer)
(Merrill, 2002).
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Figure 1.4 Sphingolipid metabolism. De novo biosynthesis pathway of sphingolipids, the
production of complex sphingolipids from ceramide, the degradation of ceramide to
sphingosine, the formation of sphingosine-1-phosphate (S1P), and the clearance of S1P
by S1P lyase. SMS, sphingomyelin synthase; SMase, sphingomyelinase; CERK,
ceramide kinase; GCS, glucosylceramide synthase; GBA, acid glucocerebrosidase; SK,
sphingosine kinase; SPP, S1P phosphatase

Serine Palmitoyltransferase (SPT)
The first step in the sphingolipid biosynthesis is the condensation of cytosolic
serine and palmitoyl-CoA, a reaction catalyzed by SPT to produce 3-ketodihydrosphingosine. SPT is encoded by the genes SPTLC1, SPTLC2, and SPTLC3.
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However, SPTLC3 has been identified in yeast, but not in mammals (Gable et al., 2000).
SPT is a member of a pyridoxal 5′-phosphate-dependent α-oxoamine synthases family.
Mammalian SPT has LCB1 and LCB2 subunits, and each SPT subunit contains several
transmembrane domains and displays type I topology. Although little is known about
SPT regulation, many factors have been reported to regulate SPT activity and its activity
is regulated transcriptionally and post-transcriptionally. The most widely known factor
that affects SPT activity is the availability of serine and palmitoyl-CoA pool. SPT is
inhibited by several synthetic and natural products. The selective inhibitors of this
enzyme are L-cycloserine and beta-chloroalanine. More potent and selective natural
inhibitors of SPT have been isolated from microorganisms which include sphingofungins,
lipoxamycin and ISP-1/myriocin. The myriocin is a potent inhibitor of SPT and is widely
used to block and identify the role of de novo sphingolipid biosynthesis (Hanada, 2003;
Wadsworth et al., 2013).

(Dihydro)ceramide Synthase (CerS)
Dihydrosphingosine is further acylated by the action of CerS. Recently, human
CerS 1-6 have been discovered as yeast homologues of the longevity assurance gene 1-6
(LASS1-6), and are encoded by six distinct genes, resulting in the generation of huge
dhCer and Cer profiles (Pewzner-Jung et al., 2006). Each CerS has substrate preference
for different lengths of fatty acyl-CoAs, thus producing distinct dhCers with different
acyl-chain lengths. For example, whereas CerS1 prefer stearoyl-CoA as a substrate and
mainly generate C18-Cer species (Venkataraman et al., 2002), CerS5 and CerS6 both
prefer palmitoyl-CoA as substrates and produce predominantly C16-Cer species
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(Riebeling et al., 2003). On the other hand, CerS2 prefer C20-C26 acyl-CoA species and
form long chain Cer species (Laviad et al., 2008). CerS3 utilizes middle and long chain
acyl-CoA and makes the corresponding Cer species (Mizutani et al., 2006) (Fig. 1.5).
These CerS proteins are localized mainly to the ER and its activity is inhibited by a
number of fungal inhibitors such as fumonisin B1 (FB1), a mycotoxin produced by
Fusarium verticillioides. The nature of the inhibition of CerS by FB1, which contains an
aminoeicosapentol backbone, is that CerS recognizes the aminopentol moiety of this
compound, which competes with the binding sites for dhSph and fatty acyl-CoA (Merrill
et al., 2001).

Dihydroceramide Desaturase (DEGS)
The last step of the de novo biosynthesis of Cer is the insertion of a 4,5-transdouble bond into dhCer by dihydroceramide Δ4-desaturase (DEGS) to generate Cer.
Michel et al. first reported the biochemical characterization of the DEGS reaction in 1997
using rat liver microsomes (Michel et al., 1997). They have shown that the DEGS uses
molecular oxygen as electron acceptor to have a hydroxyl group in the C4-position of the
dhSph, and then with NADP or NADPH as an electron donor, a dehydration reaction
occurs to produce a double bond in the C4-C5 position of dhCer. Therefore, they
confirmed that the conversion of dhCer to Cer was occurred by a desaturase and not by a
dehydrogenase. Two different DEGSs, DEGS1 and DEGS2, have been so far reported. In
bioinformatics approach, Ternes et al. identified a family of sphingolipid Δ4-desaturases
(homologs of the Drosophila melanogaster degenerative spermatocyte gene 1 (des-1))
(Ternes et al., 2002). DEGS-1, the human homolog of des-1, exhibits high dhCer Δ4-
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desaturase and very low C-4 hydroxylase activities, whereas DEGS2, another ortholog
identified in mouse and human, is similarly active as both sphinglipid C-4 hydroxylase
and Δ4-desaturase activities, resulting in the production of either phytoceramide or
ceramide. Like the previous two enzymes in the de novo sphingolipid biosynthesis
pathway, DEGS is localized in the ER membrane where it can access to dhCer species.
DEGS1 activity is largely influenced by a number of factors including the length of the
alkyl chain of the sphingoid base (C18 > C12 > C8) and fatty acid (C8 > C18), the
stereochemistry of the dhSph moiety of the substrate (D-erythro-isomer > L- or D-threoisomers), and the nature of the headgroup (dhCer: the highest activity, dhSM: some
(~20%) activity). The activity of DEGS is inhibited by several compounds, including
cyclopropene-containing ceramide, GT-11 (C8-cyclopropenylceramide; C8-CPPC)
(Triola et al., 2003; Triola et al., 2004) which is a competitive inhibitor of DEGS, and
XM462.
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Figure 1.5 De novo biosynthesis of sphingolipids highlighting the synthesis of many
ceramides with different fatty acid chain length. Biosynthesis of sphinganine, which can
be acylated by the CerS/Lass gene products with their specific fatty acyl-CoA preference.
Each dhCer can be desaturased to the corresponding Cer species, followed by the
production of more complex sphingolipids. Cer, ceramide; CerS, ceramide synthase;
dhCer, dihydroceramide; DEGS, dihydroceramide desaturase; SM, sphingomyelin

1.4.1.2 Synthesis of Complex Sphingolipids

Cer formed via the de novo sphingolipid biosynthesis pathway in the ER is
transported to the Golgi to generate more complex sphingolipids (Hannun and Obeid,
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2008). Since Cer is a lipophilic molecule, it needs to be transported either by vesicular
transport for the delivery of Cer to synthesize glucosyl-Cer (Watson and Stephens, 2005)
or by the protein Cer transfer protein (CERT), which is a cytosolic protein and
specifically delivers Cer for SM synthesis (Hanada et al., 2003). In addition, transfer of
glucosyl-Cer for complex glycosphingolipids synthesis requires FAPP2 transfer protein
(D'Angelo et al., 2007). Therefore, in the Golgi apparatus, more complex sphingolipids
such as glucosyl-, or galactosyl-Cers and sphingomyelin (SM) are generated from Cers.
Glucosyl-Cer and galactosyl-Cer are synthesized by the actions of enzymes glucosyl-Cer
synthase and Cer galactosyltransferase, respectively. Meanwhile, SM, which is the most
abundant sphingolipids in mammalian cells, is produced by the action of SM synthases
(SMS). There are at least two members of the SMS family and SMS1 and 2 are localized
to the trans-Golgi, but SMS2 is also present in the plasma membrane. The synthesis of
SM is catalyzed by the SMS enzyme, which transfers the phosphocholine headgroup
from phosphatidylcholine to Cer yielding the products SM and diacylglycerol (DAG).
The activity of SMS enzyme is inhibited by tricyclodecan-9-xanthogenate (D609)
(Amtmann, 1996). The produced SM and complex glycosphingolipids are delivered to
the plasma membrane by vesicular transport. A majority of the total SM resides at the
plasma membrane, where it plays important roles structurally and functionally (Huitema
et al., 2004).
Moreover, although Cer is mainly converted into complex sphingolipids in the
Golgi, it can also be Cer-1-phosphate through phosphorylation by Cer kinase (Gault et
al., 2010).
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1.4.1.3 Catabolism of Complex Sphingolipids and Ceramides

SM is the most abundant complex sphingolipid in mammalian cells, and it can be
broken down to maintain cellular homeostasis, which occurs by the action of
sphingomyelinase (SMase) family. The SMase family hydrolyzes phosphocholine
headgroups in the SM to produce Cer and phosphocholine. The SMase family has two
major categories based upon their pH optimum, which are the acid and neutral SMases.
Acid SMases that are present in lysosomes and the outer membrane leaflet or neutral
SMases in the inner leaflet of the bilayer can metabolize SMs to Cers and other bioactive
lipids (Marchesini and Hannun, 2004). Although the functions and regulatory
mechanisms of SMases are not well characterized, some studies have been investigated
the factors and mechanisms that control the SMases activation. Acid SMases has been
shown to be activated by the TNF receptor, oxidants, and UV radiation (Henry et al.,
2013; Zhang et al., 2001). Neutral SMases activation has also been investigated that
serum starvation (Jayadev et al., 1995), oxidative stress (Marchesini and Hannun, 2004),
treatment of vitamin D (Okazaki et al., 1994), and curcumin (Abdel Shakor et al., 2014)
activate the enzyme. Neutral SMase activation was also a necessary signaling event for
the TNF-induced human MCF-7 breast cancer cell death (Luberto et al., 2002). A number
of compounds that inhibit SMases were also found. Desipramine, which is a member of
the tricyclic antidepressant family, has been used as a selective acid SMase inhibitor by
acting on the proteolytic degradation of acid SMase. SR33557 is also a specific acid
SMase inhibitor, and NB6 is another inhibitor of the SMase gene transcription. GW4869
is a noncompetitive inhibitor of neutral SMase.

38
Catabolism of Cer occurs by the action of ceramidases (CDases) to form
sphingosine. There are two major CDases, which are acid CDase localized in the
lysosomes and neutral CDase localized in the ER and the mitochondria. After Cer is
deacylated into sphingosine, sphingosine-1-phosphate (S1P) is synthesized from
sphingosine and ATP by the action of one of the sphingosine kinases (SphK); SphK1 or
SphK2. Meanwhile, the sphingosine produced from Cer hydrolysis by acid CDase in
lysosome may exit the lysosome and salvaged into Cer and sphingolipid pathways. The
last step of the sphingolipid catabolic pathway is the degradation of S1P by S1P lyase, a
microsomal enzyme to produce 2-hexadecenal and phosphoethanolamine (Gault et al.,
2010).

1.4.2

Bioactive Sphingoid Bases and Their Roles in Cell Growth, Survival, and Death

Sphingolipids are diverse groups of lipids that play a variety of essential roles as
components of cell membrane structure and cell signaling molecules, thus affecting on
the mammalian development and physiology. Moreover, dysregulated sphingolipids
metabolism is known to occur in some diseases such as cancer, diabetes, atherosclerosis,
and neurodegenerative diseases. Over the past two decades, several sphingolipids
metabolites, such as sphingosine, Cer, and S1P were defined as bioactive lipid
messengers and regulatory molecules, and many researchers have begun to investigate
their various roles and functions. These metabolites are now clearly known to play
critical roles in regulating various cellular events including differentiation, proliferation,
apoptosis, and autophagy (Ryland et al., 2011; Zheng et al., 2006). However, as the
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sphingolipid metabolism is complex and dynamic processes, and the produced
metabolites have different or opposite functions, their relative levels and balance between
each other are important for the regulation of survival and death within the cells. For
instance, while Cer has antiproliferative and proapoptotic properties, S1P involves in
cellular proliferation and survival. Thus, a model has been previously proposed in which
the equilibrium between these two molecules, the ‘Cer/S1P rheostat’, could determine
cell fate (Cuvillier, 2002). Besides this model, recent studies have suggested that
sphingolipid metabolites are interconvertible and each metabolite has its distinct
functions. For example, Cer can be further metabolized to sphingosine by ceramidase,
which has been shown to induce apoptosis in many cell types. This sphingosine can be
further phosphorylated to form S1P by sphingosine kinase. In addition, Cer can be
generated from SM via SMases. Therefore, now it is important to understand this
complexity of sphingolipid metabolism and specific enzymes that are involved in the
pathway, and define the roles and regulation of each metabolite by the application of the
comprehensive ‘sphingodynamic’ model. This present review will focus on the roles of
several bioactive sphingolipid metabolites and their regulation.

1.4.2.1 Sphingosine

The first sphingolipid identified that exerts pleiotropic effects on protein kinase C
and other targets was sphingosine (Hannun et al., 1986; Merrill et al., 1986; Wilson et al.,
1986). Sphingosine is generated from Cer by CDase, and it, in turn, can be
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phosphorylated by sphingosine kinase to form S1P. Sphingosine has been shown to be
produced during the early stages of apoptosis, and the exogenously added sphingosine
itself also induced apoptosis in many cell types (Ahn and Schroeder, 2002; Cuvillier,
2002). Although the role of sphingosine in apoptosis was not extensively studied
compared with that of Cer, there are several defined mechanisms that could account for
sphingosine to mediate apoptosis. Treatment of sphingosine has been shown to inhibit
MAPKs, Erk-1 and Erk-2 activities, and activate JNK and p38, which are stress-activated
protein kinases. Moreover, several studies have revealed that caspases, cysteine
proteases, are activated during sphingosine-induced apoptosis. In addition, sphingosine
induces apoptosis by the mitochondrial pathway, particularly by down-regulating the
PI3K-Akt pathway (Cuvillier, 2002).

1.4.2.2 Ceramide

After sphingosine was recognized as a second messenger, Cer also became
another candidate for the sphingolipid metabolite, which may act as bioactive cellular
signaling molecule (Goldkorn et al., 1991). Cer has a variable length of fatty acid chain
attached at the carbon 2 position of long-chain sphingosine by an amide bond. It is either
synthesized via de novo synthesis by condensation of serine and palmitoyl-CoA or
generated by sphingomyelin catabolism by the action of sphingomyelinases. Now, due to
its diverse roles including the regulation of cell death and senescence, even more
emphasis has been placed on the Cer. Although there are many signaling pathways that
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are influenced by Cer, interest has focused on defining the direct targets of Cer. Several
proteins such as Cer-activated protein phosphatases (CAPPs), various protein kinases and
cathepsin D, have been identified that interact directly with Cer. The CAPPs which are
serine/threonine phosphatase, such as PP1 and PP2A, are bound and activated by Cer and
induce growth arrest or apoptosis. Targets of these CAPPs for dephosphorylation include
the retinoblastoma gene product (Rb), PKCα, protein kinase B (PKB or AKT) and Bcl-2
(Hannun and Obeid, 2008; Kolesnick, 2002; Ohanian and Ohanian, 2001). Moreover,
kinase suppressor of ras (KSR), which is a Cer-activated protein kinase (CAPK), has also
been identified. KSR is a serine/threonine kinase that phosphorylates and activate Raf to
initiate MAPK signaling cascade. In addition, PKCζ and the protease cathepsin D have
been shown to be direct targets for Cer. Activation of PKCζ by Cer has been linked
cytokines to NFκB signaling (Ohanian and Ohanian, 2001) and implicated in
proapoptotic functions. Cathepsin D has been proposed as a specific target for acid
SMase-generated Cer in lysosome and implicated in subsequent induction of
mitochondrial apoptosis.
While Cer has been proposed as an important cell-signaling messenger for the
regulation of diverse events such as differentiation, proliferation and senescence, it has
received much attention as a potential mediator of apoptosis. Intensive investigation in
the past decade has firmly established that Cer could play a key role in apoptosis
signaling in response to cytokines, anticancer drugs, or environmental stresses. Treatment
of cells with Cer has been shown to induce apoptosis by the mitochondria-mediated
pathway and down-regulation of the PI3K-Akt pathway (Ahn and Schroeder, 2002;
Radin, 2001). In addition, Cer has shown to be accumulated in the mitochondrial
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membranes after chemotherapeutic drugs or TNFα treatment and caused mitochondrial
outer membrane permeabilization by making pore, resulting in the induction of
mitochondrial apoptosis (Siskind, 2005). Recent studies have shown that addition of
exogenous Cer also induced autophagy, and the autophagy was induced by compounds
treatment such as tamoxifen, a chemotherapeutic drug, and 4-HPR in which endogenous
Cer increase was involved (Scarlatti et al., 2004; Zheng et al., 2006). In addition to the
proapoptotic and proautophagic effects of Cer, it has been implicated in the inhibitory
properties of inflammation. Treatment of Cer has been found to inhibit phosphorylation
of pro-inflammatory kinases and production of cytokines, and also decrease the
inflammatory interleukin 6 (Kitatani et al., 2009; Sun et al., 2008).
Recently, emerging results suggest that endogenous Cers with different fatty acylchain lengths appear to have distinct bioactivities. Thus, many researchers have been
investigating the role of CerS family that makes Cers as well as specific functions of
individual Cer species. These researches were enabled by the development of mass
spectrometry (MS)-based approaches for the direct quantitation of Cers over the past 15
years, instead of using a variety of indirect assays, such as enzymatic assays or TLC
separations. With the highly sensitive and specific MS-based method, each individual Cer
species with different mass could be effectively quantified even in a mixture at low nM
concentrations. Watts et al. applied this technique to investigate the changes of individual
Cer levels during apoptosis in cells for the first time, and observed specific elevations of
C16:0-Cer (Watts et al., 1999). One study found that B-cell receptor-triggered cell death
was associated with an elevation in C16:0-Cer in Ramos B-cells. The increase of this Cer
was inhibited by FB1, an inhibitor of CerS, which also inhibited several apoptotic
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hallmarks such as activation of caspases, mitochondrial damage followed by induction of
cell death, suggesting that de novo generated C16:0-Cer is involved in mitochondrial
apoptosis (Kroesen et al., 2001). More recently, numerous studies have been revealed the
changes of individual Cer levels in specific cancers, and reported the distinct functions of
each individual Cer species in the regulation of tumor growth and therapy using the
sphingolipidomic analysis. Koybasi et al. first found that only one specific Cer, C18:0-Cer
was selectively down-regulated in human head and neck squamous cell carcinoma
(HNSCC) tissues, and this Cer involved in the inhibition of cancer cell growth and may
play an important role in the regulation of cell fate (Koybasi et al., 2004). Consistently,
Karahatay et al. also found the significantly decreased levels of C18:0-Cer in HNSCC
tumors. (Karahatay et al., 2007). In contrast, this group found an increase in the levels of
C16:0-, C24:0- and C24:1-Cers in the same cancer patients. The increased levels of these Cer
species were also observed in malignant breast cancer tissues compared with benign and
normal tissues (Schiffmann et al., 2009a). One study has shown that SW620 colon cancer
cells had lower expression levels of CerS6 and significantly decreased C16:0-Cer which
resulted in the resistance to the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis. Moderate elevation in CerS6 expression reversed the
apoptotic response to TRAIL in this cell line (White-Gilbertson et al., 2009). Schiffmann
et al. also implicated an increase of C16:0-Cer by CerS6 activation from the salvage
pathway in a selective COX-2 inhibitor, celecoxib-induced toxic effects in HCT-116
colon cancer cells (Schiffmann et al., 2009b). Recent study has found that the
accumulation of long-chain Cers by CerS5 and 6 through the salvage pathway play
important role in ultraviolet light-C-induced programmed cell death of MCF-7 breast
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cancer cells (Mullen et al., 2011). However, interestingly, another recent study by Senkal
et al. revealed novel prosurvival role of C16:0-Cer against ER stress-induced apoptosis in
HNSCCs. They found that whereas C18:0-Cer showed proapoptotic roles, C16:0-Cer
showed antiapoptotic and prosurvival roles, suggesting that C16:0-Cer and C18:0-Cer
generated by CerS1 or CerS5, respectively, play opposite roles in determining cancer cell
survival or apoptosis (Senkal et al., 2010). In addition to the proapoptotic roles of C18:0Cer, it has been shown to mediate lethal autophagy induction, independent of apoptosis in
HNSCC cell lines (Sentelle et al., 2012). Taken together, although there is still
controversy in the roles of each individual Cer species, recent studies have demonstrated
the distinct roles of individual Cer species, and Cers with different fatty acyl chain
lengths may contribute to tumor growth and therapy.

1.4.2.3 Dihydrosphingosine and Sphingosine-1-phosphate

Although sphingosine and Cer have been recognized and studied as pivotal
apoptosis-inducing molecules for a long time, emerging evidence suggests that other
sphingolipid intermediates in the de novo synthesis of sphingolipid pathway also play
important roles in cell survival and death.
First, dihydrosphigosine (dhSph or sphinganine), an intermediate upstream of
CerS an enzyme sensitive to fumunosin B1, has been shown to induce apoptosis in
human colon cancer cells (Ahn and Schroeder, 2002), activation-induced T cells
(Solomon et al., 2003), and undifferentiated HL-60 and U937 leukemic cells (Jarvis et al.,
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1996; Ohta et al., 1995). Moreover, our group found that the treatment of γT, the
predominant form of vitamin E in US diet, or mixed vitamin E forms induced huge
accumulation of dhSph, resulting in the induction of human prostate cancer cell death
(Jiang et al., 2004). We also found that γTE enhanced the intracellular levels of dhSph
and inhibited PI3K-mediated Akt phosphorylation followed by induction of apoptosis and
autophagy in human prostate cancer cells (Jiang et al., 2012). In addition, safingol, the
synthetic L-threo-stereoisomer of endogenous (D-erythro-) dhSph, has been shown to
induce autophagy through inhibition of PKCs and PI3K in various cancer cells (Coward
et al., 2009). Interestingly, fumonisin B1, an inhibitor of CerS, caused the accumulation
of dhSph in tissues, serum, and urine, which appear to be responsible for the toxicity of
this mycotoxin (Merrill et al., 2001).
Sphingosine and Cer are representative sphingolipid metabolites, which are
typically associated with induction of cell death, while S1P is involved in opposite roles
such as cell proliferative, mitogenic, survival, antiapoptotic and drug resistant actions.
S1P is produced through the action of SphK from sphingosine, which is generated via
deacylation of Cer. SphK activity is increased by a number of stimuli such as growth
factors, cytokines and G protein-coupled receptors (GPCRs), but the mechanisms
regulating the activity of SphK are not yet clearly understood. The increased S1P by the
action of SphK interacts with GPCRs as extracellular signals. S1P signaling through
these GPCRs has been implicated in various cellular responses including differentiation,
migration, and mitogenesis. S1P has also been proposed to play as an intracellular second
messenger, which activate calcium release, MAPKs, phospholipase D, and p125FAK
phosphorylation, resulting in the regulation of differentiation and migration, and
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increases in proliferation of cancer cells (Pyne and Pyne, 2000). Several studies suggest
that the levels of S1P are closely linked to resistance to the cancer cell death induction,
and the apoptosis-inducing action of Cer is antagonized by S1P. S1P also increased
platelet-derived growth factor and vascular endothelial growth factor which are
associated with angiogenesis and metastasis of tumor (Catarzi et al., 2007; Heo et al.,
2009). Interestingly, S1P has been shown to induce COX-2 expression, which activates
inflammatory response and has been recognized to be linked to the cancer progression
(Snider et al., 2010).

1.4.2.4 Dihydroceramide

Dihydroceramide (DhCer) is another sphingolipid metabolite which is converted
to Cer via DEGS. The only structural difference between Cer and dhCer is the presence
or absence of a 4, 5-trans-double bond, respectively. Whereas Cer is well known
sphingolipid involved in cell death, dhCer was thought to be an inactive precursor of Cer
and a non-signaling molecule. In the early 1990’s, a study demonstrated that dhCers were
inactive in inhibition of cell growth and induction of apoptosis, in which Cers were active
in HL-60 cells (Bielawska et al., 1993). Ahn et al. also have shown that sphingosine,
dhSph, and C2-Cer inhibited growth, caused apoptosis and death of colon cancer cells,
whereas dhCer had no effect on these (Ahn and Schroeder, 2002). Several other previous
studies also have revealed and confirmed that dhCers have not been found to mimic the
effects of Cer, and they are inert compounds as compared with their potent Cer.
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However, these studies used unnatural C2 or C6 short-chain analogs instead of natural
long-chain Cer and dhCer. Stiban et al. first investigated the effects of their long-chain
analogs, and found that dhCer are not ineffective. In this study, dhCer hindered Cer
channel formation in mitochondria, resulting in the inhibition of apoptotic cell death
(Stiban et al., 2006).
On the other hand, technology used in the previous studies showing the important
roles of Cer in the induction of cell death was limited in that it could not distinguish
between Cer and dhCer. The potential effects of dhCer were recognized with the use of
liquid chromatography tandem mass spectrometry (LC-MS/MS) technology, which can
identify even different species of Cer and dhCer. For example, 4-hydroxy
phenylretinamide (4-HPR or fenretinide), a synthetic retinoid, had been thought to cause
large elevation of Cer to induce growth arrest and apoptosis in numerous cancer cells
(Erdreich-Epstein et al., 2002; Wang et al., 2003; Wang et al., 2001). However, the LCMS/MS analysis revealed that 4-HPR did not increase in Cer, but rather accumulate
dhCer by inhibiting DEGS.
DhCers are now considered as one of the bioactive sphingolipid metabolites and
have shown to be involved in important cellular responses such as cell cycle arrest
(Kraveka et al., 2007), apoptosis (Gopalan et al., 2012; Jiang et al., 2012; Jiang et al.,
2004), autophagy (Jiang et al., 2012; Signorelli et al., 2009; Zheng et al., 2006), and
oxidative stress (Idkowiak-Baldys et al., 2010). Recently, several compounds including
natural bioactives such as vitamin E forms, resveratrol, and cancer chemotherapeutic
agents have been shown to inhibit DEGS and induce subsequent increases in dhCer levels
followed by the regulation of cellular responses. Among them, our group found that γT is
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the first natural compound that has been shown to induce apoptotic cell death by
increasing intracellular dhCer and dhSph in human prostate cancer cells (Jiang et al.,
2004). Since then, subsequent studies have reported several compounds that can
modulate intracellular levels of dhCer. Fenretinide, a vitamin A analog with
chemotherapeutic properties, also enhanced intracellular dhCer by inhibition of DEGS
activity, leading to cell cycle arrest and inhibition of cell growth in human neuroblastoma
cells (Kraveka et al., 2007). Following studies from this group found that fenretinide,
which bears a structural resemblance to dhCer, directly and irreversibly inhibited DEGS
activity (Rahmaniyan et al., 2011). Moreover, resveratrol treatment showed an increase in
dhCers levels, which resulted in the induction of autophagy in gastric cancer cells.
Importantly, XM462, an inhibitor of DEGS, caused the accumulation of dhCer and it was
sufficient to have autophagy (Signorelli et al., 2009). Consistently, in the earlier studies,
Zheng et al. also showed the induction of autophagy in C2-dhCer-treated prostate cancer
cells (Zheng et al., 2006). Celecoxib, a selective COX-2 inhibitor, induced various cancer
cell death by promoting dhCer and dhSph accumulation through the inhibition of DEGS
and activation of sphingolipid biosynthesis, while depleting cells of Cers. DEGS activity
was also found to be inhibited by oxidative stress (Idkowiak-Baldys et al., 2010) or
hypoxic environment (Devlin et al., 2011), resulting in significant elevation in dhCer
levels and inhibition of cell proliferation. Again, our group has recently shown that γTE,
an analog of γT, also enhanced dhCer as well as dhSph, which lead to the induction of
apoptosis and autophagy in human cancer cells (Gopalan et al., 2012; Jiang et al., 2012).
On the other hand, γTE did not significantly affect Cer or sphingosine levels, and γTE
was much more potent than γT in these activities. Our very recent studies implicated the
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importance of dhCer increase in the γTE-mediated NFκB inhibition through increase of
ER stress and up-regulation of A20 (Wang et al., 2015).
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CHAPTER 2. SPHINGOLIPID METABOLISM IS THE INITIAL PRIMARY
TARGET OF GAMMA-TOCOTRIENOL AND PLAYS A ROLE IN CELL
DEATH INDUCTION

2.1

Abstract

Our previous studies suggest that gamma-tocotrienol (γTE) has potent anticancer
activities in cancer cells via modulation of sphingolipid metabolism. Here, by employing
liquid chromatography tandem mass spectrometry, we investigated temporal changes in
levels of sphingolipids by γTE treatment in human colon cancer HCT-116 cells.
Incubation with γTE for 16 h resulted in accumulation of dihydrosphingosine (dhSph)
and dihydroceramides (dhCer), and these changes intensified during prolonged treatment.
In contrast, γTE treatment led to a significant decrease in C16:0-ceramide (Cer) levels at 8
h, but showed no difference at 16 h or increase at 24 h, compared with controls.
Meanwhile, γTE led to a decrease in C24:1-Cer and C24:0-Cer from 8 to 24 h, but an
increase in C18:0-Cer from 16 h. Interestingly, sphingomyelins (SM) declined from 8 h but
cells showed obvious apoptosis (PARP cleavage) or autophagy (LC3 increase) only at 16
h or longer treatment with γTE. Using 13C3, 15N-labeled L-serine, we further evaluated the
effect of γTE on de novo synthesis of sphingolipids. We observed that γTE had no effect
on total de novo sphingolipid biosynthesis, but induced increases in labeled dhCers and
dhSMs, but decreases in labeled Cers, between 2-6 h. These data indicate that γTE may
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inhibit dhCer desaturase (DEGS). Consistent with these results, γTE inhibited the DEGS
activity as indicated in situ assay and in vitro assay with microsomes. The importance of
sphingolipids modulation in γTE-induced cancer cell death such as the accumulation of
dhCers and dhSph during the initial phase, and the increase of Cers and decrease of SMs
during the prolonged treatment period was supported by blocking these enhancements
using each individual enzyme inhibitors, myriocin and desipramine, respectively. Cotreatment of cells with myriocin or desipramine partially but significantly reversed the
γTE-induced cancer cell death. These results indicate that γTE exerts anticancer effects
by modulating enzyme activities in sphingolipid metabolism, specifically, by inhibition
of DEGS and activation of SM hydrolysis.

2.2

Introduction

Natural forms of vitamin E consist of α-, β-, γ- and δ-tocopherols (αT, βT, γT and
δT) and α-, β-, γ- and δ-tocotrienols (αTE, βTE, γTE and δTE). Although these forms
share the similar structures, different forms of vitamin E appear to have distinct activities
and metabolism. Among them, αT, which is the predominant vitamin E form in tissues
and plasma, and the form that is the least catabolized, is the most extensively studied.
However, the human clinical studies as well as numerous animal studies of αT in cancer
prevention resulted in inconsistent and disappointing outcomes. On the other hand, other
forms of vitamin E, although they are low in tissues due to the extensive catabolism,
appeared to have unique and strong anticancer activities. Especially, γTE has been shown
to have potent anticancer effects in various types of cancer cells (Jiang, 2014; Moya-
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Camarena and Jiang, 2012). However, the molecular mechanism by which γTE exerts its
anticancer effects are not understood yet.
Recently, our group has shown that γT and γTE induced apoptosis and autophagy
through mechanisms involving dhCer and dhSph accumulation in prostate and breast
cancer cells, and this modulation of sphingolipid played an important role in γT and γTEinduced cell death (Gopalan et al., 2012; Jiang et al., 2012; Jiang et al., 2004).
Sphingolipids constitute an essential component of cell membrane and also are important
signaling molecules that regulate cell growth, differentiation, senescence and apoptosis
(Hannun and Obeid, 2008; Ryland et al., 2011; Zheng et al., 2006). The levels of
endogenous sphingolpids are controlled by de novo synthesis pathway and dynamic
metabolisms involving catabolic pathways and synthetic pathways of complex
sphingolipids. Briefly, de novo sphingolipid synthesis begins in the endoplasmic
reticulum from condensation of palmitoyl-CoA and serine into 3-ketodihydrosphingosine by serine palmitoyltransferase (SPT). The intermediate 3ketodihydrosphingosine is rapidly reduced to dihydrosphingosine (dhSph), followed by
acylation by a family of (dihydro)ceramide synthases (CerSs) using fatty acyl-CoAs to
generate the corresponding dihydroceramide (dhCer) subspecies. In mammals, there are
six identified genes that encode CerS, and each CerS has substrate preference for
different lengths of fatty acyl CoAs, thus producing distinct dhCers with different acylchain lengths. Dihydroceramide desaturase (DEGS) inserts a 4,5-trans double bond in
dhCers to make the final product, ceramide (Cer). In the Golgi apparatus, more complex
sphingolipids such as glucosyl- or galactosyl-Cers and sphingomyelin (SM) by the
actions of glucosyl-Cer synthase, Cer galactosyltransferase, and SM synthases (SMS),
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repectively, can be generated from Cers (Fig. 2.3A). As for the degradation pathways,
Cer is broken down by ceramidases into sphingosine (Sph), which may be salvaged into
sphingolipid pathways or can be phosphorylated to form sphingosine-1-phosphate (S1P).
Also, Cer can be generated by breakdown of SM through the action of acid or neutral
SMases, which operate at different pH optima (Hannun and Obeid, 2008; Hannun and
Obeid, 2011; Kitatani et al., 2008; Marchesini and Hannun, 2004).
Among different species of sphingolipids, only Cers and S1P have been focused
to be bioactive molecules. On the other hand, dhCers were thought to be an inactive
precursor of Cer, which is a well-known sphingolipid metabolite involved in cell death
(Zheng et al., 2006). However, technology used in the previous studies showing the
important roles of Cer in the induction of cell death was limited in that it could not
distinguish between Cer and dhCer. Recent studies, using liquid chromatography tandem
mass spectrometry (LC-MS/MS) technology which can identify even different species of
Cer and dhCer, have shown dhCers to be involved in important cellular responses such as
cell cycle arrest (Kraveka et al., 2007), apoptosis (Gopalan et al., 2012; Jiang et al., 2012;
Stiban et al., 2006), autophagy (Jiang et al., 2012; Signorelli et al., 2009; Zheng et al.,
2006), and oxidative stress (Idkowiak-Baldys et al., 2010).
Therefore, we hypothesize that the sphingolipid pathway may be also an important
target for the anti-proliferative effects of γTE in other cancer cells. In this study, we
investigated the anticancer effects and mechanisms of γTE in human cancer cells and our
study revealed that modulation of sphingolipid was the primary target of γTE in the
induction of cancer cell death.
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2.3

Materials and Methods

2.3.1

Materials and reagents

γTE (97-99%), a gift from BASF (Ludwigshafen, Germany), was dissolved in
DMSO at 100 mM and then diluted to 5 mM in fatty acid-free BSA (10 mg/ml).
Sphingolipid standards were obtained from Avanti Polar Lipids (Alabaster, AL). CHAPS
was purchased from Thermo Fisher Scientific. C8-cyclopropenylceramide (C8-CPPC)
was purchased from Matreya LLC (Pleasant Gap, PA). Myriocin from Mycelia Sterilia,
desipramine, GW4869, 13C3, 15N-labeled L-serine, N-acetyl cysteine (NAC), dimethyl
sulfoxide (DMSO), [3-(4,5)-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide]
(MTT), and all other chemicals were from Sigma (St Louis, MO).

2.3.2

Cell culture and treatment

Human colon cancer HCT-116 and breast cancer MCF-7 cells were obtained from
American Type Culture Collection (Manassas, VA). Cells were routinely cultured in
growth media containing 10% fetal bovine serum (FBS) at 37 °C in 5% CO2. HCT-116
cells were cultured in McCoy’s 5A modified medium. MCF-7 cells were incubated in
Dulbecco’s modified eagle medium (DMEM) supplemented with 0.1% insulin. At the
time of experiments, cells were seeded in each medium with 10% FBS either at a density
of 4 x 104 cells/well in 24-well plates or at a density of 7-8 x 105 cells in 10-cm dishes.
Unless otherwise indicated, for experiment, cells were seeded in 10-cm dishes except
MTT assay. After overnight attachment, media were replaced with fresh DMEM

55
containing 1% FBS and γTE or other compounds. All the treatment solutions were
freshly prepared for each experiment.

2.3.3

MTT assay

Cell viability was examined by MTT assay to estimate mitochondrial
dehydrogenase activity. In living cells, the enzyme reduces MTT to form formazan which
was dissolved in DMSO and measured the absorbance at 570 nm by using a microplate
reader (SpectraMax 190, Molecular Devices, Sunnyvale, CA).

2.3.4

Lipid extraction

Total lipids were extracted as previously described (Merrill et al., 2005). Briefly,
cell pellets were resuspended in methanol/chloroform/water (10:5:1 [v/v/v]) after the
addition of internal standard mixture containing 0.5 nmol C12:0/C25:0-Cers, C12:0-SM, and
C17-Sph/dhSph (Avanti Polar Lipids, Alabaster, AL). The suspension was dispersed
fully by tip sonication for 20 sec and then incubated overnight at 48 °C. 100 µL of
solvent was used to determine the amount of total choline-containing phospholipids by an
enzymatic colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang et al., 2004). 75 µL
of 1 M KOH in methanol was added to the rest of the solvent and sonicated for 30 min.
After sonication, samples were incubated at 37 °C for 2 h and dried in a nitrogen
evaporator.
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2.3.5

Measurement of sphingolipids using liquid chromatography tandem mass
spectrometry (LC-MS/MS)

Samples for sphingolipids analysis were resolved again in methanol and sonicated
to disperse, then centrifuged to clarify before transferring to test vials for quantification.
The LC-MS/MS method was slightly modified based on the method of Merrill et al.
(Merrill et al., 2005). Analyses were performed using the Agilent 6460 triple quadrupole
mass spectrometer coupled with the Agilent 1200 Rapid Resolution HPLC (Agilent
Technologies, Santa Clara, CA) with detection of sphingolipids in positive mode by
multiple reaction monitoring (MRM) technique. The HPLC mobile phases consisted of
methanol-H2O-formic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v;
RB); both RA and RB contain 5 mM ammonium formate. For measurement of ceramides
and sphingoid bases, Agilent column XDB-C18 (4.6 x 50 mm) with particle size of 1.8
μm, was used with isocratic run (100% B) or gradient (0-1 min, 20% B, 10-13 min, 100%
B and 15-20 min at 20% B), respectively. For measurement of sphingomyelins, Agilent
Zorbax XDB-C8 (2.1 x 50 mm) with particle size of 3.4 μm, was used with gradient (0-1
min, 20% B, 10-20 min, 100% B, 22-30 min, 20% B). The MS/MS parameters were as
follows: gas temperature, 325-350 °C; gas flow rate, 7-10 L/min; nebulizer pressure, 4550 psi; capillary voltage, 3500 V; The fragmentor voltage was 100 V and collision energy
was 12-20 V. Precursor-to-product ion transitions for each sphingolipid were used
according to the method of Merrill et al. (Merrill et al., 2005).
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2.3.6

De novo sphingolipids analysis

HCT-116 cells were treated with either 400 μM 13C3, 15N-labeled L-serine alone
or with a combination of 400 μM 13C3, 15N-labeled L-serine and 20 μM of γTE for 30
min, 2 h, 3 h and 6 h. Lipids were extracted and de novo synthesized sphingolipids were
measured using LC-MS/MS.

2.3.7

In Situ dihydroceramide desaturase assay

C8:0-dihydroceramide (C8:0-dhCer) was used as the substrate for the DEGS. HCT116 cells were pretreated with either γTE or C8-CPPC as a positive control, followed by
10 μM of C8:0-dhCer incubation for 1 h. The cells were collected and lipids were
extracted. The levels of products (C8:0-ceramide and C8:0-sphingomyelin) were detected
by LC-MS/MS.

2.3.8

In Vitro dihydroceramide desaturase assay

Microsomes were prepared and used as the DEGS enzyme source for this assay
(Rahmaniyan et al., 2011). Livers from male Wistar rats were rinsed in ice-cold PBS and
homogenized in buffer (0.25 M sucrose, 10 mM HEPES, 1 mM EDTA, pH 7.4) with a
homogenizer in ice. The homogenate was centrifuged at 800 x g for 10min first and the
supernatant was re-centrifuged at 10,000 x g for 15 min followed by ultracentrifugation
of the resulting supernatant at 104,000 x g for 1 h. The microsomal pellet was
resuspended in potassium phosphate buffer (50 mM, pH 7.4) and aliquots were stored at 80 °C until use. Protein amount was quantified by using a bicinchoninic acid (BCA)
protein assay kit (Pierce, Rockford, IL). For the assay, substrate (C8:0-dhCer) and tested

58
compounds were dried under a stream of nitrogen, followed by resuspension in CHAPS
(1.1 mg/10 μl of water). 500 μg of microsomal protein was mixed with reaction buffer
(20 mM bicine, pH 8.5, 50 mM NaCl, and 50 mM sucrose) and then the tested
compounds were added, followed by 30 min pre-incubation at room temperature. 2 mM
of NADH and 10 μM of C8:0-dhCer were added and the mixture was incubated for 20 min
at 37 °C with shaking. Lipid extraction was conducted directly after reaction and the
product (C8:0-ceramide) was quantified by LC-MS/MS.

2.3.9

Transmission Electron Microscopy (TEM)

After treatment, cells were fixed with 2% glutaldehyde in 0.1 M cacodylate buffer
(pH 7.4) for 1 h at room temperature. After primary fixation, the attached cells were
scraped and pooled together with the floating cells. All the cells were then centrifuged
and washed twice with cacodylate buffer and once with water. A secondary fixation in
reduced osmium containing 1% OsO4 and 1.5% agarose and then diced and dehydrated in
ethanol with a concentration gradient. The ultrathin sections were stained with 2%
uranylacetate in 70% methanol for 5 min and lead citrate for 3 min. Finally, the cell
images were taken by a FEI/Philips CM-10 bio-twin transmission electron microscope
(FEI Company, Hillsboro, OR) using an acceleration voltage of 80 kV. Cells and the
inner ultrastructure were observed in different magnification.

2.3.10 Western Blotting
Cells were lysed in lysis buffer containing Tris-EDTA, 1% SDS, 2 mM Na3VO4
and protease inhibitor cocktails (Sigma). Total proteins which were quantified by BCA
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protein assay kit were denatured by boiling in Laemmli buffer for 5 min at 95 °C. Equal
amount of proteins (15-30 µg) were separated on acrylamide gels by SDS-electrophoresis
and then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore,
Bilerica, MA, USA), and probed by antibodies. Membranes were exposed to
chemiluminescent reagent (PerkinElmer) and visualized on Kodak film with an M35A XOmat processor (Kodak). The antibodies used in the study were as follows: DEGS1
(Novus Biologicals, Littleton, CO), membrane bound microtubule-associated protein
light chain 3 (LC3; MBL international, Woburn, MA), poly (ADP-ribose) polymerase-1
(PARP-1) and Actin (Santa Cruz Biotechnology, Santa Cruz, CA), phosphorylated JNK
at Thr-183 and Tyr-185 (p-JNK), and total JNK (Cell Signaling Technology, Danvers,
MA).

2.3.11 Statistics
Statistical significance was determined using a Student’s t-test. p-values of < 0.05
were considered to be statistically significant.

2.4

2.4.1

Results

Temporal changes of sphingolipids induced by γTE

We investigated the effects of γTE on sphingolipid metabolism using LC-MS/MS
in human colon HCT-116 cancer cells. During the initial 8 h treatment, γTE caused
significant decreases of C16:0-Cer, C18:0-Cer, C24:1-Cer and C24:0-Cer, resulting in the
significant decreases in total Cers. However, individual Cer, which have been shown to
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have distinct bioactivities (Hannun and Obeid, 2011; Senkal et al., 2010; Sentelle et al.,
2012), appeared to respond differently to γTE in the longer time treatment. For example,
C16:0-Cer in γTE-treated cells returned to the control levels at 16 h but exceeded the
control at 24 h. Compared with controls, C18:0-Cer was enhanced in γTE-treated cells at
16 h, whereas C24-Cers remained lower than controls during the prolonged treatment
period (Fig. 2.1A). Meanwhile, γTE induced significant increases of dhCers and dhSph
starting at 16 h, thus cells accumulated high levels of dhCers and dhSph at 16 h and 24 h
treatment with γTE (Figs. 2.1B and C). As to SM, while dhSMs increased during 16-24 h
incubation, SMs declined at 8 h compared with controls (Figs. 2.1D and E; Table 2.1).
Furthermore, we observed similar sphingolipid modulatory effects of γTE on human
breast MCF-7 cancer cells (Fig. 2.2; Table 2.2).
These data suggest that the initial action of γTE is likely to inhibit DEGS, which
is evident by the increase of dhSph and dhCers and decrease of Cers, similar phenomena
reported with DEGS knockout model (Ruangsiriluk et al., 2012; Siddique et al., 2013).
During prolonged treatment, γTE may induce C16:0-SM hydrolysis, which explains the
subsequent increase of C16:0-Cer during prolonged incubation times. On the other hand,
another possible explanation for increased C16:0-Cer and decreased SM is that the
conversion of Cer to SM may be inhibited.
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Figure 2.1 Effects of γTE on sphingolipid metabolism in HCT-116 cells. HCT-116 cells
were treated with 20 μM of γTE for 8, 16, and 24 h. The sphingolipid levels including
(A) total Cers, C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-Cer, (B) total dhCers, (C) dhSph,
(D) total SMs, C16:0-SM, and C24:1-SM, and (E) total dhSMs were determined by LCMS/MS. Results are shown as mean ± SEM for at least three independent experiments.
*p < 0.05 and **p < 0.01 indicate a significant difference between treated and control
cells.
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Figure 2.2 Effects of γTE on sphingolipid metabolism in MCF-7 cells. MCF-7 cells were
treated with 20 μM γTE for 8 h or 16 h. The sphingolipid levels including (A) total
dhCers, (B) C16:0-dhCer, (C) dhSph, (D) C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-Cer, (E)
total dhSMs, and (F) total SMs were determined by LC-MS/MS. Results are shown as
mean ± SEM for five independent experiments. *p < 0.05 and **p < 0.01 indicate a
significant difference between treated and control cells.
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2.4.2

De novo synthesis of sphingolipids with labeled serine

To evaluate whether γTE has impact on de novo sphingolipid biosynthesis (Fig.
2.3A), 13C3, 15N- L-serine was added to culture media to trace only newly synthesized
sphingolipids. Similar to those observed effects of γTE on sphingolipid metabolism
above, γTE led to an increase of de novo synthesized dhCers and decrease in de novo
Cers after 2 h, supporting the notion that DEGS is inhibited (Figs. 2.3B and C).
Interestingly, compared with control cells, labeled dhSM and SM, which represented
newly synthesized dhSM and SM, also significantly increased at 2 h in γTE-treated cells,
while SMs returned to the control levels at 3 h (Figs. 2.3D and E). These results indicate
that the conversion of C16:0-Cer to C16:0-SM was stimulated at the initial stage of
treatment, despite the decrease of C16:0-Cer in cells. As a result, the decrease of Cers due
to inhibition of DEGS was intensified by increased SM synthesis. The continuous
increase of de novo dhSM was probably a result of enhanced de novo dhCer, which led to
limited accumulation of dhCer during the first few hours (Figs. 2.1B and E). On the other
hand, we did not see significant difference between control and γTE-treated cells in total
labeled sphingolipids (Fig. 2.1F), suggesting that the overall sphingolipid synthesis was
not enhanced (Table 2.3).
Since labeled C16:0-Cer is decreased, the increase of overall C16:0-Cer in the
subsequent time (24 h) and decrease of SM is likely due to hydrolysis of C16:0-SM, which
is obvious at 8 h incubation.
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De novo synthesis of sphingolipid
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Figure 2.3 Effects of γTE on de novo sphingolipid biosynthesis in HCT-116 cells. (A)
The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin synthase;
SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM 13C3, 15Nlabeled L-serine alone as control or with a combination of 400 μM 13C3, 15N-labeled Lserine and 20 µM γTE for 0.5, 2, 3, and 6 h. The amount of each labeled de novo
sphingolipid including (B) total and C16:0-dhCers, (C) total, C16:0-, C24:1- and C24:0-Cers,
and (D) total, C16:0- and C24:1-SMs, and (E) total and C16:0-dhSMs were determined by
LC-MS/MS. (F) Total amounts of all the de novo synthesized sphingolipids were
calculated. Results are shown as mean ± SEM for three independent experiments. *p <
0.05 and **p < 0.01 indicate a significant difference between treated and control cells.
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2.4.3

Direct evidence that γTE inhibits DEGS

We found that γTE treatment increased de novo synthesized dhCers, but led to
decrease in de novo Cers, suggesting that γTE decreases DEGS protein expression or
inhibits DEGS-catalyzed enzyme reactions. γTE treatment did not affect the DEGS
protein expression on HCT-116 cells as determined by western blotting (Fig. 2.4A). Next,
to determine whether the observed sphingolipid change results from inhibition of DEGS
enzyme activity, both in situ and in vitro assays were conducted. In the assays, the nonphysiological C8:0-dhCer was used as a substrate for the DEGS, and measured the C8:0sphingolipid products by LC-MS/MS; specifically C8:0-Cer with C8:0-SM or C8:0-Cer for
in situ and in vitro DEGS assays, respectively. In situ DEGS activity was evaluated in
intact HCT-116 cells. C8-CPPC, a known competitive inhibitor of DEGS (Triola et al.,
2003), inhibited DEGS activity, and showed ~75% reduction of the C8:0-sphingolipids
production. The relative inhibition of DEGS activity by 20 µM of γTE for 6 h and 8 h
was ~40% and ~45%, respectively (Fig. 2.4B). In addition, the direct effect of γTE on
DEGS activity was determined using rat liver microsomes. In this direct in vitro DEGS
assay, γTE showed a modest DEGS activity inhibition by only ~10% at a concentration
of 20 μM, and ~25% at 100 μM (Fig. 2.4C). The requirement of higher concentration of
γTE for the DEGS inhibitory effects in in vitro assay could be due to limitation in
permeability through the cell membrane of γTE. These results indicated that γTE inhibits
DEGS activity, but not expression.
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Figure 2.4 Effects of γTE on DEGS expression and activity. (A) HCT-116 cells were
treated with 20 μM γTE for 8, 16, and 24 h and the protein levels of DEGS-1 were
detected by western blotting. (B) In situ DEGS assay: HCT-116 cells were pretreated
with either 20 μM γTE or 1 μM C8-CPPC as a positive control, followed by 10 μM C8:0dhCer incubation as a substrate for the enzyme for 1 h. The cells were collected and
lipids were extracted. The levels of C8:0-sphingolipid products were detected by LCMS/MS. (B) In vitro DEGS assay using rat liver microsomes: Microsomes were used as
the enzyme source for this assay. The microsomal proteins in reaction buffer were premixed with either 20 or 100 μM γTE or 10 μM C8-CPPC for 30 min, followed by
addition of 2 mM NADH and 10 μM C8:0-dhCer and incubation for 20 min at 37 °C.
Total lipids were extracted immediately after reaction, and the product was quantified by
LC-MS/MS. The data are mean ± SD of three independent experiments. *p < 0.05 and
**p < 0.01 indicate a significant difference between treated and control cells.
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2.4.4

Temporal changes of cell death markers

γTE treatment caused PARP cleavage, as indicated by the appearance of the 89
kDa cleavage product from 16 h in HCT-116 cells. γTE treatment also increased levels of
p-JNK, which is a stress marker, in HCT-116 cells, as consistent with the p-JNK
upregulation by γTE in MCF-7 cells (Gopalan et al., 2012). The induction of autophagy
in γTE-treated HCT-116 cells was first investigated by using LC3-II, a marker of
autophagy. Interestingly, γTE treatment also led to an increase of LC3-II expression from
16 h (Fig 2.5A). It is important to note that the initial autophagy or apoptosis (at 16 h but
not 8 h) is not due to decrease of C16:0-Cer or C24-Cers, but might be facilitated by
increased dhSph, dhCer and increased C18:0-Cer.
We further examined the morphological analysis using TEM. As shown in Fig.
2.5B, control HCT-116 cells appeared normal, displaying abundant microvilli at the cell
surface, abundant organelles in the cytoplasm, and well-organized nuclei with clear
nuclear membrane. However, cells treated with γTE for 21 h showed evidence of
apoptosis characterized by cell shrinkage, loss of microvilli, loss of nuclear membrane
and chromatin condensation. These data suggest that γTE treatment induced apoptosis
and autophagy.
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Figure 2.5 Induction of apoptosis and autophagy by γTE in HCT-116 cells. (A) HCT-116
cells were treated with 20 μM of γTE for 6, 8, and 16 h. Expression levels of full-length
and cleaved PARP, LC3-II, Actin as a loading control, and levels of p-JNK and JNK
were examined by western blotting. (B) HCT-116 cells were treated with 20 μM of γTE
for 21 h. The morphology of HCT-116 cells was imaged by TEM. Representative TEM
images of control group and γTE-treated group are shown in this figure.
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2.4.5

The role of sphingolipid modulation in γTE-induced cell death

To evalulate the involvement and importance of de novo sphingolipid modulation
in γTE-induced cancer cell death, we used two inhibitors of enzymes in sphingolipid
biosynthesis pathway to block the specific effects of γTE on sphingolipid metabolism.
Since the above results (Figs. 2.1B and C) have shown that γTE treatment induced
accumulation of intracellular dhCers and dhSph, which are known to be toxic to cancer
cells (Ahn and Schroeder, 2002; Jiang et al., 2004), we used myriocin, a specific inhibitor
of serine palmitoyltransferase to inhibit the increase of these sphingoid bases.
Interestingly, co-treatment of cells with myriocin showed partial but significant
protection from the γTE-caused cancer cell death, as assayed by MTT assay. The
importance of sphingolipid modulation in γTE-induced cell death was further confirmed
by western blot experiments. Co-incubation of myriocin with γTE slightly but clearly
prevented the γTE-induced PARP cleavage and LC3-II induction (Fig. 2.6A). These data
suggest that the accumulation of dhSph and dhCers plays an important role in γTEinduced apoptosis, autophagy and subsequent cancer cell death.
During the prolonged treatment time, γTE led to an increase of Cers, but induced
a significant decrease in SMs (Fig. 2.1) with the still lower de novo synthesized Cers
compared with control (Fig. 2.2B), suggesting that γTE may induce SM hydrolysis by
activating SMases. As Cers have been known to induce apoptosis, autophagy and cell
death, we investigated the role of the increased Cers from SMs via SMases in γTEinduced cancer cell death by using desipramine and GW4869 to inhibit acid or neutral
SMases, respectively. Co-treatment of cells with desipramine but not GW4869 (data not
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shown) with γTE partially but significantly reversed γTE-induced cancer cell death (Fig.
2.6B), suggesting that the increase of Cers from SMs through the acid SMase activation
may in part contribute to γTE-induced colon cancer cell death.

75

Figure 2.6 Protective effects of inhibitors of enzymes in sphingolipid metabolism on
γTE-induced cancer cell death. (A) HCT-116 cells were treated with 10 or 20 μM of γTE
with or without 3-6 μM of myriocin, a specific inhibitor of serine palmitoyltransferase to
block the de novo sphingolipid pathway. After 48 h of treatment, relative cell viability
was measured by MTT assay compared with control. In addition, after 16 h of treatment,
the cells were collected and analyzed for detection of PARP cleavage and LC3-II
expression. Western blots in this figure are representative of three or more independent
experiments. (B) HCT-116 cells were treated with 15 μM of γTE with or without 10 μM
of desipramine, an inhibitor of acid SMase for 24 h. Relative cell viability was measured
by MTT assay compared with control. The data are mean ± SEM of at least three
independent experiments. *p < 0.05 indicates a significant difference.
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Figure 2.7 NAC, an antioxidant, did not reverse γTE-induced modulation of
sphinoglipids in HCT-116 cells. HCT-116 cells were treated with either 20 μM γTE or 1
mM NAC alone or with a combination of γTE and NAC for 8 h. The sphingolipid levels
including (A) C16:0-dhCer, C24:1-dhCer, C24:0-dhCer, and dhSph, (B) C16:0-Cer, C24:1-Cer,
and C24:0-Cer, (C) C16:0-dhSM, C24:1-dhSM, C16:0-SM, and C24:1-SM were determined by
LC-MS/MS. Results are shown as mean ± SD for two independent experiments.
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Table 2.1 Effect of γTE on sphingolipid metabolism in HCT-116 cells. HCT-116 cells
were treated with 20 µM γTE for 8, 16, and 24 h. The amount of each sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 5 independent experiments. *p <
0.05, **p < 0.01, significant difference between control and γTE-treated cells. Cer,
ceramide; dhCer, dihydroceramide; Sph, sphingosine; dhSph, dihydrosphingosine; S1P,
sphingosine-1-phosphate; SM, sphingomyelin; dhSM, dihydrosphingomyelin

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
8
16
24

Control
2.19 ± 0.23
2.41 ± 0.22
2.09 ± 0.17

γTE 20 µM
0.95 ± 0.22**
2.17 ± 0.24
3.96 ± 0.76**

Control
0.038 ± 0.006
0.028 ± 0.003
0.025 ± 0.003

γTE 20 µM
0.033 ± 0.006*
0.082 ± 0.013**
0.14 ± 0.027**

Control
0.023 ± 0.004
0.020 ± 0.003
0.018 ± 0.003

γTE 20 µM
0.017 ± 0.005*
0.042 ± 0.009**
0.065 ± 0.014**

Control
0.20 ± 0.031
0.26 ± 0.086
0.21 ± 0.056

γTE 20 µM
0.068 ± 0.010**
0.095 ± 0.018**
0.15 ± 0.030

Control
1.02 ± 0.26
1.79 ± 0.22
1.47 ± 0.18

γTE 20 µM
0.47 ± 0.16**
0.66 ± 0.082**
0.94 ± 0.20**

Control
1.22 ± 0.22
2.56 ± 0.29
2.10 ± 0.24

γTE 20 µM
0.30 ± 0.10**
0.35 ± 0.057**
0.44 ± 0.10**

C18:0-Cer
Hours
8
16
24
C20:0-Cer
Hours
8
16
24
C22:0-Cer
Hours
8
16
24
C24:1-Cer
Hours
8
16
24
C24:0-Cer
Hours
8
16
24
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C26:1-Cer
Hours
8
16
24

Control
0.096 ± 0.008
0.23 ± 0.036
0.18 ± 0.027

γTE 20 µM
0.067 ± 0.013*
0.11 ± 0.021**
0.15 ± 0.040

Control
0.090 ± 0.006
0.15 ± 0.046
0.13 ± 0.037

γTE 20 µM
0.031 ± 0.015*
0.043 ± 0.014**
0.049 ± 0.018**

Control
4.88 ± 0.25
7.44 ± 0.75
6.22 ± 0.56

γTE 20 µM
1.93 ± 0.18**
3.54 ± 0.29**
5.88 ± 1.04

C26:0-Cer
Hours
8
16
24
Total Cers
Hours
8
16
24

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
8
16
24

Control
0.091 ± 0.030
0.18 ± 0.027
0.21 ± 0.031

γTE 20 µM
0.31 ± 0.036
2.22 ± 0.18**
4.09 ± 0.78**

Control
0.0018 ± 0.0003
0.0010 ± 0.0001
0.0013 ± 0.0002

γTE 20 µM
0.011 ± 0.003*
0.1 ± 0.025**
0.17 ± 0.034**

Control
0.00029 ± 0.0002
0.00092 ± 0.0003
0.0011 ± 0.0003

γTE 20 µM
0.0066 ± 0.0026
0.042 ± 0.013**
0.06 ± 0.013**

Control
0.0038 ± 0.0014
0.0074 ± 0.0037
0.0090 ± 0.0034

γTE 20 µM
0.018 ± 0.0046*
0.033 ± 0.0077**
0.042 ± 0.0082**

C18:0-dhCer
Hours
8
16
24
C20:0-dhCer
Hours
8
16
24
C22:0-dhCer
Hours
8
16
24
C24:1-dhCer
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Control
0.010 ± 0.004
0.021 ± 0.006
0.031 ± 0.003

γTE 20 µM
0.060 ± 0.010*
0.14 ± 0.016**
0.17 ± 0.026**

Control
0.010 ± 0.004
0.046 ± 0.011
0.059 ± 0.014

γTE 20 µM
0.035 ± 0.007*
0.075 ± 0.004*
0.084 ± 0.015

Control
0.00063 ± 0.0004
0.0025 ± 0.001
0.0027 ± 0.001

γTE 20 µM
0.0093 ± 0.002
0.037 ± 0.010**
0.034 ± 0.011*

Hours
8
16
24
Total dhCers

Control
0.00069 ± 0.0007
0.00092 ± 0.0007
0.0013 ± 0.0008

γTE 20 µM
0.0022 ± 0.0011
0.011 ± 0.0060
0.0063 ± 0.0054

Hours
8
16
24

Control
0.12 ± 0.035
0.26 ± 0.029
0.32 ± 0.035

γTE 20 µM
0.45 ± 0.045
2.66 ± 0.16**
4.65 ± 0.82**

Hours
8
16
24
C24:0-dhCer
Hours
8
16
24
C26:1-dhCer
Hours
8
16
24
C26:0-dhCer

Sphingoid bases (pmol/µg PC)
Sph
Control
0.42 ± 0.18
0.30 ± 0.080
0.30 ± 0.067

γTE 20 µM
0.40 ± 0.11
0.40 ± 0.053
0.48 ± 0.048*

Hours
8
16
24

Control
0.046 ± 0.013
0.043 ± 0.007
0.051 ± 0.007

γTE 20 µM
0.12 ± 0.015
2.46 ± 0.39*
5.89 ± 0.98**

Hours

Control

γTE 20 µM

Hours
8
16
24
dhSph

S1P
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8
16
24

0.021 ± 0.002
0.0087 ± 0.001
0.013 ± 0.005

0.019 ± 0.004
0.012 ± 0.002
0.016 ± 0.002

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
8
16
24

Control
39.09 ± 8.17
56.18 ± 6.99
52.58 ± 7.07

γTE 20 µM
26.99 ± 4.48**
37.93 ± 4.40**
37.78 ± 5.14**

Control
0.47 ± 0.19
0.63 ± 0.15
0.53 ± 0.12

γTE 20 µM
0.44 ± 0.14
1.12 ± 0.20**
1.55 ± 0.32**

Control
0.43 ± 0.18
0.53 ± 0.12
0.51 ± 0.13

γTE 20 µM
0.40 ± 0.17*
0.81 ± 0.22*
0.95 ± 0.25*

Control
1.62 ± 0.69
2.17 ± 0.45
2.64 ± 1.03

γTE 20 µM
1.57 ± 0.66
2.65 ± 0.72
3.20 ± 1.29

Control
6.23 ± 2.44
8.72 ± 1.66
10.37 ± 3.44

γTE 20 µM
6.32 ± 2.22
9.65 ± 2.07
10.50 ± 3.77

Control
0.29 ± 0.13
0.40 ± 0.094
0.60 ± 0.27

γTE 20 µM
0.36 ± 0.16**
0.76 ± 0.18**
1.00 ± 0.44*

Control
48.13 ± 11.76

γTE 20 µM
36.09 ± 7.71**

C18:0-SM
Hours
8
16
24
C20:0-SM
Hours
8
16
24
C22:0-SM
Hours
8
16
24
C24:1-SM
Hours
8
16
24
C26:1-SM
Hours
8
16
24
Total SMs
Hours
8
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16
24

68.62 ± 9.02
67.23 ± 11.73

52.91 ± 7.62**
54.99 ± 10.54*

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
8
16
24

Control
5.25 ± 1.88
7.32 ± 1.58
7.72 ± 1.62

γTE 20 µM
6.48 ± 2.13
18.73 ± 3.42**
26.29 ± 4.98**

Control
0.13 ± 0.074
0.11 ± 0.032
0.12 ± 0.030

γTE 20 µM
0.19 ± 0.093
1.13 ± 0.25**
1.54 ± 0.37**

Control
0.24 ± 0.20
0.10 ± 0.035
0.12 ± 0.038

γTE 20 µM
0.15 ± 0.092
0.56 ± 0.14**
0.74 ± 0.23**

Control
0.30 ± 0.20
0.26 ± 0.11
0.34 ± 0.12

γTE 20 µM
0.35 ± 0.24
0.82 ± 0.27**
0.96 ± 0.38**

Control
0.41 ± 0.33
0.37 ± 0.22
0.51 ± 0.21

γTE 20 µM
0.41 ± 0.32
0.73 ± 0.27**
0.94 ± 0.36*

Control
0.031 ± 0.027
0.025 ± 0.013
0.034 ± 0.015

γTE 20 µM
0.032 ± 0.025
0.15 ± 0.052**
0.24 ± 0.094*

Control
6.37 ± 2.72
8.19 ± 1.92

γTE 20 µM
7.61 ± 2.89
22.13 ± 4.32**

C18:0-dhSM
Hours
8
16
24
C20:0-dhSM
Hours
8
16
24
C22:0-dhSM
Hours
8
16
24
C24:0-dhSM
Hours
8
16
24
C26:0-dhSM
Hours
8
16
24
Total dhSMs
Hours
8
16
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24

8.84 ± 1.98

30.71 ± 6.19**

Table 2.2 Effect of γTE on sphingolipid metabolism in MCF-7 cells. MCF-7 cells were
treated with 20 µM γTE for 8, and 16 h. The amount of each sphingolipid was determined
by LC-MS/MS. Data are mean ± SEM of 5 independent experiments. *p < 0.05, **p <
0.01, significant difference between control and γTE-treated cells.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
8
16

Control
1.68 ± 0.28
1.90 ± 0.30

γTE 20 µM
1.32 ± 0.29*
3.61 ± 0.89**

Control
0.15 ± 0.030
0.16 ± 0.029

γTE 20 µM
0.12 ± 0.023
0.39 ± 0.13**

Control
0.039 ± 0.009
0.039 ± 0.008

γTE 20 µM
0.035 ± 0.009
0.10 ± 0.031**

Control
0.20 ± 0.040
0.22 ± 0.057

γTE 20 µM
0.16 ± 0.042
0.34 ± 0.12*

Control
6.08 ± 1.91
6.98 ± 2.22

γTE 20 µM
4.44 ± 1.11
7.66 ± 2.29

Control
1.32 ± 0.41
1.44 ± 0.42

γTE 20 µM
0.75 ± 0.18**
0.99 ± 0.31**

Control
0.12 ± 0.037
0.18 ± 0.043

γTE 20 µM
0.092 ± 0.022
0.11 ± 0.036**

C18:0-Cer
Hours
8
16
C20:0-Cer
Hours
8
16
C22:0-Cer
Hours
8
16
C24:1-Cer
Hours
8
16
C24:0-Cer
Hours
8
16
C26:1-Cer
Hours
8
16
C26:0-Cer
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Hours
8
16
Total Cers
Hours
8
16

Control
0.019 ± 0.011
0.028 ± 0.015

γTE 20 µM
0.018 ± 0.009
0.017 ± 0.009

Control
9.61 ± 2.41
10.96 ± 2.70

γTE 20 µM
6.93 ± 1.38
13.21 ± 3.26

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
8
16

Control
0.11 ± 0.030
0.15 ± 0.036

γTE 20 µM
0.22 ± 0.047
1.76 ± 0.43**

Control
0.0036 ± 0.001
0.0033 ± 0.0005

γTE 20 µM
0.0056 ± 0.001
0.10 ± 0.036*

Control
0.00058 ± 0.0001
0.00090 ± 0.0002

γTE 20 µM
0.0016 ± 0.0003*
0.022 ± 0.0080**

Control
0.0017 ± 0.0003
0.0029 ± 0.0005

γTE 20 µM
0.0041 ± 0.001
0.030 ± 0.009*

Control
0.025 ± 0.010
0.036 ± 0.016

γTE 20 µM
0.098 ± 0.026*
0.33 ± 0.095*

Control
0.00093 ± 0.0009
0.0019 ± 0.0012

γTE 20 µM
0.0061 ± 0.0053
0.028 ± 0.016

Control
0.14 ± 0.036
0.20 ± 0.042

γTE 20 µM
0.34 ± 0.064*
2.28 ± 0.52**

C18:0-dhCer
Hours
8
16
C20:0-dhCer
Hours
8
16
C22:0-dhCer
Hours
8
16
C24:1-dhCer
Hours
8
16
C24:0-dhCer
Hours
1
2
Total dhCers
Hours
8
16
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Sphingoid bases (pmol/µg PC)
Sph
Hours
8
16

Control
0.72 ± 0.14
0.80 ± 0.17

γTE 20 µM
0.40 ± 0.10*
0.58 ± 0.11**

Control
0.047 ± 0.014
0.059 ± 0.016

γTE 20 µM
0.054 ± 0.019
0.21 ± 0.058**

Control
0.019 ± 0.004
0.019 ± 0.005

γTE 20 µM
0.021 ± 0.003
0.017 ± 0.005

dhSph
Hours
8
16
S1P
Hours
8
16

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
8
16

Control
20.72 ± 7.15
25.80 ± 7.59

γTE 20 µM
19.42 ± 4.81
20.93 ± 5.51**

Control
1.46 ± 0.34
1.79 ± 0.21

γTE 20 µM
1.51 ± 0.19
1.70 ± 0.22

Control
1.02 ± 0.13
1.37 ± 0.073

γTE 20 µM
1.16 ± 0.030
1.50 ± 0.088

Control
1.44 ± 0.67
1.86 ± 0.67

γTE 20 µM
1.54 ± 0.57
2.05 ± 0.85

Control
10.15 ± 3.43
12.38 ± 3.41

γTE 20 µM
10.40 ± 2.67
11.44 ± 2.94

Control

γTE 20 µM

C18:0-SM
Hours
8
16
C20:0-SM
Hours
8
16
C22:0-SM
Hours
8
16
C24:1-SM
Hours
8
16
C26:1-SM
Hours
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8
16

3.32 ± 0.53
4.29 ± 0.89

3.84 ± 0.42
5.23 ± 0.48

Control
38.11 ± 12.10
47.50 ± 12.38

γTE 20 µM
37.86 ± 8.36
42.85 ± 9.89

Total SMs
Hours
8
16

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
8
16

Control
3.69 ± 1.00
4.81 ± 0.94

γTE 20 µM
5.66 ± 0.95**
10.91 ± 1.51**

Control
0.29 ± 0.078
0.36 ± 0.045

γTE 20 µM
0.50 ± 0.067
1.10 ± 0.037**

Control
0.29 ± 0.044
0.41 ± 0.064

γTE 20 µM
0.48 ± 0.078**
1.09 ± 0.092**

Control
0.17 ± 0.048
0.21 ± 0.042

γTE 20 µM
0.23 ± 0.048
0.43 ± 0.11*

Control
0.13 ± 0.031
0.17 ± 0.011

γTE 20 µM
0.21 ± 0.023
0.41 ± 0.031**

Control
0.056 ± 0.014
0.11 ± 0.057

γTE 20 µM
0.069 ± 0.025
0.17 ± 0.043

Control
4.62 ± 1.16
6.07 ± 0.97

γTE 20 µM
7.14 ± 1.03*
14.11 ± 1.52**

C18:0-dhSM
Hours
8
16
C20:0-dhSM
Hours
8
16
C22:0-dhSM
Hours
8
16
C24:0-dhSM
Hours
8
16
C26:0-dhSM
Hours
8
16
Total dhSMs
Hours
8
16

86

Table 2.3 Effect of γTE on de novo sphingolipid biosynthesis in HCT-116 cells. HCT116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as control or
with a combination of 400 µM 13C3, 15N-labeled L-serine and 20 µM γTE for 0.5, 2, 3,
and 6 h. The amount of each labeled de novo sphingolipid was determined by LCMS/MS. Data are mean ± SEM of 3 independent experiments. *p < 0.05, **p < 0.01,
significant difference between control and γTE-treated cells.

Ceramides (pmol/µg PC)
De novo C16:0-Cer
Hours
0.5
2
3
6

Control
0.10 ± 0.018
0.54 ± 0.025
0.65 ± 0.045
0.64 ± 0.004

γTE 20 µM
0.090 ± 0.015
0.44 ± 0.023**
0.35 ± 0.033**
0.19 ± 0.008**

Control
0.16 ± 0.024
0.69 ± 0.087
0.85 ± 0.096
0.89 ± 0.029

γTE 20 µM
0.15 ± 0.008
0.78 ± 0.15
0.80 ± 0.029
0.55 ± 0.029**

Control
0.13 ± 0.020
0.52 ± 0.069
0.68 ± 0.087
0.88 ± 0.086

γTE 20 µM
0.12 ± 0.003
0.55 ± 0.10
0.57 ± 0.049*
0.43 ± 0.027**

Control
0.38 ± 0.058
1.75 ± 0.18
2.18 ± 0.20
2.41 ± 0.12

γTE 20 µM
0.36 ± 0.023
1.77 ± 0.27
1.71 ± 0.060*
1.18 ± 0.050**

De novo C24:1-Cer
Hours
0.5
2
3
6
De novo C24:0-Cer
Hours
0.5
2
3
6
De novo total Cers
Hours
0.5
2
3
6

Dihydroceramides (pmol/µg PC)
De novo C16:0-dhCer
Hours
0.5

Control
0.011 ± 0.002

γTE 20 µM
0.010 ± 0.002
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2
3
6

0.026 ± 0.005
0.030 ± 0.006
0.042 ± 0.007

0.039 ± 0.011*
0.052 ± 0.012**
0.11 ± 0.022**

De novo C24:1-dhCer
Hours
0.5
2
3
6

γTE 20 µM
0.0015 ± 0.0006
0.0062 ± 0.003
0.0074 ± 0.002
0.021 ± 0.004*

Control
0.00094 ± 0.0003
0.0025 ± 0.001
0.0025 ± 0.0009
0.0038 ± 0.0009

De novo C24:0-dhCer
γTE 20 µM
0.0018 ± 0.001
0.0033 ± 0.002
0.0048 ± 0.003
0.012 ± 0.006

Hours
Control
0.5
0.0010 ± 0.001
2
0.0031 ± 0.002
3
0.0025 ± 0.001
6
0.0051 ± 0.003
De novo total dhCers
Hours
0.5
2
3
6

γTE 20 µM
0.014 ± 0.003
0.049 ± 0.015*
0.064 ± 0.016**
0.15 ± 0.032**

Control
0.013 ± 0.003
0.032 ± 0.007
0.035 ± 0.008
0.051 ± 0.010

Sphingoid bases (pmol/µg PC)
De novo Sph
Hours
0.5
2
3
6

Control
0.038 ± 0.024
0.072 ± 0.021
0.065 ± 0.008
0.078 ± 0.008

γTE 20 µM
0.022 ± 0.011
0.062 ± 0.005
0.054 ± 0.021
0.034 ± 0.012**

Sphingomyelins (pmol/µg PC)
De novo C16:0-SM
Hours
0.5
2
3
6
De novo C18:0-SM

Control
0.35 ± 0.10
0.77 ± 0.21
1.18 ± 0.40
2.74 ± 0.64

γTE 20 µM
0.31 ± 0.071
0.97 ± 0.29*
1.43 ± 0.32
2.61 ± 0.50
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Hours
0.5
2
3
6

Control
0.011 ± 0.003
0.013 ± 0.002
0.012 ± 0.004
0.024 ± 0.004

γTE 20 µM
0.011 ± 0.002
0.012 ± 0.004
0.016 ± 0.005
0.045 ± 0.014*

Control
0.11 ± 0.031
0.18 ± 0.051
0.27 ± 0.090
0.54 ± 0.12

γTE 20 µM
0.14 ± 0.029
0.24 ± 0.077**
0.38 ± 0.16
1.47 ± 0.73

Control
0.47 ± 0.13
0.96 ± 0.27
1.46 ± 0.50
3.31 ± 0.76

γTE 20 µM
0.45 ± 0.10
1.22 ± 0.37**
1.83 ± 0.48
4.13 ± 1.22

De novo C24:1-SM
Hours
0.5
2
3
6
De novo total SMs
Hours
0.5
2
3
6

Dihydrosphingomyelins (pmol/µg PC)
De novo C16:0-dhSM
Hours
0.5
2
3
6

Control
0.10 ± 0.020
0.18 ± 0.029
0.24 ± 0.039
0.52 ± 0.045

γTE 20 µM
0.10 ± 0.012
0.27 ± 0.055*
0.39 ± 0.084**
1.51 ± 0.17**
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Discussion

Our current study demonstrates that γTE induced apoptosis and autophagy in
human colon cancer cells by modulating sphingolipids metabolism. γTE treatment caused
huge accumulation of intracellular dhSph and dhCers, important sphingolipid
intermediates in de novo biosynthesis pathway, which appear to mediate cell death (Ahn
and Schroeder, 2002; Jiang et al., 2004). In particular, γTE led to increase in de novo
dhCers and decrease in de novo Cers as early as after 2 h incubation and these changes
intensified during prolonged treatment, supporting the notion that DEGS is inhibited by
γTE. Consistently, γTE inhibited DEGS activity without affecting its protein expression.
Importantly, the modulation of these sphingolipids by γTE occurred prior to any signs of
cell death. Moreover, individual Cers, which appear to have distinct bioactivities
(Hannun and Obeid, 2011; Senkal et al., 2010; Sentelle et al., 2012), showed different
responses by γTE treatment. γTE treatment led to significant decrease in C16:0-Cer at 8 h,
but showed no difference at 16 h or increase at 24 h, compared with controls. On the
other hand, while C24-Cers decreased from 8 to 24 h, C18:0-Cer increased from 16 h by
γTE. Interestingly, SM decreased from 8 h but cells showed obvious apoptosis or
autophagy only at 16 h or longer treatment with γTE. In addition, chemically blocking the
increase of dhSph and dhCers, or the increase of Cers via SM hydrolysis by myriocin or
desipramine, repectively, partially counteracted γTE-caused cell death, indicating that
modulation of sphingolipids plays an important role in γTE-induced cancer cell death.
We showed that γTE led to marked accumulation of dhSph and dhCers in human
colon and breast cancer cells. On the other hand, we did not observe a significant increase
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of total Cers until the prolonged treatment with γTE. Although sphingosine and Cer have
long been recognized and studied as pivotal apoptosis-inducing molecules (Woodcock,
2006), emerging evidence suggests that other sphingolipid intermediates in the de novo
biosynthesis pathway also play important roles in determining cell fate (Ahn and
Schroeder, 2002; Jarvis et al., 1996; Kraveka et al., 2007; Ohta et al., 1995; Signorelli et
al., 2009; Solomon et al., 2003; Zheng et al., 2006). For instance, previous studies in our
group found that γT, the predominant form of vitamin E in US diet, as well as γTE
enhanced the intracellular levels of dhSph and dhCers which played significant roles in
the induction of apoptosis and autophagy in human prostate and breast cancer cells
(Gopalan et al., 2012; Jiang et al., 2012; Jiang et al., 2004). Consistent with these studies,
co-treatment of cells with myriocin, a specific inhibitor of the first reaction in the de novo
sphingolipid synthesis pathway to block the increase of these two sphingoid bases,
partially but significantly reversed γTE-induced colon cancer cell death, indicating that
the accumulation of dhSph and dhCers plays important roles in γTE-induced colon cancer
cell death.
We identified that DEGS, an enzyme for the conversion of dhCer to Cers, is the
initial target of γTE in its modulation of sphingolipid metabolism followed by cancer cell
death. Specifically, in the serine-labeled study with γTE to only trace the effect of γTE on
de novo biosynthesis pathway of sphingolipids, γTE caused rapid increase of de novo
dhCers, but significant decrease of de novo Cers as early as after 2 h incubation,
suggesting that DEGS-catalyzed reaction is likely to be inhibited as a result of γTE
treatment (Fig. 2.3). Consistently, γTE inhibited DEGS activity in both in situ and in vitro
assays, having no impact on its protein expression (Fig. 2.4). However, it is worth noting
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that higher concentration of γTE was needed to have its inhibitory effect on DEGS
activity when we used rat liver microsomes as an enzyme source. It may be due to
limitation in permeability through the microsomal membrane of γTE under the cell-free
environment.
DEGS is a key enzyme regulating the balance of dhCer and Cer as it catalyzes the
insertion of a 4,5-trans-double bond into dhCer to generate Cer. Michel et al. first
reported the biochemical characterization of the DEGS reaction in 1997 using rat liver
microsomes (Michel et al., 1997). They have shown that the DEGS uses molecular
oxygen as electron acceptor to have a hydroxyl group into the C4-position of the dhSph,
and then with NADH or NADPH as electron donor, a dehydration reaction occurs to
produce a double bond in the C4-C5 position of dhCer. Therefore, they confirmed that
the conversion of dhCer to Cer was occurred by a desaturase, not by a dehydrogenase.
Two different DEGSs, DEGS1 and DEGS2, have been so far reported. In bioinformatics
approach, Ternes et al. identified a family of sphingolipid Δ4-desaturases (homologs of
the Drosophila melanogaster degenerative spermatocyte gene 1 (des-1)). DEGS-1, the
human homolog of des-1, exhibits high dhCer Δ4-desaturase and very low C-4
hydroxylase activities, whereas DEGS2, another ortholog identified in mouse and human,
is similarly active as both sphinglipid C-4 hydroxylase and Δ4-desaturase activities,
resulting in the production of either phyto-Cer or Cer. Recently, DEGS activity was also
found to be inhibited by resveratrol (Signorelli et al., 2009), celecoxib (Schiffmann et al.,
2009b), fenretinide (Rahmaniyan et al., 2011), hydrogen peroxide (Idkowiak-Baldys et
al., 2010) or hypoxic environment (Devlin et al., 2011). Furthermore, as several
phytochemicals are shown to induce oxidative stress as prooxidants (Babich et al., 2011;
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Fujisawa et al., 2004; Galati et al., 2002) and oxidative stress can inhibit DEGS activity
followed by dhCer accumulation (Idkowiak-Baldys et al., 2010), we investigated whether
γTE also inhibits DEGS activity by acting as prooxidant. However, we found that Nacetylcysteine (NAC), an antioxidant, did not reverse γTE-induced modulation of
sphingolipid metabolism (Fig. 2.7), suggesting that the inhibition of DEGS by γTE is not
affected by NAC and these sphingolipid modulation did not caused by prooxidant effects
of γTE.
In addition to the accumulation of dhSph and dhCers, γTE treatment had an
impact on Cer species. Interestingly, the effects of γTE on specific Cer species were
different. For instance, γTE treatment led to significant decrease in C16:0-Cer during the
initial phase, but increase in the longer time treatment. While γTE caused increase in
C18:0-Cer, it led to continuous decreases in C24:1- and C24:0-Cers. Interestingly, recent
emerging results suggest that endogenous Cers with different fatty acyl-chain lengths
appear to have distinct bioactivities. C18:0-Cer generated by CerS1 has been found to
induce apoptosis and lethal autophagy (Senkal et al., 2010; Sentelle et al., 2012). In
contrast, C16:0-Cer generated by CerS5/6 have been proposed to have opposed roles of
anti-apoptosis to C18:0-Cer (Senkal et al., 2010). However, several other studies found
that this Cer also plays important roles in apoptotic cell death (Mullen et al., 2011;
Schiffmann et al., 2009b; White-Gilbertson et al., 2009). Therefore, further investigation
should be conducted to determine the role of individual Cer species and to characterize
the effects of γTE on individual CerSs and Cers.
During prolonged treatment, γTE led to increase in Cers, especially C16:0- and
C18:0-Cers, but decrease in SMs. Two main enzymes may contribute to the levels of Cers
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and SMs, which are SMSs in the de novo synthesis pathway and SMases in the SM
hydrolysis. In our de novo sphingolipids studies using 13C3, 15N- L-serine, we found that
since labeled C16:0-Cer is still decreased and the conversion of C16:0-Cer to C16:0-SM is
stimulated at the initial stage of γTE treatment, we reason that the increase of Cers in the
longer time treatment is likely caused by SM hydrolysis via the action of SMases. Cotreatment of cells with desipramine but not GW4869 partially but significantly
counteracted γTE-induced cancer cell death, indicating that the increase of Cers from
SMs through acid SMase-catalyzed SM hydrolysis may in part involved in γTE-induced
colon cancer cell death.
In summary, our data strongly suggest that γTE-induced apoptosis, autophagy and
cell death are mediated by modulation of sphingolipid metabolism as its primary target.
The lipidomic analysis using LC-MS/MS reveals that γTE-exerted anticancer effects are
caused by initial inhibition of DEGS activity and subsequent activation of SM hydrolysis
via acid SMase.
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CHAPTER 3. 13’-CARBOXYCHROMANOLS, LONG-CHAIN VITAMIN E
METABOLITES, INDUCE APOPTOSIS AND AUTOPHAGY BY
MODULATING SPHINGOLIPID METABOLISM IN DIFFERENT TYPES OF
CANCER CELLS

3.1

Abstract

13’-Carboxychromanol (13’-COOH) is a major vitamin E metabolite excreted in
feces. Here we investigated anticancer activities of δT-13’-COOH and δTE-13’-COOH,
which are metabolites of delta-tocopherol (δT) or delta-tocotrienol (δTE), respectively.
Both 13’-COOHs inhibited the growth and induced apoptosis and autophagy in human
colon (HCT-116, HT-29), breast (MCF-7), and pancreatic (PANC-1, MiaPaca-2) cancer
cells with the IC50 of 8-20 µM. In these activities, 13’-COOHs were much stronger than
tocopherols. Using liquid chromatography tandem mass spectrometry, we found that δT13’-COOH increased intracellular dihydrosphingosin and dihydroceramides but
decreased C16:0-ceramide within 2 h treatment. During longer treatment, δT-13’-COOH
enhanced all sphingoid bases including ceramides while decreased sphingomyelins.
Modulation of sphingolipids by 13’-COOHs was observed prior to or coinciding with
appearance of cell death markers including PARP cleavage and LC3-II increase. The
importance of sphingolipid modulation was supported by the observation that
pharmaceutically blocking the increase of these sphingolipids partially counteracted 13’-
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COOH-induced cell death. Further mechanistic studies indicated that 13’-COOH
inhibited dihydroceramide desaturase without affecting its protein expression and may
activate sphingomyelin hydrolysis to enhance ceramides. In agreement with these cellbased studies, δTE-13’-COOH significantly decreased colon tumor multiplicity induced
by AOM with two cycles of 1.5% DSS without any apparent toxicity even when the
dietary supplementation was started after AOM injection. Moreover, δTE-13’-COOH
attenuated 1.8% DSS-induced colon inflammation, indicating that δTE-13’-COOH is
able to attenuate colitis and its promoted tumorigenesis in vivo. Our mechanistic study
demonstrates that 13’-COOHs have potent anticancer effects by modulating enzyme
activities in sphingolipid metabolism in cancer cells.

3.2

Introduction

Cumulative cancer risk is estimated to be 30% and 22% in men and women,
respectively, by age 75 in developed area worldwide (Jemal et al., 2011). Natural forms
of vitamin E that consist of α-, β-, γ- and δ-tocopherol (αT, βT, γT and δT) and α-, β-, γand δ-tocotrienol (αTE, βTE, γTE and δTE), are potentially good cancer
chemoprevention agents as they are known to be safe and specific forms of vitamin E
have been shown to have cancer prevention effects. Specifically, γT, mixed tocopherols
and tocotrienols have been demonstrated to inhibit the development of colon, prostate
and breast cancer in various preclinical models (Jiang, 2014; Moya-Camarena and Jiang,
2012). Despite these exciting findings, the anticancer effects may not directly be rooted
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in vitamin E alone because many forms of vitamin E are not highly bioavailable as a
result of their extensive metabolism in vivo.
Tocopherols and tocotrienols, with exception for αT, are readily metabolized by
cytochrome P450-catalyzed ω-hydroxylation and oxidation to 13’-carboxychromanols
(13’-COOH), which are then further catabolized via β-oxidation to generate various
shorter chain carboxychromanols or sulfation to form sulfated carboxychromanols (Jiang,
2014; Jiang et al., 2007; Sontag and Parker, 2002). Importantly, carboxychromanols and
their sulfated counterparts have been detected in rodent plasma and liver upon
supplementation of γT and γTE (Freiser and Jiang, 2009; Jiang et al., 2007). Recently,
long-chain carboxychromanols are found at high levels in feces from mice fed diet
supplemented with γT or δT, and 13’-COOHs appear to be major fecal excreted
carboxychromanols (Bardowell et al., 2012a; Bardowell et al., 2012b; Jiang et al., 2013).
Considering significant quantities of carboxychromanols in vivo, it is of importance to
examine potential bioactivities of these metabolites.
Emerging studies have demonstrated that long-chain carboxychromanols have
interesting bioactivities that are relevant to disease prevention and therapy (Jiang, 2014).
In particular, we have demonstrated that δT-13’-COOH, a long-chain carboxychromanol
from δT, competitively inhibits cyclooxygenase (COX-1 and COX-2) (Jiang et al., 2008)
and is much stronger than short-chain carboxychromanols and unmetabolized vitamin E
forms in these effects. δT-13’-COOH also inhibits 5-lipoxygenase (5-LOX) activity,
whereas vitamin E forms do not inhibit the enzyme directly (Jiang et al., 2011). These
results indicate that δT-13’-COOH is a unique dual inhibitor of COX-1/COX-2 and 5LOX (Jiang, 2014; Jiang et al., 2008; Jiang et al., 2011), and is therefore useful as anti-
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inflammatory and anticancer agents as both COXs and 5-LOX have been recognized to
play significant roles in inflammation and cancer (Wang and Dubois, 2010). In addition,
Birringer et al. (Birringer et al., 2010) demonstrated that 13’-COOHs metabolized from
αT or δT induced apoptosis in human HepG2 cells. However, the anticancer study of
13’-COOHs was limited to this liver cell line and the underlying mechanism was not
completely understood. In the present study, we investigated the effect of δT-13’-COOH
and δTE-13’-COOH (a metabolite from δTE) (Fig. 3.1) on the proliferation of various
types of cancer cells including colon, pancreas, and breast. Since vitamin E forms have
been shown to exert anticancer effects via modulating sphingolipids (Jiang et al., 2012;
Jiang et al., 2004), we further investigated whether 13’-COOHs are capable of altering
sphingolipid metabolism and the role of modulation of sphingolipids in 13’-COOHexerted anticancer activities. We also examined the anti-inflammatory effects and
anticancer efficacy of δTE-13’-COOH supplementation against DSS-caused colon
inflammation and AOM-induced and DSS-promoted colon tumorigenesis in male Balb/c
mice, respectively.
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Figure 3.1 The structures of (A) natural forms of vitamin E and (B) 13’-COOHs, vitamin
E metabolites of δT and δTE.
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3.3

Materials and Methods

3.3.1

Materials and reagents

δT-13’-COOH and δTE-13’-COOH (>95% pure) were synthesized as previously
described (Maloney and Hecht, 2005). γT (≥96%) and δT (93-97%) were purchased from
Sigma (St Louis, MO) and Suppleco (Bellefonte, PA), and γTE (97-99%) was a gift from
BASF (Ludwigshafen, Germany). C8-cyclopropenylceramide (C8-CPPC) was purchased
from Matreya LLC (Pleasant Gap, PA). All sphingolipid standards were obtained from
Avanti Polar Lipids (Alabaster, AL). CHAPS (3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulfonate) was purchased from Thermo Fisher Scientific.
Myriocin from Mycelia Sterilia, 13C3, 15N-labeled L-serine, dimethyl sulfoxide (DMSO),
[3-(4,5)-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide] (MTT), and all other
chemicals were from Sigma.

3.3.2

Cell culture and treatment

Human colon (HCT-116 and HT-29), breast (MCF-7), and pancreatic (PANC-1
and MiaPaCa-2) cancer cells, and human normal colonic epithelial CCD841CoN cells
were obtained from American Type Culture Collection (Manassas, VA). Cells were
routinely cultured in growth media containing 10% fetal bovine serum (FBS) at 37 °C in
5% CO2. HT-29 and PANC-1 cells were cultured in Dulbecco’s modified eagle medium
(DMEM), and HCT-116 cells were cultured in McCoy’s 5A modified medium. MCF-7
and MiaPaCa-2 cells were incubated in DMEM supplemented with 2.5% horse serum or
0.1% insulin, respectively. CCD841CoN cells were cultured in Eagle’s minimum
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essential medium (EMEM). For experiments, cells were seeded in the corresponding
medium with 10% FBS either at a density of 4 x 104 cells/well in 24-well plates or at a
density of 7-8 x 105 cells in 10-cm dishes. After overnight attachment, media were
replaced with fresh DMEM containing 1% FBS and 13’-COOHs or other compounds. All
the treatment solutions were freshly prepared for each experiment. Vitamin E forms were
dissolved in DMSO at 100 mM and then diluted to fatty acid-free BSA (10 mg/ml).

3.3.3

MTT assay

Cell viability was examined by MTT assay to estimate mitochondrial
dehydrogenase activity as previously described (Jiang et al., 2004).

3.3.4

Flow cytometry with Annexin V and Propidium Iodide staining

Both floating and attached cells were collected by trypsinization after treatment.
Cells were stained with Annexin-V-Flous staining kit (Roche Applied Science,
Indianapolis, IN), and apoptosis (Annexin V: Ex = 488 nm; Em = 518 nm) and necrosis
(Propidium Iodide: Ex = 488-540 nm; Em = 617 nm) were evaluated by Beckman
Coulter FC500 (Beckman Coulter, Miami, FL) and BD FACS Aria III cell sorter (BD
Biosciences, San Jose, CA) with FlowJo software system.

3.3.5

Western Blotting

Cells were lysed in lysis buffer containing Tris-EDTA, 1% SDS, 2 mM Na3VO4
and protease inhibitor cocktails (Sigma). Total proteins were quantified by bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL) and were denatured by boiling in
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Laemmli buffer (Bio-rad, Hercules, CA) for 5 min at 95 °C. Equal amount of proteins
(15-30 µg) were separated on acrylamide gels by SDS-electrophoresis and then
transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Bilerica, MA),
and probed by antibodies. Membranes were exposed to chemiluminescent reagent
(PerkinElmer, Waltham, MA) and visualized on Kodak film with an M35A X-Omat
processor (Kodak, Rochester, NY). The antibodies used in the study were as follows:
membrane bound microtubule-associated protein light chain 3 (LC3; MBL international,
Woburn, MA), Caspase-9, poly (ADP-ribose) polymerase-1 (PARP-1) and Actin (Santa
Cruz Biotechnology, Santa Cruz, CA), and DEGS1 (Novus Biologicals, Littleton, CO).

3.3.6

Lipid extraction

Lipid was extracted as previously described (Merrill et al., 2005). Briefly, cell
pellets were resuspended in 500 µL of methanol, 250 µL of chloroform and 50 µL of
water after the addition of 20 µL of internal standard mixture containing 25 µM of C12:0ceramide, C25:0-ceramide, C17-sphingosine, C17-sphinganine, and C12:0-sphingomyelin
(Avanti Polar Lipids, Alabaster, AL). The suspension was dispersed fully by tip
sonication for 20 sec and then incubated overnight at 48 °C. 100 µL of solvent was used
to determine the amount of total choline-containing phospholipids by an enzymatic
colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang et al., 2004). 75 µL of 1M
potassium hydroxide in methanol was added to the rest of the solvent and sonicated for
30 min. After sonication, samples were incubated at 37 °C for 2 h and evaporated under a
stream of nitrogen.
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3.3.7

Measurement of sphingolipids using liquid chromatography tandem mass
spectrometry (LC-MS/MS)

Samples were resolved in methanol and sonicated to disperse, then centrifuged to
clarify before transferring to test vials for quantification. The LC-MS/MS analyses were
performed using the Agilent 6460 triple quadrupole mass spectrometer coupled with the
Agilent 1200 Rapid Resolution HPLC (Agilent Technologies, Santa Clara, CA) with
detection of sphingolipids in positive mode by multiple reaction monitoring (MRM)
technique (Merrill et al., 2005). The HPLC mobile phases consisted of methanol-H2Oformic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v; RB); both RA and
RB contain 5 mM ammonium formate. For measurement of Cers and sphingoid bases,
Agilent column XDB-C18, particle size 1.8 µm, 4.6 x 50 mm was used with isocratic run
(100% B) or gradient (0-1 min, 20% B, 10-13 min, 100% B and 15-20 min at 20% B),
respectively. For measurement of SMs, Agilent Zorbax XDB-C8, particle size 3.5 µm,
2.1 x 50 mm was used with gradient (0-1 min, 20% B, 10-20 min, 100% B, 22-30 min,
20% B). The MS/MS parameters were as follows: gas temperature, 325-350 °C; gas flow
rate, 7-10 L/min; nebulizer pressure, 45-50 psi; capillary voltage, 3500 V; The
fragmentor voltage was 100 V and collision energy was 12-20 V. Precursor-to-product
ion transitions for each sphingolipid were used according to the method of Merrill et al.
(Merrill et al., 2005).

3.3.8

De novo sphingolipids analysis

HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone
or with a combination of 400 µM 13C3, 15N-labeled L-serine and 20 µM of δT-13’-COOH
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for 0.5, 1, 1.5, 2 and 4 h. Lipid was extracted and de novo synthesized sphingolipids were
measured using LC-MS/MS.

3.3.9 Dihydroceramide desaturase (DEGS) assay
For the in vitro assay of DEGS, HCT-116 cells were treated with either 20 µM
δT-13’-COOH or 1 µM C8-CPPC for 1 or 2 h. Cells were collected and homogenized in
a buffer (5 mM Hepes, pH 7.4, containing 50 mM sucrose) and kept on ice for 10 min.
The cell homogenate was centrifuged at 250 x g for 5 min at 4 °C to remove unbroken
cells. Reaction was started by addition of C8:0-dhCer as a non-physiological substrate for
DEGS and NADH for an hour at 37 °C.
In another in vitro assay, rat liver microsomes were prepared as described
(Rahmaniyan et al., 2011). Briefly, livers from male Wistar rats were rinsed in ice-cold
PBS and homogenized in buffer (0.25 M sucrose, 10 mM HEPES, 1 mM EDTA, pH 7.4)
in ice. The homogenate was centrifuged at 800 x g for 10 min and the supernatant was
centrifuged at 10,000 x g for 15 min. The resulting supernatant was ultracentrifuged at
104,000 x g for 1 h to obtain microsomal pellet, which was then resuspended in
potassium phosphate buffer (50 mM, pH 7.4) and stored at -80 °C until use. In
preparation for the assay, C8:0-dhCer and tested compounds were dried under a stream of
nitrogen, followed by resuspension in CHAPS (1.1 mg/10 µl of water). Microsomal
fraction (500 µg of protein) was mixed with reaction buffer (20 mM bicine, pH 8.5, 50
mM NaCl, and 50 mM sucrose) and added with tested compounds, followed by 30 min
pre-incubation at room temperature. 2 mM of NADH and 10 µM of C8:0-dhCer were
added and the mixture was incubated for 20 min at 37 °C with shaking. Lipid extraction
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was conducted directly after reaction and the products (C8:0-Cer and C8:0-SM) were
quantified by LC-MS/MS.

3.3.10 Animal studies
The animal use protocol was approved by the Animal Care and Use Committee at
Purdue University. δTE-13’-COOH was isolated from the African Garcinia kola bitter
nut according to the method described by Terashima et al. (Terashima et al., 1997), and
modified δTE-13’-COOH-enriched AIN-93G purified diet was prepared by adding 0.22
g/kg δTE-13’-COOH.
In animal study 1 (AOM-DSS study), colon tumorigenesis was initiated by
injection of azoxymethane (AOM; Sigma) and promoted by two cycles of dextran sodium
sulfate (DSS; molecular weight of 36,000-50,000, MP Biochemicals, Solon, OH) at 1.5%
in drinking water. Male Balb/c mice at 5-6 weeks of age from Harlan (Indianapolis, IN)
were injected a dose of AOM (9.5 mg/kg body weight, i.p.) or the vehicle (sterile saline)
after a week of acclimatization. A week later, AOM-injected mice were randomized into
control or δTE-13’-COOH-supplemented groups, and they were given 1.5% DSS in
drinking water for 1 week. The mice were started to be supplemented with either AIN93G diet (for Non-AOM/DSS group; n=6, and AOM/DSS control diet group; n=17) or
δTE-13’-COOH-enriched AIN-93G diet (for AOM/DSS δTE-13’-COOH
supplementation group; n=15). Two weeks after first cycle of DSS administration, mice
in AOM/DSS groups were again given the 2nd cycle of 1.5% DSS in drinking water for a
week (Fig. 3.10A). Animals were observed and weighed daily and food intake was
measured once a week. Fecal scoring as an indicator of colitis with combined scores of
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rectal bleeding and stool consistency was evaluated daily and scored as follows (rectal
bleeding: 0 = no blood, 0.5 = feces with tiny spots of bleeding, 1 = feces with blood less
than 50% of area, 2 = feces with half-sized bleeding, and 3 = feces with blood more than
50% of area; stool consistency: 0 = normal, 1 = a little bit soft, 2 = soft, and 3 = very soft
and diarrhea). During tissue harvest, colons were removed, rinsed with cold saline, cut
open longitudinally from rectum to cecum. Lengths and weights of each colon tissue
were measured and tumors were examined.
In animal study 2 (DSS study), to investigate the anti-inflammatory effects of
δTE-13’-COOH against colitis, colon inflammation was induced by feeding mice with
one cycle of 1.8% DSS in drinking water for 8 days in 5-6-week-old male Balb/c mice
(Harlan). On the same day of DSS feeding started, the mice were supplemented with
either AIN-93G diet (for Non-DSS group; n=8, and DSS control diet group; n=12) or
δTE-13’-COOH-enriched AIN-93G diet (for DSS δTE-13’-COOH supplementation
group; n=12; Fig 3.11A). During the study, animals were observed and weighed, and
their fecal scorings were evaluated daily as described above, and food intake was
measured once at the end of the study.

3.3.11 Statistics
Statistical significance was determined using a Student’s t-test. P < 0.05 was
considered statistically significant.
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3.4

3.4.1

Results

13’-COOHs inhibited proliferation of various human cancer cells

We investigated the effect of δT- or δTE-13’-COOH on cell proliferation using
MTT assays in various human cancer cell lines. We found that δT-13’-COOH inhibited
the growth of human colon (HCT-116, HT-29), breast (MCF-7) and pancreatic (PANC-1,
MiaPaCa-2) cancer cells in a time- and dose-dependent manner (Fig. 3.2A) with the IC50
values (estimated after 24 h incubation) of 8.9 µM, 8.6 µM and 13.5 µM in HCT-116,
HT-29, and MCF-7 cells, respectively. In addition, δTE-13’-COOH also showed
antiproliferative effects with IC50 values (at 24 h) of 16 µM, 17 µM and 19.7 µM in
HCT-116, HT-29, and MCF-7 cells, respectively (Fig. 3.2B). In these activities, δT-13’COOH was more potent than δTE-13’-COOH, and both 13’-COOHs were stronger than
tocopherols (Fig. 3.2C). Interestingly, although human colon HT-29 cancer cells showed
more resistance than HCT-116 cells to the treatment of γT and γTE (Fig. 3.2C), 13’COOHs showed similar anticancer effects in both cell lines (Figs. 3.2A and B). In
addition, human normal colonic epithelial cells, CCD841CoN, were used as a control cell
line. δT-13’-COOH and δTE-13’-COOH showed about 2-fold higher IC50 values (at 24
h) in CCD841CoN cells compared with cancer cells (Fig. 3.2D).
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Figure 3.2 Anti-proliferative effects of 13’-COOHs derived from δT or δTE on various
cancer cells. (A) The effects of δT-13’-COOH on human colon (HCT-116, HT-29),
breast (MCF-7) and pancreatic (PANC-1, MiaPaCa-2) cancer cells. (B) The effects of
δTE-13’-COOH on human colon (HCT-116, HT-29) and breast (MCF-7) cancer cells.
(C) The effects of natural forms of vitamin E on human colon (HCT-116, HT-29) and
pancreatic (PANC-1) cancer cells. (D) The effects of δT-13’-COOH and δTE-13’-COOH
on human normal colonic epithelial (CCD841CoN) cells. Relative cell viability was
measured after treatment with 13’-COOHs or natural forms of vitamin E at the stated
concentrations and time by MTT assay compared with control. IC50 of 24 h is shown. The
data are mean ± SD for at least three independent experiments, each performed in
duplicate. *p < 0.05 and **p < 0.01 indicate a significant difference between treated and
control cells.

3.4.2

13’-COOHs induced apoptosis and autophagy in various types of cancer cells
Based on microscopic examination, 13’-COOHs appeared to induce cell death as

indicated by detachment and shrinkage of cells during prolonged treatment. Consistently,
both δT-13’-COOH and δTE-13’-COOH induced early and late-stage apoptosis in HCT116 cells compared with controls, as indicate by enhanced annexin V staining that is
associated with externalization of phosphatidylserine to the cytoplasmic membrane (Fig.
3.3A). Furthermore, 13’-COOHs caused PARP cleavage and caspase-9 activation (Fig.
3.3B). Similar to the results from MTT assays, δT-13’-COOH appeared to be stronger
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than δTE-13’-COOH in the induction of apoptosis. In addition to apoptosis, δT- and
δTE-13’-COOHs treatment led to an increase of LC3-II, a marker of autophagy (Fig.
3.3C). We also observed similar biochemical changes in MCF-7 cells (data not shown).
These results demonstrated that δT- and δTE-13’-COOH induced apoptosis and
autophagy in human cancer cells.
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Figure 3.3 Induction of apoptosis and autophagy by 13’-COOHs in cancer cells. (A)
HCT-116 cells were treated with 20 μM δT-13’-COOH or δTE-13’-COOH for 24 h.
Induction of apoptosis and necrosis was quantified by annexin V and PI staining.
Representative diagrams of FACS are shown here. Expression levels of (B) full-length
and cleaved caspase-9 and PARP, and (C) LC3-II in HCT-116 cells after treatment with
10 or 20 μM of δT-13’-COOH or δTE-13’-COOH were examined by western blotting.
Western blots in this figure are representative of three or more independent experiments.
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3.4.3

13’-COOHs modulated sphingolipids in HCT-116 and MCF-7 cells

We have demonstrated that modulation of sphingolipid pathway plays a role in γT
and γTE-induced death in human prostate and breast cancer cells (Gopalan et al., 2012;
Jiang et al., 2012; Jiang et al., 2004). Here we investigated effects of 13’-COOHs on
sphingolipid metabolism using LC-MS/MS. Compared with controls, δT-13’-COOH
dose-dependently increased total dihydroceramides (dhCers) (Fig. 3.4A), individual
dhCer including C16:0- (Fig. 3.4B), C18:0-, C24:1- and C24:0-dhCers (data not shown), and
dihydrosphingosine (dhSph) (Fig. 3.4C). Interestingly, δT-13’-COOH (20 μM) enhanced
C16:0-dhCer and dhSph at 1 h after incubation, which was prior to any signs of cell
morphological changes. Consequently, cells accumulated high levels of dhCers and
dhSph after incubation for 8-16 h. In contrast to dhCer, the effect of 13’-COOHs on
individual ceramides (Cer) varied with treatment time, concentrations, and specific
ceramide species. Specifically, compared with controls, δT-13’-COOH induced a
significant decrease of C16:0-Cer after 2 h incubation, but enhanced this sphingoid base
during longer treatment (8 h or 16 h incubation). δT-13’-COOH at 20 μM increased C18:0Cer after 4 h treatment, while treatment of δT-13’-COOH at 10 and 20 μM caused
opposite effects on C24-Cers (Fig. 3.4D). For sphingomyelin (SM), δT-13’-COOH led to
persistent decrease in all types of SM species starting at 2 h (Fig. 3.4E; Table 3.1).
Besides HCT-116 cells, we observed similar modulatory effects of δT-13’-COOH on
MCF-7 cells (Fig. 3.5; Table 3.2). Furthermore, δTE-13’-COOH at 20 µM induced
similar modulation of sphingolipids to that by δT-13’-COOH (Fig. 3.6; Table 3.3),
although less potent than its δT analog.
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Figure 3.4 Effects of δT-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT116 cells were treated with 10 or 20 μM δT-13’-COOH with increasing treatment times
as indicated (1, 2, 4, 8, or 16 h). The sphingolipid levels including (A) total dhCers, (B)
C16:0-dhCer, (C) dhSph, (D) total, C16:0-, C18:0-, C24:1-, and C24:0-Cers and (E) total SMs
were determined by LC-MS/MS. Results are shown as mean ± SEM for at least three
independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference
between treated and control cells.

115

Figure 3.5 Effects of δT-13’-COOH on sphingolipid metabolism in MCF-7 cells. MCF-7
cells were treated with 10 or 20 μM δT-13’-COOH for 4 h or 8 h. The sphingolipid levels
including (A) total dhCers, (B) C16:0-dhCer, (C) C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0Cer and (D) total SMs were determined by LC-MS/MS. Results are shown as mean ± SD
for two independent experiments.
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Figure 3.6 Effects of δTE-13’-COOH on sphingolipid metabolism in HCT-116 cells.
HCT-116 cells were treated with 10 or 20 μM δTE-13’-COOH for 8 h or 16 h. The
sphingolipid levels including (A) total dhCers, (B) C16:0-dhCer, (C) dhSph, (D) C16:0-Cer,
C18:0-Cer, C24:1-Cer, and C24:0-Cer and (E) total SMs were determined by LC-MS/MS.
Results are shown as mean ± SD for two independent experiments.

3.4.4

13’-COOHs modulated de novo biosynthesis of sphingolipids

Since 13’-COOHs elevated dhCer and dhSph that are important sphingoid bases
in de novo synthesis of sphingolipid pathway (Fig. 3.7A), we used 13C3, 15N-labeled Lserine, a substrate for making sphingolipids with palmitoyl-CoA, to trace the effect on the
newly synthesized sphingolipids. We observed that δT-13’-COOH treatment induced a
significant increase in labeled dhCers in a time-dependent manner (Fig. 3.7B) but
resulted in decrease of Cers including C16:0-, C24:1- and C24:0-Cers as early as 0.5 h to 2 h
(Fig. 3.7C). δT-13’-COOH significantly suppressed de novo synthesis of C16:0- and C24:1SMs (Fig. 3.7D). Despite elevation of newly-made dhCer, δT-13’-COOH significantly
reduced the total amount of newly synthesized sphingolipids (Fig. 3.7E; Table 3.4) as a
result of diminished synthesis of SM and Cer that are much more abundant than dhCer.
These results thus indicate that δT-13’-COOH inhibits overall de novo biosynthesis of
sphingolipids.
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Figure 3.7 Effects of δT-13’-COOH on de novo sphingolipid biosynthesis in HCT-116
cells. (A) The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin
synthase; SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM
13
C3, 15N-labeled L-serine alone as control or with a combination of 400 μM 13C3, 15Nlabeled L-serine and 20 μM δT-13’-COOH for 0.5, 1, 1.5, 2, and 4 h. The amount of each
labeled de novo sphingolipid including (B) total dhCers, (C) total, C16:0-, C24:1- and C24:0Cers, and (D) total, C16:0- and C24:1-SMs were determined by LC-MS/MS. (E) Total
amounts of all the de novo synthesized sphingolipids were calculated. Results are shown
as mean ± SEM for three independent experiments. *p < 0.05 and **p < 0.01 indicate a
significant difference between treated and control cells.
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3.4.5

13’-COOHs inhibited DEGS activity without affecting its protein expression

Based on the observation that δT-13’-COOH increased newly synthesized dhCers
but decreased Cers, we reason that δT-13’-COOH likely inhibits the enzyme reaction or
protein expression of dihydroceramide desaturase (DEGS), which is responsible for
addition of the 4,5-trans-double bond of dhCer (Fig. 3.7A). The western blot data
revealed that δT-13’-COOH had no effect on DEGS-1 protein expression in HCT-116
cells (Fig. 3.8A). We then examined potential effect of δT-13’-COOH on the DEGS
enzyme activity. In the in vitro DEGS assay with cell homogenates, 1 or 2 h preincubation of δT-13’-COOH inhibited DEGS activity by about 38% or 47%, respectively.
C8-CPPC, a known competitive inhibitor of DEGS (Triola et al., 2003), inhibited the
enzyme activity by about 95% (Fig. 3.8B). On the other hand, δT-13’-COOH did not
show the inhibition of DEGS enzyme activity in another in vitro DEGS assay using rat
liver microsome (data not shown).
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Figure 3.8 Effects of δT-13’-COOH on DEGS expression and activity. (A) HCT-116
cells were treated with 10 or 20 μM δT-13’-COOH for 8 or 16 h and the protein levels of
DEGS-1 and actin as a loading control were detected by western blotting. (B) HCT-116
cells were treated with either 20 μM δT-13’-COOH or 1 μM C8-CPPC as a positive
control for indirect in vitro DEGS assay. After 1 h or 2 h of treatment, cells were
collected and homogenized. Using the homogenates, reaction was started for an hour in
37 °C followed by addition of C8:0-dhCer as a substrate for DEGS with NADH. The
levels of products which are C8:0-sphingolipids were analyzed by using LC-MS/MS. The
data are mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01 indicate
a significant difference between treated and control cells.
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3.4.6

The role of sphingolipid modulation in 13’-COOH-induced cell death

Since 13’-COOHs induced accumulation of intracellular dhCer and dhSph, which
are known to induce cell stress and/or death (Ahn and Schroeder, 2002; Jiang et al., 2012;
Jiang et al., 2004), we used myriocin, a specific inhibitor of serine palmitoyltransferase,
to block the increase of these sphingoid bases. Interestingly, co-treatment of cells with
myriocin showed partial reversion of 13’-COOH-induced LC3-II expression (Fig. 3.9A),
but had no effect on PARP-1 cleavage (data not shown). These data suggest that
elevation of dhCer and dhSph may play a role in 13’-COOHs-induced autophagy.
Cers have been known to be potent inducer of apoptosis (Kolesnick, 2002; Radin,
2001; Woodcock, 2006). Because 13’-COOHs decreased Cers synthesis in the de novo
pathway (Fig. 3.7C), we reason that the increase of Cers (Fig. 3.4D) after longer
treatment is likely caused by hydrolysis of SM via sphingomyelinase (SMase). To
establish the role of Cers from SMs in 13’-COOH-induced cancer cell death, we used
desipramine and GW4869 to inhibit acid or neutral SMases, respectively. Co-treatment of
GW4869 but not desipramine (data not shown) with 13’-COOHs partially counteracted
anti-proliferation by 13’-COOHs (Fig. 3.9B). These data suggest that SM hydrolysis
through the neutral SMase activation may in part contribute to 13’-COOHs-induced
anticancer effects.
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Figure 3.9 Protective effects of inhibitors of enzymes in sphingolipid metabolism on 13’COOHs-induced cancer cell death. (A) HCT-116 cells were treated with 20 μM δT- or
δTE-13’-COOH with or without 3 μM myriocin, a specific inhibitor of serine
palmitoyltransferase to block the de novo sphingolipid pathway. After 16 h of treatment,
the cells were collected and analyzed for detection of LC3-II expression. Western blots in
this figure are representative of three or more independent experiments. LC3-II protein
levels were quantified from the blots. The data are mean ± SEM of three or four
independent experiments. *p < 0.05 and **p < 0.01; #p < 0.05 and ##p < 0.01 versus
control indicate a significant difference. (B) HCT-116 cells were treated with 5 or 10 μM
δT-13’-COOH or 10 μM δTE-13’-COOH with or without 5 μM GW4869, an inhibitor of
neutral SMase for 24 h. Relative cell viability was measured by MTT assay compared
with control. The data are mean ± SD of three independent experiments. *p < 0.05 and
**p < 0.01 indicate a significant difference.
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3.4.7

δTE-13’-COOH supplementation attenuated colon inflammation and inhibited
tumorigenesis induced by AOM with two cycles of 1.5% DSS in mice
To examine whether the anticancer effect of 13’-COOH can be translated into

whole body system, we investigated the effectiveness of δTE-13’-COOH
supplementation against AOM-induced and DSS-promoted colon tumorigenesis in male
Balb/c mice. The body weights and the amounts of food intake of AOM/DSS-treated
δTE-13’-COOH-supplemented group were similar to those of the control diet group, and
δTE-13’-COOH supplementation showed no apparent signs of toxicity throughout the
experiment (Figs. 3.10B and C). δTE-13’-COOH supplementation attenuated colon
inflammation induced by two-cycles of 1.5% DSS as indicated by significantly attenuated
scores of rectal bleeding on day 6 of 2nd cycle DSS administration (Fig. 3.10D), and
significantly attenuated DSS-caused colon L/W ratio reduction compared with the control
diet group (Fig. 3.10E). After 43 days, AOM/DSS-treated control diet group had 4.7 ±
0.3 tumors per mouse in the colon, but AOM/DSS-δTE-13’-COOH supplementation
group showed beneficial effects with a significantly lower number of colon tumors (3.1 ±
0.3; p < 0.01; Fig. 3.10F) even the supplementation was started 7 days after AOM
injection. Interestingly, when the tumors were categorized as small (< 2 mm2) or large (>
2 mm2) sizes, supplementation of δTE-13’-COOH after AOM/DSS treatment
significantly decreased the number of large tumors by 58% (p < 0.05), which are closely
associated with the development of malignancy, although it did not significantly decrease
the number of small tumors. All these tumors were primarily found in the middle to rectal
part of the distal colon.
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Figure 3.10 Effects of δTE-13’-COOH on colon tumorigenesis induced by AOM with
two cycles of 1.5% DSS. (A) The design of AOM/DSS study. (B) Body weight and (C)
food intake of each group during the days after supplementation started. The effects of
δTE-13’-COOH on (D) fecal scorings during DSS cycle 1 and 2, and (E) ratio of colon
L/W. (F) The effects of δTE-13’-COOH on colon tumor multiplicity and polyps with
sizes of < 2 mm2 or > 2 mm2 in the AOM/DSS study (mean ± SEM, n = 15-17). *p <
0.05 and **p < 0.01 differences between control and δTE-13’-COOH supplementation
group.

3.4.8

δTE-13’-COOH supplementation attenuated colon inflammation induced by one
cycle of 1.8% DSS in mice
We further examined whether δTE-13’-COOH has any direct effects on colon

inflammation caused by one cycle of 1.8% DSS. Similar to the results from AOM/DSS
study above, the body weights and the amount of food intake were not different between
groups (Figs. 3.11B and C). Treatment with one cycle of 1.8% DSS resulted in colon
bleeding and diarrhea, and δTE-13’-COOH supplementation significantly decreased this
fecal scoring compared with the control-diet group (Figs. 3.11D-F), indicating that δTE13’-COOH alleviated colon inflammation induced by DSS.
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Figure 3.11 Effects of δTE-13’-COOH on colon inflammation induced by one cycle of
1.8% DSS. (A) The design of DSS study. (B) Body weight and (C) food intake of each
group during the study. The effects of δTE-13’-COOH on (D) rectal bleeding, (E) stool
consistency, and (F) total fecal scorings during the DSS study (mean ± SEM, n = 12). *p
< 0.05 and **p < 0.01 differences between control and δTE-13’-COOH supplementation
group.
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3.4.9

Combined treatment of specific natural vitamin E forms with their long-chain
metabolites exhibited synergistic or additive antiproliferative effects
Since parental vitamin E forms and their metabolites coexist in in vivo system, we

evaluated whether the combined treatment of vitamin E forms and their long-chain
metabolites has synergistic antiproliferative effects in colon cancer cells using MTT
assay. Human colon HCT-116 cancer cells were treated with lower doses of δT or δT13’-COOH alone or with their combination for 72 h. Treatment of cells with 5-10 μM δT
or 2.5-5 μM δT-13’-COOH had no or little effect on cell growth, but combinded
treatment of δT with δT-COOH induced a significant inhibition of cell growth in a dosedependent manner (Fig. 3.12A). HCT-116 cells were also treated with lower doses of
δTE or δTE-13’-COOH alone or with their combination for 72 h. Similar to the combined
effects of δT and δT-13’-COOH, 2.5-5 μM δTE or 2.5-5μM had no effect on cell growth,
but their combination exhibited a significant additive or synergistic antiproliferative
effects (Fig. 3.12B).
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Figure 3.12 Effects of combined treatment of specific vitamin E forms with their longchain metabolites on cancer cell growth. HCT-116 cells were treated with (A) δT, δT13’-COOH, and their combination or (B) δTE, δTE-13’-COOH, and their combination
for 72 h. Relative cell viability was measured after treatment with individual natural
forms of vitamin E or their metabolites alone or with a combination at the stated
concentrations by MTT assay compared with control. The data are mean ± SD for three
independent experiments, each performed in duplicate.
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Table 3.1 Effect of δT-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT116 cells were treated with 10 or 20 µM δT-13’-COOH for 1, 2, 4, 8 and 16 h. The
amount of each sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of at
least 3 independent experiments. *p < 0.05, **p < 0.01, significant difference between
control and δT-13’-COOH-treated cells. Cer, ceramide; dhCer, dihydroceramide; Sph,
sphingosine; dhSph, dihydrosphingosine; S1P, sphingosine-1-phosphate; SM,
sphingomyelin; dhSM, dihydrosphingomyelin

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
1
2
4
8
16

Control
2.33 ± 0.40
3.04 ± 0.06
2.27 ± 0.26
2.41 ± 0.18
2.91 ± 0.15

δT-13' 10 µM
1.96 ± 0.12
1.92 ± 0.10**
1.81 ± 0.19**
2.00 ± 0.28*
3.36 ± 0.05*

δT-13' 20 µM
1.84 ± 0.15
2.15 ± 0.13**
2.36 ± 0.23
2.76 ± 0.21*
6.23 ± 0.47*

Control
0.061 ± 0.005
0.063 ± 0.004
0.051 ± 0.012
0.041 ± 0.004
0.040 ± 0.002

δT-13' 10 µM
0.062 ± 0.007
0.052 ± 0.002
0.050 ± 0.013
0.037 ± 0.003
0.052 ± 0.001**

δT-13' 20 µM
0.076 ± 0.014
0.072 ± 0.004
0.079 ± 0.021**
0.064 ± 0.003**
0.091 ± 0.005**

Control
0.043 ± 0.012
0.045 ± 0.006
0.036 ± 0.003
0.028 ± 0.003
0.028 ± 0.000

δT-13' 10 µM
0.039 ± 0.007
0.038 ± 0.005**
0.044 ± 0.017
0.029 ± 0.002
0.046 ± 0.002**

δT-13' 20 µM
0.044 ± 0.008
0.059 ± 0.006**
0.085 ± 0.024**
0.063 ± 0.005**
0.081 ± 0.005**

Control
0.45 ± 0.14
0.55 ± 0.074
0.30 ± 0.092
0.27 ± 0.043
0.26 ± 0.010

δT-13' 10 µM
0.52 ± 0.096
0.56 ± 0.063
0.58 ± 0.19**
0.36 ± 0.027
0.51 ± 0.020**

δT-13' 20 µM
0.60 ± 0.11
0.77 ± 0.069**
0.83 ± 0.23**
0.53 ± 0.17
0.78 ± 0.049**

Control
2.62 ± 0.55
3.25 ± 1.28

δT-13' 10 µM
2.13 ± 0.52**
2.13 ± 0.58

δT-13' 20 µM
2.35 ± 0.46
2.65 ± 0.59

C18:0-Cer
Hours
1
2
4
8
16
C20:0-Cer
Hours
1
2
4
8
16
C22:0-Cer
Hours
1
2
4
8
16
C24:1-Cer
Hours
1
2
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4
8
16

1.06 ± 0.03
1.48 ± 0.40
2.00 ± 0.34

0.90 ± 0.07*
1.03 ± 0.30**
1.43 ± 0.27**

1.32 ± 0.07**
1.87 ± 0.42**
2.65 ± 0.42

Control
2.74 ± 0.50
3.48 ± 1.10
1.25 ± 0.16
1.70 ± 0.29
2.92 ± 0.28

δT-13' 10 µM
2.64 ± 0.62
2.93 ± 0.73
1.66 ± 0.22**
2.20 ± 0.42**
3.59 ± 0.51*

δT-13' 20 µM
2.63 ± 0.55
2.81 ± 0.69
1.24 ± 0.11
1.51 ± 0.27
2.11 ± 0.33*

Control
0.27 ± 0.044
0.36 ± 0.13
0.12 ± 0.013
0.15 ± 0.016
0.23 ± 0.009

δT-13' 10 µM
0.22 ± 0.045**
0.23 ± 0.064**
0.11 ± 0.011
0.097 ± 0.015**
0.13 ± 0.010**

δT-13' 20 µM
0.23 ± 0.034
0.27 ± 0.063
0.14 ± 0.012
0.18 ± 0.017**
0.29 ± 0.013

Control
0.14 ± 0.076
0.19 ± 0.12
0.11 ± 0.009
0.13 ± 0.016
0.24 ± 0.005

δT-13' 10 µM
0.11 ± 0.064
0.12 ± 0.068
0.097 ± 0.009
0.11 ± 0.020**
0.13 ± 0.014**

δT-13' 20 µM
0.12 ± 0.063
0.13 ± 0.072
0.098 ± 0.008
0.12 ± 0.019
0.16 ± 0.010**

Control
8.66 ± 0.71
10.97 ± 2.57
5.20 ± 0.57
6.21 ±0.90
8.63 ±0.78

δT-13' 10 µM
7.68 ± 1.02
7.97 ±1.30**
5.25 ±0.71
5.87 ±1.03
9.24 ± 0.86

δT-13' 20 µM
7.89 ± 0.84
8.91 ± 1.27
6.16 ± 0.67**
7.08 ± 0.86**
12.39 ± 0.84

C24:0-Cer
Hours
1
2
4
8
16
C26:1-Cer
Hours
1
2
4
8
16
C26:0-Cer
Hours
1
2
4
8
16
Total Cers
Hours
1
2
4
8
16

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
1
2
4
8
16
C18:0-dhCer

Control
0.073 ± 0.009
0.11 ± 0.004
0.060 ± 0.005
0.087 ± 0.007
0.23 ± 0.022

δT-13' 10 µM
0.092 ± 0.004
0.13 ± 0.015
0.13 ± 0.024*
0.26 ± 0.031**
1.04 ± 0.060**

δT-13' 20 µM
0.12 ± 0.017*
0.28 ± 0.031*
0.33 ± 0.017**
1.13 ± 0.092**
3.40 ± 0.43**
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Hours
1
2
4
8
16

Control
0.0016 ± 0.0001
0.0016 ± 0.0001
0.0016 ± 0.0003
0.0015 ± 0.0002
0.0017 ± 0.0003

δT-13' 10 µM
0.0017 ± 0.0003
0.0015 ± 0.0001
0.0022 ± 0.0007
0.0023 ± 0.0004
0.0060 ± 0.0008**

δT-13' 20 µM
0.0025 ± 0.0005
0.0035 ± 0.0003*
0.0041 ± 0.0005
0.011 ± 0.0024*
0.027 ± 0.0024**

Control
0.0008 ± 0.0003
0.0009 ± 0.0002
0.0006 ± 0.0001
0.0006 ± 0.0001
0.0011 ± 0.0000

δT-13' 10 µM
0.0007 ± 0.0001
0.0012 ± 0.0003
0.0013 ± 0.0006
0.0020 ± 0.0005*
0.0058 ± 0.0006**

δT-13' 20 µM
0.0012 ± 0.0005
0.0020 ± 0.0002
0.0038 ± 0.0009*
0.143 ± 0.14
0.013 ± 0.003**

Control
0.0035 ± 0.0012
0.0037 ± 0.001
0.0030 ± 0.001
0.0034 ± 0.0002
0.0059 ± 0.001

δT-13' 10 µM
0.0035 ± 0.001
0.0053 ± 0.001*
0.0098 ± 0.004
0.014 ± 0.0024**
0.048 ± 0.0060**

δT-13' 20 µM
0.0059 ± 0.0012
0.012 ± 0.0016**
0.032 ± 0.0084**
0.279 ± 0.23
0.069 ± 0.011**

Control
0.0065 ± 0.001
0.0080 ± 0.003
0.0045 ± 0.001
0.0079 ± 0.001
0.025 ± 0.004

δT-13' 10 µM
0.0058 ± 0.001
0.0068 ± 0.014
0.0105 ± 0.001**
0.024 ± 0.004**
0.071 ± 0.005*

δT-13' 20 µM
0.0079 ± 0.001
0.015 ± 0.003
0.025 ± 0.001**
0.082 ± 0.007**
0.15 ± 0.013**

Control
0.0078 ± 0.001
0.0080 ± 0.001
0.0056 ± 0.0004
0.011 ± 0.001
0.039 ± 0.005

δT-13' 10 µM
0.0060 ± 0.0004
0.011 ± 0.003
0.020 ± 0.003*
0.053 ± 0.009**
0.22 ± 0.014**

δT-13' 20 µM
0.0067 ± 0.001
0.017 ± 0.004
0.025 ± 0.001**
0.074 ± 0.004**
0.13 ± 0.013**

Control
0.00025 ± 0.0002
0.00022 ± 0.0002
0.00064 ± 0.0003
0.00073 ± 0.0004
0.0041 ± 0.001

δT-13' 10 µM
0.00016 ± 0.0002
0.00023 ± 0.0002
0.00060 ± 0.0004
0.0017 ± 0.001
0.0080 ± 0.001

δT-13' 20 µM
0.00054 ± 0.0005
0.00054 ± 0.0005
0.0015 ± 0.001
0.0088 ± 0.001
0.020 ± 0.003**

C20:0-dhCer
Hours
1
2
4
8
16
C22:0-dhCer
Hours
1
2
4
8
16
C24:1-dhCer
Hours
1
2
4
8
16
C24:0-dhCer
Hours
1
2
4
8
16
C26:1-dhCer
Hours
1
2
4
8
16
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Total dhCers
Hours
1
2
4
8
16

Control
0.093 ± 0.009
0.13 ± 0.007
0.075 ± 0.004
0.11 ± 0.008
0.31 ± 0.032

δT-13' 10 µM
0.11 ± 0.005
0.16 ± 0.017
0.17 ± 0.033*
0.35 ± 0.047**
1.44 ± 0.10**

δT-13' 20 µM
0.15 ± 0.021
0.33 ± 0.036*
0.42 ± 0.027**
1.73 ± 0.44**
3.82 ± 0.47**

Sphingoid bases (pmol/µg PC)
Sph
Hours
1
2
4
8
16

Control
0.80 ± 0.10
1.03 ± 0.32
0.63 ± 0.14
0.40 ± 0.057
0.43 ± 0.023

δT-13' 10 µM
1.00 ± 0.31
0.85 ± 0.22*
0.56 ± 0.14
0.38 ± 0.064
0.37 ± 0.027

δT-13' 20 µM
1.01 ± 0.33
0.92 ± 0.29
0.62 ± 0.14
0.41 ± 0.035
0.45 ± 0.037

Control
0.057 ± 0.017
0.062 ± 0.008
0.054 ± 0.012
0.064 ± 0.003
0.059 ± 0.005

δT-13' 10 µM
0.068 ± 0.009
0.067 ± 0.007*
0.064 ± 0.003
0.060 ± 0.009
0.12 ± 0.006**

δT-13' 20 µM
0.11 ± 0.032**
0.12 ± 0.015
0.14 ± 0.016*
0.51 ± 0.18*
1.90 ± 0.24**

Control
0.025 ± 0.007
0.016 ± 0.006
0.011 ± 0.002
0.014 ± 0.005
0.013 ± 0.003

δT-13' 10 µM
0.019 ± 0.005
0.015 ± 0.004
0.0065 ± 0.001
0.021 ± 0.006
0.013 ± 0.002

δT-13' 20 µM
0.029 ± 0.008
0.019 ± 0.003
0.012 ± 0.001
0.014 ± 0.004
0.015 ± 0.002

dhSph
Hours
1
2
4
8
16
S1P
Hours
1
2
4
8
16

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
1
2
4
8
16
C18:0-SM

Control
54.41 ± 4.37
64.18 ± 6.12
51.09 ± 3.76
64.19 ± 3.16
100.55 ± 13.49

δT-13' 10 µM
56.25 ± 5.70
55.41 ± 1.62
52.39 ± 2.37
49.32 ± 5.61**
58.11 ± 7.22**

δT-13' 20 µM
54.49 ± 6.22
54.51 ± 2.77*
40.89 ± 2.23
39.78 ± 2.80**
48.45 ± 5.62**
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Hours
1
2
4
8
16

Control
0.69 ± 0.068
0.78 ± 0.079
0.67 ± 0.037
0.69 ± 0.025
0.74 ± 0.078

δT-13' 10 µM
0.69 ± 0.079
0.68 ± 0.046
0.66 ± 0.030
0.59 ± 0.055*
0.58 ± 0.043**

δT-13' 20 µM
0.66 ± 0.092
0.68 ± 0.062*
0.54 ± 0.009**
0.53 ± 0.020**
0.54 ± 0.083**

Control
0.57 ± 0.092
0.68 ± 0.089
0.62 ± 0.051
0.62 ± 0.029
0.63 ± 0.047

δT-13' 10 µM
0.60 ± 0.095*
0.62 ± 0.052
0.66 ± 0.046
0.57 ± 0.030
0.53 ± 0.027*

δT-13' 20 µM
0.56 ± 0.11
0.60 ± 0.068
0.55 ± 0.017
0.49 ± 0.040**
0.46 ± 0.064*

Control
3.31 ± 0.87
3.89 ± 0.73
2.84 ± 0.35
2.73 ± 0.19
3.11 ± 0.19

δT-13' 10 µM
3.31 ± 0.75
3.56 ± 0.41
3.28 ± 0.49*
2.93 ± 0.32
3.00 ± 0.02

δT-13' 20 µM
3.21 ± 0.71
3.50 ± 0.52*
2.56 ± 0.29*
2.23 ± 0.16*
2.32 ± 0.41*

Control
15.13 ± 3.31
17.69 ± 3.23
14.94 ± 3.03
12.66 ± 1.51
13.11 ± 1.24

δT-13' 10 µM
14.55 ± 3.49
15.92 ± 1.41
15.76 ± 3.46
10.88 ± 1.47*
9.16 ± 0.86**

δT-13' 20 µM
14.25 ± 3.49
15.63 ± 2.12
12.65 ± 2.28**
8.92 ± 1.22**
7.43 ± 1.15**

Control
0.79 ± 0.19
0.96 ± 0.15
0.98 ± 0.27
0.76 ± 0.18
0.74 ± 0.11

δT-13' 10 µM
0.75 ± 0.19
0.82 ± 0.05
1.09 ± 0.29
0.60 ± 0.14*
0.45 ± 0.04**

δT-13' 20 µM
0.72 ± 0.19
0.78 ± 0.07*
0.89 ± 0.21
0.55 ± 0.13**
0.46 ± 0.11**

Control
74.90 ± 8.79
88.18 ± 10.37
71.14 ± 5.94
81.65 ± 1.86
118.88 ± 15.07

δT-13' 10 µM
76.16 ± 10.25
77.01 ± 3.10
73.84 ± 4.43
64.89 ± 5.26**
71.82 ± 8.03**

δT-13' 20 µM
73.90 ± 10.75
75.69 ± 5.59*
58.09 ± 0.88
52.50 ± 2.29**
59.64 ± 7.39**

C20:0-SM
Hours
1
2
4
8
16
C22:0-SM
Hours
1
2
4
8
16
C24:1-SM
Hours
1
2
4
8
16
C26:1-SM
Hours
1
2
4
8
16
Total SMs
Hours
1
2
4
8
16
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Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
1
2
4
8
16

Control
6.60 ± 0.38
8.42 ± 1.63
8.12 ± 0.75
9.18 ± 1.04
9.49 ± 0.98

δT-13' 10 µM
6.43 ± 0.27
7.60 ± 1.52**
8.85 ± 1.61
9.68 ± 0.65
10.73 ± 1.03

δT-13' 20 µM
6.53 ± 0.53
7.59 ± 1.38*
7.57 ± 1.28
8.24 ± 0.91*
10.08 ± 1.68

Control
0.14 ± 0.010
0.18 ± 0.027
0.29 ± 0.078
0.26 ± 0.065
0.74 ± 0.078

δT-13' 10 µM
0.15 ± 0.012
0.17 ± 0.041
0.28 ± 0.077
0.24 ± 0.044
0.58 ± 0.043

δT-13' 20 µM
0.14 ± 0.018
0.16 ± 0.027**
0.24 ± 0.071
0.22 ± 0.052
0.54 ± 0.083

Control
0.13 ± 0.017
0.15 ± 0.015
0.22 ± 0.018
0.18 ± 0.035
0.13 ± 0.032

δT-13' 10 µM
0.14 ± 0.025
0.14 ± 0.022
0.22 ± 0.032
0.18 ± 0.029
0.16 ± 0.034**

δT-13' 20 µM
0.14 ± 0.031
0.13 ± 0.020
0.20 ± 0.027
0.16 ± 0.037*
0.14 ± 0.035

Control
0.37 ± 0.067
0.47 ± 0.061
0.69 ± 0.12
0.49 ± 0.061
0.32 ± 0.051

δT-13' 10 µM
0.39 ± 0.038
0.46 ± 0.069
0.67 ± 0.10
0.55 ± 0.078
0.59 ± 0.098**

δT-13' 20 µM
0.37 ± 0.039
0.44 ± 0.072
0.61 ± 0.11
0.49 ± 0.079
0.50 ± 0.14

Control
0.55 ± 0.13
0.71 ± 0.080
1.05 ± 0.58
0.46 ± 0.13
0.45 ± 0.069

δT-13' 10 µM
0.49 ± 0.071
0.61 ± 0.081*
1.23 ± 0.71
0.50 ± 0.086
0.81 ± 0.12**

δT-13' 20 µM
0.48 ± 0.071
0.64 ± 0.12
0.89 ± 0.46
0.40 ± 0.11
0.55 ± 0.18

Control
0.07 ± 0.007

δT-13' 10 µM
0.06 ± 0.004*

δT-13' 20 µM
0.06 ± 0.006

C18:0-dhSM
Hours
1
2
4
8
16
C20:0-dhSM
Hours
1
2
4
8
16
C22:0-dhSM
Hours
1
2
4
8
16
C24:0-dhSM
Hours
1
2
4
8
16
C26:0-dhSM
Hours
1
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2
4
8
16

0.08 ± 0.011
0.13 ± 0.061
0.05 ± 0.024
0.04 ± 0.010

0.08 ± 0.020
0.13 ± 0.071
0.05 ± 0.016
0.12 ± 0.084

0.08 ± 0.017
0.12 ± 0.057
0.05 ± 0.014
0.04 ± 0.013

Control
7.87 ± 0.61
10.02 ± 1.76
10.50 ± 1.01
10.63 ± 1.30
10.58 ± 1.15

δT-13' 10 µM
7.65 ± 0.22
9.06 ± 1.73**
11.38 ± 2.04
11.20 ± 0.78
12.57 ± 1.29

δT-13' 20 µM
7.73 ± 0.51
9.03 ± 1.61*
9.64 ± 1.40
9.56 ± 1.12*
11.49 ± 2.08

Total dhSMs
Hours
1
2
4
8
16

Table 3.2 Effect of δT-13’-COOH on sphingolipid metabolism in MCF-7 cells. MCF-7
cells were treated with 10 or 20 µM δT-13’-COOH for 4 and 8 h. The amount of each
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 2 independent
experiments.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
4
8

Control
1.49 ± 0.082
1.48 ± 0.14

δT-13' 10 µM
1.30 ± 0.17
1.23 ± 0.007

δT-13' 20 µM
1.56 ± 0.006
2.23 ± 0.23

Control
0.10 ± 0.015
0.094 ± 0.001

δT-13' 10 µM
0.084 ± 0.0004
0.071 ± 0.001

δT-13' 20 µM
0.086 ± 0.005
0.11 ± 0.001

Control
0.020 ± 0.0018
0.018 ± 0.0006

δT-13' 10 µM
0.021 ± 0.0005
0.022 ± 0.0014

δT-13' 20 µM
0.026 ± 0.0014
0.033 ± 0.0023

Control
0.056 ± 0.024
0.060 ± 0.038

δT-13' 10 µM
0.070 ± 0.051
0.079 ± 0.057

δT-13' 20 µM
0.068 ± 0.048
0.11 ± 0.096

Control
13.19 ± 1.19
13.57 ± 1.71

δT-13' 10 µM
12.21 ± 1.59
12.60 ± 1.26

δT-13' 20 µM
18.75 ± 1.51
25.52 ± 3.41

C18:0-Cer
Hours
4
8
C20:0-Cer
Hours
4
8
C22:0-Cer
Hours
4
8
C24:1-Cer
Hours
4
8
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C24:0-Cer
Control
2.34 ± 0.31
2.34 ± 0.20

δT-13' 10 µM
3.59 ± 0.24
5.34 ± 0.092

δT-13' 20 µM
2.56 ± 0.026
4.00 ± 0.082

Hours
4
8
Total Cers

Control
0.26 ± 0.10
0.27 ± 0.025

δT-13' 10 µM
0.41 ± 0.031
0.51 ± 0.0001

δT-13' 20 µM
0.45 ± 0.019
0.74 ± 0.035

Hours
4
8

Control
17..45 ± 1.67
17.84 ± 2.12

δT-13' 10 µM
17.68 ± 2.08
19.85 ± 1.41

δT-13' 20 µM
23.51 ± 1.56
32.75 ± 3.69

Hours
4
8
C26:1-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
4
8

Control
0.093 ± 0.035
0.11 ± 0.022

δT-13' 10 µM
0.12 ± 0.027
0.13 ± 0.030

δT-13' 20 µM
0.14 ± 0.007
0.29 ± 0.018

Control
0.0019 ± 0.0005
0.0022 ± 0.0006

δT-13' 10 µM
0.0028 ± 0.0007
0.0036 ± 0.0009

δT-13' 20 µM
0.004 ± 0.0006
0.0029 ± 0.0001

Control
0.00051 ±
0.0003
0.0019 ± 0.0004

δT-13' 10 µM

δT-13' 20 µM

0.0028 ± 0.0016
0.0044 ± 0.00001

0.0039 ± 0.0012
0.0091 ± 0.0009

Control
0.085 ± 0.0070
0.055 ± 0.0067

δT-13' 10 µM
0.096 ± 0.018
0.11 ± 0.036

δT-13' 20 µM
0.24 ± 0.062
0.41 ± 0.088

Control
0.18 ± 0.029
0.16 ± 0.017

δT-13' 10 µM
0.22 ± 0.011
0.25 ± 0.0049

δT-13' 20 µM
0.39 ± 0.053
0.71 ± 0.071

C18:0-dhCer
Hours
4
8
C22:0-dhCer
Hours
4
8
C24:1-dhCer
Hours
4
8
Total dhCers
Hours
4
8

Sphingoid bases (pmol/µg PC)
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Sph
Hours
4
8

Control
0.51 ± 0.11
0.47 ± 0.0036

δT-13' 10 µM
0.43 ± 0.017
0.40 ± 0.045

δT-13' 20 µM
0.49 ± 0.11
0.46 ± 0.064

Hours
4
8

Control
0.010 ± 0.0004
0.013 ± 0.005

δT-13' 10 µM
0.016 ± 0.008
0.010 ± 0.0001

δT-13' 20 µM
0.013 ± 0.001
0.012 ± 0.004

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
4
8

Control
32.77 ± 4.04
34.30 ± 0.38

δT-13' 10 µM
31.70 ± 0.15
30.49 ± 0.09

δT-13' 20 µM
23.85 ± 0.34
23.92 ± 1.44

Control
1.73 ± 0.33
1.79 ± 0.11

δT-13' 10 µM
1.73 ± 0.13
1.62 ± 0.17

δT-13' 20 µM
1.29 ± 0.10
1.25 ± 0.22

Control
0.90 ± 0.18
0.92 ± 0.023

δT-13' 10 µM
0.93 ± 0.056
0.86 ± 0.11

δT-13' 20 µM
0.60 ± 0.019
0.62 ± 0.094

Control
2.09 ± 0.67
1.92 ± 0.13

δT-13' 10 µM
2.06 ± 0.25
2.18 ± 0.30

δT-13' 20 µM
1.30 ± 0.068
1.43 ± 0.34

Control
14.23 ± 3.11
12.66 ± 0.61

δT-13' 10 µM
12.96 ± 0.0033
11.89 ± 0.13

δT-13' 20 µM
8.88 ± 0.32
9.36 ± 0.66

Control
3.26 ± 0.88
2.58 ± 0.12

δT-13' 10 µM
2.58 ± 0.016
2.51 ± 0.028

δT-13' 20 µM
1.72 ± 0.12
1.73 ± 0.13

Control
54.98 ± 9.21

δT-13' 10 µM
51.96 ± 0.60

δT-13' 20 µM
37.64 ± 0.082

C18:0-SM
Hours
4
8
C20:0-SM
Hours
4
8
C22:0-SM
Hours
4
8
C24:1-SM
Hours
4
8
C26:1-SM
Hours
4
8
Total SMs
Hours
4
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8

54.17 ± 0.85

49.55 ± 0.64

38.35 ± 2.87

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
4
8

Control
3.84 ± 0.39
4.38 ± 0.14

δT-13' 10 µM
4.72 ± 0.027
4.96 ± 0.14

δT-13' 20 µM
3.30 ± 0.14
3.85 ± 0.21

Control
0.24 ± 0.040
0.26 ± 0.010

δT-13' 10 µM
0.28 ± 0.021
0.30 ± 0.033

δT-13' 20 µM
0.18 ± 0.006
0.18 ± 0.026

Control
0.18 ± 0.055
0.18 ± 0.0005

δT-13' 10 µM
0.21 ± 0.020
0.23 ± 0.035

δT-13' 20 µM
0.12 ± 0.017
0.12 ± 0.030

Control
0.16 ± 0..054
0.13 ± 0.0033

δT-13' 10 µM
0.18 ± 0.021
0.21 ± 0.024

δT-13' 20 µM
0.10 ± 0.0026
0.12 ± 0.023

Control
0.096 ± 0.029
0.080 ± 0.0017

δT-13' 10 µM
0.11 ± 0.013
0.13 ± 0.016

δT-13' 20 µM
0.066 ± 0.0021
0.076 ± 0.015

Control
0.027 ± 0.0084
0.021 ± 0.0003

δT-13' 10 µM
0.032 ± 0.0045
0.031 ± 0.0017

δT-13' 20 µM
0.016 ± 0.0023
0.020 ± 0.0057

Control
4.54 ± 0.58
5.04 ± 0.13

δT-13' 10 µM
5.55 ± 0.052
5.86 ± 0.25

δT-13' 20 µM
3.79 ± 0.12
4.37 ± 0.31

C18:0-dhSM
Hours
4
8
C20:0-dhSM
Hours
4
8
C22:0-dhSM
Hours
4
8
C24:0-dhSM
Hours
4
8
C26:0-dhSM
Hours
4
8
Total dhSMs
Hours
4
8

Table 3.3 Effect of δTE-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT116 cells were treated with 10 or 20 µM δTE-13’-COOH for 8 and 16 h. The amount of
each sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 2
independent experiments.
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Ceramides (pmol/µg PC)
C16:0-Cer
Hours
8
16

Control
2.43 ± 0.036
2.82 ± 0.080

δTE-13' 10 µM
1.79 ± 0.0047
1.69 ± 0.070

δTE-13' 20 µM
2.20 ± 0.051
3.04 ± 0.26

Control
0.043 ± 0.003
0.039 ± 0.001

δTE-13' 10 µM
0.035 ± 0.001
0.030 ± 0.002

δTE-13' 20 µM
0.050 ± 0.002
0.066 ± 0.010

Control
0.025 ± 0.001
0.027 ± 0.001

δTE-13' 10 µM
0.021 ± 0.002
0.018 ± 0.002

δTE-13' 20 µM
0.052 ± 0.001
0.064 ± 0.012

Control
0.22 ± 0.016
0.23 ± 0.005

δTE-13' 10 µM
0.24 ± 0.0004
0.21 ± 0.001

δTE-13' 20 µM
0.49 ± 0.005
0.55 ± 0.049

Control
2.58 ± 0.27
2.68 ± 0.029

δTE-13' 10 µM
1.92 ± 0.049
1.49 ± 0.010

δTE-13' 20 µM
2.46 ± 0.12
2.26 ± 0.15

Control
2.64 ± 0.14
3.40 ± 0.007

δTE-13' 10 µM
3.42 ± 0.22
4.15 ± 0.026

δTE-13' 20 µM
3.12 ± 0.30
3.22 ± 0.26

Control
0.21 ± 0.007
0.27 ± 0.008

δTE-13' 10 µM
0.17 ± 0.008
0.16 ± 0.008

δTE-13' 20 µM
0.21 ± 0.014
0.21 ± 0.004

Control
0.16 ± 0.030
0.23 ± 0.001

δTE-13' 10 µM
0.16 ± 0.003
0.19 ± 0.003

δTE-13' 20 µM
0.16 ± 0.001
0.13 ± 0.011

Control
8.31 ± 0.49
9.70 ± 0.042

δTE-13' 10 µM
7.76 ± 0.28
7.94 ± 0.098

δTE-13' 20 µM
8.74 ± 0.48
9.55 ± 0.24

C18:0-Cer
Hours
8
16
C20:0-Cer
Hours
8
16
C22:0-Cer
Hours
8
16
C24:1-Cer
Hours
8
16
C24:0-Cer
Hours
8
16
C26:1-Cer
Hours
8
16
C26:0-Cer
Hours
8
16
Total Cers
Hours
8
16

Dihydroceramides (pmol/µg PC)
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C16:0-dhCer
Hours
8
16

Control
0.19 ± 0.02
0.42 ± 0.002

δTE-13' 10 µM
0.38 ± 0.03
0.52 ± 0.02

δTE-13' 20 µM
0.85 ± 0.01
1.86 ± 0.22

Control
0.0011 ± 0.0001
0.0020 ± 0.0006

δTE-13' 10 µM
0.0017 ± 0.0004
0.0020 ± 0.0001

δTE-13' 20 µM
0.0035 ± 0.00003
0.0087 ± 0.0005

Control
0.0010 ± 0.0004
0.0004 ± 0.0001

δTE-13' 10 µM
0.0010 ± 0.0002
0.0013 ± 0.0002

δTE-13' 20 µM
0.0047 ± 0.0019
0.0086 ± 0.0009

Control
0.0043 ± 0.0011
0.0080 ± 0.0002

δTE-13' 10 µM
0.0076 ± 0.0013
0.013 ± 0.0010

δTE-13' 20 µM
0.022 ± 0.0019
0.053 ± 0.0029

Control
0.016 ± 0.001
0.043 ± 0.001

δTE-13' 10 µM
0.035 ± 0.001
0.050 ± 0.005

δTE-13' 20 µM
0.076 ± 0.010
0.14 ± 0.001

Control
0.028 ± 0.007
0.066 ± 0.005

δTE-13' 10 µM
0.083 ± 0.011
0.16 ± 0.011

δTE-13' 20 µM
0.086 ± 0.007
0.21 ± 0.019

Control
0.24 ± 0.033
0.54 ± 0.003

δTE-13' 10 µM
0.51 ± 0.040
0.74 ± 0.018

δTE-13' 20 µM
1.04 ± 0.007
2.28 ± 0.20

C18:0-dhCer
Hours
8
16
C20:0-dhCer
Hours
8
16
C22:0-dhCer
Hours
8
16
C24:1-dhCer
Hours
8
16
C24:0-dhCer
Hours
8
16
Total dhCers
Hours
8
16

Sphingoid bases (pmol/µg PC)
Sph
Hours
8
16

Control
0.52 ± 0.067
0.37 ± 0.043

δTE-13' 10µM
0.42 ± 0.009
0.35 ± 0.008

δTE-13' 20µM
0.39 ± 0.097
0.39 ± 0.063

Control
0.049 ± 0.006
0.043 ± 0.005

δTE-13' 10µM
0.054 ± 0.003
0.074 ± 0.004

δTE-13' 20µM
0.12 ± 0.00002
0.15 ± 0.013

dhSph
Hours
8
16
S1P
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Hours
8
16

Control
0.025 ± 0.007
0.013 ± 0.007

δTE-13' 10µM
0.025 ± 0.001
0.019 ± 0.002

δTE-13' 20µM
0.019 ± 0.003
0.011 ± 0.004

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
8
16

Control
55.88 ± 8.96
71.01 ± 2.01

δTE-13' 10µM
54.47 ± 4.88
60.66 ± 3.38

δTE-13' 20µM
44.53 ± 0.39
50.29 ± 2.19

Control
0.69 ± 0.16
0.59 ± 0.060

δTE-13' 10µM
0.70 ± 0.092
0.65 ± 0.066

δTE-13' 20µM
0.58 ± 0.037
0.58 ± 0.043

Control
0.60 ± 0.21
0.44 ± 0.037

δTE-13' 10µM
0.63 ± 0.19
0.57 ± 0.084

δTE-13' 20µM
0.53 ± 0.085
0.54 ± 0.094

Control
2.52 ± 0.83
1.99 ± 0.25

δTE-13' 10µM
2.85 ± 0.74
2.97 ± 0.29

δTE-13' 20µM
2.08 ± 0.25
2.55 ± 0.27

Control
9.52 ± 2.93
7.98 ± 0.68

δTE-13' 10µM
9.30 ± 2.02
8.85 ± 0.66

δTE-13' 20µM
6.70 ± 0.28
6.65 ± 0.29

Control
0.55 ± 0.22
0.39 ± 0.049

δTE-13' 10µM
0.47 ± 0.14
0.43 ± 0.033

δTE-13' 20µM
0.33 ± 0.028
0.33 ± 0.038

Control
75.64 ± 15.77
86.85 ± 3.84

δTE-13' 10µM
74.35 ± 9.95
81.38 ± 5.36

δTE-13' 20µM
58.38 ± 0.62
65.20 ± 1.17

C18:0-SM
Hours
8
16
C20:0-SM
Hours
8
16
C22:0-SM
Hours
8
16
C24:1-SM
Hours
8
16
C26:1-SM
Hours
8
16
Total SMs
Hours
8
16

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
8
16

Control
6.71 ± 1.44
7.89 ± 1.63

δTE-13' 10µM
8.80 ± 1.08
13.28 ± 0.61

δTE-13' 20µM
7.44 ± 0.32
10.26 ± 0.60
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C18:0-dhSM
Hours
8
16

Control
0.14 ± 0.045
0.10 ± 0.019

δTE-13' 10µM
0.17 ± 0.034
0.18 ± 0.014

δTE-13' 20µM
0.15 ± 0.009
0.19 ± 0.023

Control
0.11 ± 0..037
0.064 ± 0.011

δTE-13' 10µM
0.11 ± 0.029
0.14 ± 0.023

δTE-13' 20µM
0.10 ± 0.020
0.15 ± 0.026

Control
0.31 ± 0.12
0.20 ± 0.039

δTE-13' 10µM
0.37 ± 0.14
0.60 ± 0.11

δTE-13' 20µM
0.27 ± 0.052
0.50 ± 0.080

Control
0.37 ± 0.17
0.26 ± 0.061

δTE-13' 10µM
0.40 ± 0.15
0.78 ± 0.14

δTE-13' 20µM
0.24 ± 0.035
0.48 ± 0.018

Control
0.030 ± 0.013
0.016 ± 0.0050

δTE-13' 10µM
0.023 ± 0.0084
0.033 ± 0.0008

δTE-13' 20µM
0.017 ± 0.0068
0.023 ± 0.0013

Control
8.55 ± 2.13
9.21 ± 1.88

δTE-13' 10µM
10.82 ± 1.68
16.10 ± 1.00

δTE-13' 20µM
8.90 ± 0.55
12.44 ± 0.80

C20:0-dhSM
Hours
8
16
C22:0-dhSM
Hours
8
16
C24:0-dhSM
Hours
8
16
C26:0-dhSM
Hours
8
16
Total dhSMs
Hours
8
16

Table 3.4 Effect of δT-13’-COOH on de novo sphingolipid biosynthesis in HCT-116
cells. HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as
control or with a combination of 400 µM 13C3, 15N-labeled L-serine and 20 µM δT-13’COOH for 0.5, 1, 1.5, 2, and 4 h. The amount of each labeled de novo sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p <
0.05, **p < 0.01, significant difference between control and δT-13’-COOH-treated cells.

Ceramides (pmol/µg PC)
De novo C16:0-Cer
Hours
0.5
1
1.5
2

Control
0.081 ± 0.016
0.26 ± 0.015
0.33 ± 0.046
0.40 ± 0.059

δT-13' 20 µM
0.023 ± 0.010**
0.10 ± 0.0074**
0.18 ± 0.036**
0.25 ± 0.044**
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4

0.63 ± 0.038

0.41 ± 0.010**

Control
0.17 ± 0.063
0.40 ± 0.11
0.53 ± 0.19
0.65 ± 0.19
0.72 ± 0.077

δT-13' 20 µM
0.069 ± 0.038**
0.22 ± 0.060**
0.38 ± 0.16**
0.53 ± 0.18**
0.62 ± 0.041

Control
0.13 ± 0.052
0.31 ± 0.064
0.38 ± 0.12
0.51 ± 0.15
0.75 ± 0.021

δT-13' 20 µM
0.048 ± 0.020**
0.13 ± 0.023**
0.22 ± 0.079**
0.32 ± 0.078**
0.54 ± 0.038**

Control
0.37 ± 0.13
0.97 ± 0.15
1.25 ± 0.36
1.56 ± 0.39
2.09 ± 0.071

δT-13' 20 µM
0.14 ± 0.068**
0.45 ± 0.088**
0.78 ± 0.28**
1.11 ± 0.28**
1.58 ± 0.068*

De novo C24:1-Cer
Hours
0.5
1
1.5
2
4
De novo C24:0-Cer
Hours
0.5
1
1.5
2
4
De novo total Cers
Hours
0.5
1
1.5
2
4

Dihydroceramides (pmol/µg PC)
De novo C16:0-dhCer
Hours
0.5
1
1.5
2
4

Control
0.013 ± 0.0029
0.028 ± 0.0086
0.029 ± 0.0038
0.030 ± 0.0059
0.056 ± 0.014

δT-13' 20 µM
0.0058 ± 0.0014*
0.028 ± 0.010
0.045 ± 0.0024*
0.08 ± 0.0094**
0.24 ± 0.065**

De novo total dhCers
Hours
0.5
1
1.5
2
4

Control
0.013 ± 0.0029
0.028 ± 0.0086
0.029 ± 0.0038
0.030 ± 0.0059
0.079 ± 0.025

δT-13' 20 µM
0.0058 ± 0.0014*
0.028 ± 0.010
0.045 ± 0.0024*
0.080 ± 0.0094**
0.32 ± 0.11**
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Sphingomyelins (pmol/µg PC)
De novo C16:0-SM
Control
0.56 ± 0.049
0.77 ± 0.034
1.05 ± 0.078
1.52 ± 0.11
2.00 ± 0.66

δT-13' 20 µM
0.47 ± 0.045
0.55 ± 0.041*
0.67 ± 0.092**
0.99 ± 0.080**
0.89 ± 0.12**

Control
0.017 ± 0.0043
0.026 ± 0.0077
0.027 ± 0.0078
0.031 ± 0.0034
0.030 ± 0.0038

δT-13' 20 µM
0.026 ± 0.0092
0.023 ± 0.0078
0.022 ± 0.0046
0.031 ± 0.0057
0.026 ± 0.0014

Hours
0.5
1
1.5
2
4
De novo C18:0-SM
Hours
0.5
1
1.5
2
4
De novo C24:1-SM
Hours
0.5
1
1.5
2
4
De novo total SMs
Hours
0.5
1
1.5
2
4

Control
0.12 ± 0.016
0.16 ± 0.028
0.19 ± 0.025
0.26 ± 0.031
0.36 ± 0.10

δT-13' 20 µM
0.11 ± 0.015
0.11 ± 0.011**
0.12 ± 0.007**
0.17 ± 0.018**
0.17 ± 0.029**

Control
0.71 ± 0.058
0.97 ± 0.056
1.31 ± 0.052
1.85 ± 0.058
2.59 ± 0.79

δT-13' 20 µM
0.62 ± 0.061
0.69 ± 0.025*
0.84 ± 0.078**
1.22 ± 0.062**
1.18 ± 0.15**

Dihydrosphingomyelins (pmol/µg PC)
De novo C16:0-dhSM
Hours
0.5
1
1.5
2
4

Control
0.76 ± 0.0084
0.11 ± 0.012
0.14 ± 0.011
0.17 ± 0.011
0.23 ± 0.040

δT-13' 20 µM
0.077 ± 0.011
0.090 ± 0.0031
0.12 ± 0.013
0.20 ± 0.014
0.25 ± 0.025
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De novo total dhSMs
Hours
0.5
1
1.5
2
4

δT-13' 20 µM
0.086 ± 0.015
0.10 ± 0.0056
0.13 ± 0.012
0.22 ± 0.0034
0.29 ± 0.026

Control
0.085 ± 0.010
0.12 ± 0.0053
0.16 ± 0.0042
0.19 ± 0.016
0.26 ± 0.050

3.5

Discussion

We show that vitamin E long-chain metabolites, δT- and δTE-13’-COOH, inhibit
the proliferation and induce apoptosis and autophagy in human colon, breast and
pancreatic cancer cells. In these anticancer effects, δT-13’-COOH appears to be more
potent than δTE-13’-COOH, and both 13’-COOHs are much stronger than tocopherols
and slightly stronger than γTE. Using a lipidomic approach with LC-MS/MS, we
demonstrate for the first time that 13’-COOHs profoundly modulate sphingolipid
metabolism. Specifically, 13’-COOH treatment quickly increased dhCers and dhSph,
subsequently enhanced Cers and decreased SMs. The importance of sphingolipid
modulation in 13’-COOH-induced anticancer effects is supported by three lines of
evidence. First, 13’-COOH-caused increase of dhCers and dhSph took place prior to any
manifestation of cell death, and subsequent elevation of Cers occurred prior to and
coinciding with LC3-II increase and PARP cleavage. Secondly, dhCers, dhSph and Cers,
which are enhanced by 13’-COOHs, have been shown to induce antiproliferation, cell
stress and death in different types of cancer cells (Jiang et al., 2012; Jiang et al., 2004;
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Zheng et al., 2006). Furthermore, chemically blocking the increase of dhCers and dhSph
by myriocin or Cers by suppressing SM hydrolysis partially reversed 13’-COOHmediated cell death.
We identify DEGS in the de novo synthesis of sphingolipid pathway as an initial
inhibitory target by 13’-COOHs based on their temporal modulation of endogenous and
newly synthesized sphingolipids. Specifically, in the study with 13C3, 15N-labeled L-serine
for tracing newly-made sphingolipids, 13’-COOHs caused rapid increase of dhCers, but
profoundly decreased Cers like C16:0- and C24-Cers and SMs through de novo synthesis.
This observation strongly suggests that DEGS-catalyzed conversion of dhCers to Cers is
compromised. Consistently, the similar pattern of sphingolipid changes was reported in
DEGS knockout model (Ruangsiriluk et al., 2012; Siddique et al., 2013). We further
show that despite having no impact on DEGS protein expression, δT-13’-COOH
inhibited the enzyme activity in an in vitro assay. On the other hand, we did not observe
inhibition of DEGS when rat’s microsome was used, which may be caused by limited
access of 13’-COOHs to microsomal membrane under cell-free condition possibly due to
lack of proper transportation.
DEGS was first proposed as a potential inhibitory target for γT that induced
intracellular accumulation of dhCers and dhSph without changing total Cers in prostate
cancer cells (Jiang et al., 2004). Similar effects on sphingolipids were observed by other
known anticancer agents including γTE (Gopalan et al., 2012; Jiang et al., 2012),
resveratrol (Signorelli et al., 2009), fenretinide (or 4-HPR) (Rahmaniyan et al., 2011) and
celecoxib, a selective COX-2 inhibitor (Schiffmann et al., 2009b). Resveratrol and
celecoxib have further been demonstrated to inhibit DEGS enzyme activity in cell
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homogenates or intact cells, respectively (Schiffmann et al., 2009b; Signorelli et al.,
2009). Recently, DEGS activity was found to be inhibited by hydrogen peroxide
(Idkowiak-Baldys et al., 2010) or during hypoxia (Devlin et al., 2011). Interestingly,
phenolic compounds are known to have prooxidant effects including presumably
increasing hydrogen peroxide in vitro and the prooxidant activity can be counteracted by
N-acetylcysteine (NAC) (Babich et al., 2009; Fujisawa et al., 2004). In our studies, we
found that NAC did not reverse 13’-COOHs’-induced cell death (data not shown) or γTEinduced modulation of sphingolipids (Jang Y and Jiang Q, unpublished data). We
therefore conclude that the modulation of dhCers and inhibition of DEGS is not likely
caused by prooxidant activity, which is also supported by the inhibition of DEGS by
celecoxib that is not a prooxidant.
The use of LC-MS/MS approach revealed that 13’-COOHs have differential
effect on different forms of Cers. For instance, compared with controls, 13’-COOH
initially decreased C16:0-Cer but enhanced it after longer treatment, while caused a
continuous increase of C18:0-Cer. This is an intriguing observation because recent studies
demonstrate that endogenous Cers with specific fatty acid chain lengths have distinct or
sometimes opposed roles in proliferation and death (Hannun and Obeid, 2011; Senkal et
al., 2010; Sentelle et al., 2012). For instance, C16:0-Cer and C18:0-Cer generated by Cer
synthases 5/6 (CerS5/6) and CerS1 have been shown to have anti- and pro-apoptosis
properties (Senkal et al., 2010), respectively. Besides proapoptotic, C18:0-Cer has been
found to induce lethal autophagy (Sentelle et al., 2012). The increase of C18:0-Cer
therefore may contribute to 13’-COOH-caused apoptosis and autophagy. In addition, the
distinct effect on different Cer species suggests that 13’-COOH may have different
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impact on CerS1 or CerS5/6 in addition to inhibition of DEGS. This is supported by an
increase of dhSph, a key substrate of CerSs. Further investigation should be conducted to
characterize the effect of 13’-COOH on these Cer synthases.
The observation that 13’-COOHs increased Cers and decreased SM during
prolonged treatment is likely resulted from involvement of multi-pathways and enzymes.
Cellular levels of Cers and SMs are determined by the balance between de novo synthesis
and SM hydrolysis via SMases (Fig. 3.7A). Cers are de novo synthesized in the ER and
then converted to SMs by SM synthases (SMS) in the Golgi. SMs are the most abundant
sphingolipids located in membranes and can be hydrolyzed to regenerate Cers by acid or
neutral SMases (Marchesini and Hannun, 2004). In the current study, given that 13’COOHs inhibited DEGS and therefore led to decrease in de novo synthesized Cers, we
reason that an increase of Cers in the prolonged treatment is likely caused by SMasemediated SM hydrolysis, which resulted in further decrease of SMs in addition to the
reduced synthesis via the de novo pathway. Acid SMases are known to be present in
lysosomes and the outer membrane leaflet and have been shown to be activated by
TNFα, oxidants, and UV radiation (Henry et al., 2013; Marchesini and Hannun, 2004;
Zhang et al., 2001). Neutral SMases are found in the inner leaflet of the bilayer (Hannun
and Obeid, 2008), and are stimulated by serum starvation (Jayadev et al., 1995), oxidative
stress (Marchesini and Hannun, 2004), treatment of vitamin D (Okazaki et al., 1994) and
curcumin (Abdel Shakor et al., 2014). Neutral SMase activation was also a necessary
signaling event for the TNF-induced human MCF-7 breast cancer cell death (Luberto et
al., 2002). Here we found that co-treatment with neutral SMase inhibitor GW4869 but not
an acid SMase inhibitor significantly counteracted 13’-COOHs-induced cancer cell death,
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suggesting that neutral SMase-catalyzed SM hydrolysis may be involved. However, we
cannot completely rule out the possibility that SMS was inhibited by 13’-COOHs so that
Cers were accumulated with simultaneous decrease of SMs.
Our finding that 13’-COOHs have potent anti-proliferation effect and induce cell
death in various types of cancer cells has physiological implications. Previous studies
have demonstrated that γT and mixed tocopherols are effective in suppression of colon
tumorigenesis in preclinical mouse models (Jiang et al., 2013; Ju et al., 2009; Newmark
et al., 2006). Interestingly, 13’-COOHs have been identified as a predominant fecal
excreting vitamin E metabolite and found at relatively high levels in feces of mice fed γT
or δT supplementation (Bardowell et al., 2012a; Bardowell et al., 2012b; Jiang et al.,
2013). Since 13’-COOHs appear to be much stronger than un-metabolized tocopherols in
induction of death in colon cancer cells, 13’-COOHs likely contribute to the anticancer
effects of tocopherol supplements against colon cancer in vivo. Furthermore, given the
anticancer and anti-inflammatory activities possessed by 13’-COOHs, these compounds
are potentially excellent agents for chemoprevention. Consistently, our animal studies
showed that δTE-13’-COOH effectively attenuated DSS-caused colon inflammation and
AOM/DSS-induced tumor development in mice, which mimic colitis and colitispromoted colon cancer, respectively.
In summary, we have demonstrated for the first time that 13’-COOHs, long-chain
metabolites of vitamin E, induce apoptosis and autophagy by modulating sphingolipids in
various types of cancer cells. Our results indicate that 13’-COOHs initially targets DEGS
and subsequently activate SM hydrolysis possibly via neutral SMase during cell death
process. This anticancer activity together with dual inhibition of COXs and 5-LOX
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strongly suggest that 13’-COOHs likely play significant roles in the chemoprevention
effect by vitamin E forms in vivo and that long-chain carboxychromanols may be novel
preventative and therapeutic agents against cancer.
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CHAPTER 4. TARGETING SPHINGOLIPID METABOLISM FOR THE
ANTICANCER EFFECTS OF VARIOUS CHEMOPREVENTIVE COMPOUNDS

4.1

Abstract

Phytochemicals have been shown to exert anticancer activities, but the underlying
mechanisms; in particular, the first important target has not been completely identified
yet. We have earlier shown that specific vitamin E forms, phenolic compounds in various
classes of phytochemicals, and 13’-carboxychromanols, long-chain vitamin E metabolites
induced cancer cell death by modulation of sphingolipid metabolism as an initial primary
target. In this study, we investigated whether other chemopreventive compounds
including representative phytochemicals (curcumin, resveratrol, epigallocatechin gallate
(EGCG), quercetin, sulforaphane), ER stress inducers (dithiothreitol, thapsigargin), and
chemotherapeutic drugs (doxorubicin, camptothecin) also show anticancer effects by
modulation of sphingolipid metabolism using a sphingolipidomic analysis via employing
liquid chromatography tandem mass spectrometry (LC-MS/MS) in human colon cancer
HCT-116 cells. We show that all the tested compounds modulated sphingolipid
metabolism in HCT-116 cells. Specifically, while the effects of individual compounds on
different Ceramide (Cer) species with distinct chain-length of fatty acyl-CoA were
different, all tested compounds increased the levels of dihydroceramides (dhCers)
compared with controls. For instance, curcumin increased C24-Cers, but decreased C16:0-
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Cer, and resveratrol and DTT decreased the levels of all different species of Cers. On the
other hand, while sulforaphane, quercentin, thapsigargin, doxorubicin and camptothecin
increased all Cers, EGCG did not affect on the Cer levels during our tested treatment
times. Moreover, we found that curcumin and quercetin significantly inhibited DEGS
enzyme activities. Interestingly, these changes in sphingolipid metabolism by the tested
compounds occurred quickly and prior to any manifestation of cell death. These data
demonstrated that modulation of sphingolipid metabolism might be a general mechanism
for the anticancer effects of various chemopreventive compounds against cancer, and
inhibition of DEGS enzyme might be the initial primary target of their anticancer actions.

4.2

Introduction

Colon cancer is one of the leading causes of cancer-related deaths in the United
States (Siegel et al., 2015). Since there are no effective treatment for advanced cancer,
chemoprevention becomes a promising strategy to reduce cancer-caused death.
Chemoprevention against cancer includes antiproliferation and induction of death in
malignant cells, and therefore stops or delays the onset of metastasis. Epidemiological
studies have consistently shown that intake of high levels of fruits and vegetables is
inversely associated with cancer incidence (Block et al., 1992; Steinmetz and Potter,
1996). Recently, numerous dietary plant phytochemicals have been extensively studied
and have exhibited cancer preventive activities through modulation of multiple signaling
pathways and proteins, which are involved in cellular proliferation, differentiation, and
apoptosis (Johnson, 2007; Lee et al., 2011; Surh, 2003). However, the underlying
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mechanisms especially the first primary target of their anticancer effects is not
understood yet.
Cellular metabolism, including sphingolipid metabolism, is emerging as
promising targets as sphingolipids are closely associated with cell survival and death
(Hannun and Obeid, 2008; Ryland et al., 2011; Zheng et al., 2006). Sphingolipids are
structural components of cell membranes and play important roles in signal transduction.
De novo sphingolipid biosynthesis starts in the endoplasmic reticulum with the
condensation of palmitoyl-CoA and serine into 3-ketosphinganine by serine
palmitoyltransferase, which rapidly reduced to dihydrosphingosine (dhSph) by 3ketosphinganine reductase. A family of (dihydro)ceramide synthases (CerSs) attached
fatty acyl-CoA with variable chain lengths to dhSph to generate the corresponding
dihydroceramide (dhCer) subspecies. DhCer desaturase (DEGS) introduces a 4,5-trans
double bond in dhCer, thus generating ceramide (Cer). The Cer is transported to the
Golgi apparatus to generate more complex sphingolipids such as glycosyl-, or galactosylCers and sphingomyelin (SM) by the actions of enzymes glucosyl-Cer synthase, Cer
galactosyltransferase, or SM synthases, respectively (Hannun and Obeid, 2008).
DhCers were believed to be a non-signaling molecule and an inactive precursor of
Cer, which is a well-known sphingolipid metabolite, especially involved in the regulation
of apoptosis (Kolesnick, 2002; Radin, 2001; Woodcock, 2006). However, the potential
effectiveness of dhCers has become recognized with the development of the new
technology, LC-MS/MS, which can identify and distinguish the different species of Cer
and dhCer. Since then, several recent studies reported that the increase of dhCers is
related to the induction of cell cycle arrest (Kraveka et al., 2007), apoptosis (Gopalan et
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al., 2012; Jiang et al., 2012; Stiban et al., 2006), and autophagy (Jiang et al., 2012;
Signorelli et al., 2009; Zheng et al., 2006), and some compounds and environmental
factors such as vitamin E forms (γT and γTE) (Gopalan et al., 2012; Jiang et al., 2012;
Jiang et al., 2004), fenretinide (Rahmaniyan et al., 2011), resveratrol (Signorelli et al.,
2009), celecoxib (Schiffmann et al., 2009b), oxidative stress (Idkowiak-Baldys et al.,
2010), and hypoxia (Devlin et al., 2011) are known to induce accumulation of
intracellular dhCers. In addition, the regulation of DEGS, an enzyme that converts dhCer
into Cer, thus controls the levels of each sphingolipid metabolite became important, as
genetic or chemical inhibition of DEGS was reported to induce accumulation of dhCer
(Kraveka et al., 2007; Ruangsiriluk et al., 2012; Siddique et al., 2013).
We have previously shown that γTE and 13’-carboxychromanol, a long-chain
vitamin E metabolite, induced colon cell death by inhibition of DEGS as an initial target,
resulting in the accumulation of intracellular dhCers (Jang Y and Jiang Q, unpublished
data). Therefore, the objectives of this study were to investigate whether like vitamin E
forms, other chemopreventive compounds also modulate sphingolipid metabolism as a
general pathway, and to determine whether this modulation is an initial primary target for
their anticancer activities. Here, we demonstrated that various chemopreventive
compounds (Fig. 4.1) including representative phytochemicals (curcumin, resveratrol,
epigalloatecin gallate (EGCG), quercetin, sulforaphane), endoplasmic reticulum (ER)
stress inducers (dithiothreitol (DTT), thapsigargin), and chemotherapeutic drugs
(doxorubicin, camptothecin) induced increases of dhCers and modulation of Cers by
interrupting de novo sphingolipid metabolism as their initial primary target.
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Figure 4.1 The structures of (A) representative phytochemicals, (B) ER stress inducers
and (C) cancer chemotherapeutic drugs. (A) Representative phytochemicals: curcumin,
resveratrol, quercetin, EGCG, and sulforaphane. (B) ER stress inducers: DTT and
thapsigargin. (C) Cancer chemotherapeutic drugs: doxorubicin and camptothecin.

4.3

Materials and Methods

4.3.1

Materials and reagents

Curcumin (≥90%), resveratrol (≥98%), and epigallocatechin gallate (EGCG;
≥98%) were purchased from Sigma (St Louis, MO). Quercetin (≥95%), sulforaphane
(≥90%), dithiothreitol (DTT; ≥99%), thapsigargin (≥98%), doxorubicin (98-102%), and
camptothecin (≥90%) were purchased from Cayman Chemical (Ann Arbor, MI). All
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sphingolipid standards were obtained from Avanti Polar Lipids (Alabaster, AL). C8cyclopropenylceramide (C8-CPPC) was purchased from Matreya LLC (Pleasant Gap,
PA). 13C3, 15N-labeled L-serine, Dimethyl sulfoxide (DMSO), [3-(4,5)-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide] (MTT), and all other chemicals were from Sigma.

4.3.2

Cell culture and treatment

Human colon cancer HCT-116 cells were obtained from American Type Culture
Collection (Manassas, VA). Cells were routinely cultured in McCoy’s 5A modified
growth medium containing 10% fetal bovine serum (FBS) at 37 °C in 5% CO2. For
experiments, cells were seeded in the growth medium with 10% FBS either at a density
of 4 x 104 cells/well in 24-well plates or at a density of 7-8 x 105 cells in 10-cm dishes.
After overnight attachment, media were replaced with fresh Dulbecco’s modified eagle
medium (DMEM) containing 1% FBS with tested compounds. All the treatment solutions
were freshly prepared for each experiment. All the tested compounds were dissolved in
DMSO and the same amount of DMSO was added to control group.

4.3.3

MTT assay

Cell viability was examined by the estimation of mitochondrial dehydrogenase
activity that reduces MTT to form formazan which was dissolved in DMSO and
measured the absorbance at 570 nm by using a microplate reader (SpectraMax 190,
Molecular Devices, Sunnyvale, CA) (Mosmann, 1983).
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4.3.4

Lipid extraction

Lipids were extracted according to a previously published method (Merrill et al.,
2005). Briefly, cell pellets were resuspended in methanol/chloroform/water (10:5:1
[v/v/v]), after the addition of internal standard mixture containing 0.5 nmol of C12:0-Cer,
C25:0-Cer, C17-sphingosine, C17-dhSph, and C12:0-SM (Avanti Polar Lipids, Alabaster,
AL). The suspension was tip sonicated and then incubated overnight at 48 °C. A total of
100 µL of suspension was used to determine the amount of total choline-containing
phospholipids by an enzymatic colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang
et al., 2004) 75 µL of 1M KOH in methanol was added to the rest of the suspension and
sonicated for 30 min. Samples were incubated at 37 °C for 2 h and evaporated under a
stream of nitrogen.

4.3.5

Measurement of sphingolipids using liquid chromatography tandem mass
spectrometry (LC-MS/MS)

Immediately before the LC-MS/MS analyses, the prepared samples above were
resolved in methanol, sonicated, and then briefly centrifuged. The LC-MS/MS analyses
were performed using the Agilent 6460 triple quadrupole mass spectrometer coupled with
the Agilent 1200 Rapid Resolution HPLC (Agilent Technologies, Santa Clara, CA) with
identification of each sphingolipid in positive mode by multiple reaction monitoring
(MRM) technique (Merrill et al., 2005). The HPLC mobile phases consisted of methanolH2O-formic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v; RB); both RA
and RB contain 5 mM ammonium formate. For measurement of Cers and sphingoid
bases, Agilent column XDB-C18 (4.6 x 50 mm) with particle size of 1.8 µm, was used
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with isocratic run (100% B) or gradient (0-1 min, 20% B, 10-13 min, 100% B and 15-20
min at 20% B), respectively. For measurement of SMs, Agilent Zorbax XDB-C8 (2.1 x
50 mm) with particle size of 3.5 µm, was used with gradient (0-1 min, 20% B, 10-20 min,
100% B, 22-30 min, 20% B). The MS/MS parameters were as follows: gas temperature,
325-350 °C; gas flow rate, 7-10 L/min; nebulizer pressure, 45-50 psi; capillary voltage,
3500 V; The fragmentor voltage was 100 V and collision energy was 12-20 V. Precursorto-product ion transitions for each sphingolipid were used according to the method of
Merrill et al. (Merrill et al., 2005).

4.3.6

De novo sphingolipids anlaysis

HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone
or with a combination of 400 µM 13C3, 15N-labeled L-serine and 10 µM of curcumin for
20, 30, 60 and 90 min. Lipids were extracted and de novo synthesized sphingolipids were
measured using LC-MS/MS.

4.3.7

Dihydroceramide desaturase (DEGS) assays

In Vitro DEGS assay - HCT-116 cells were treated with either a tested compound
or 1 µM C8-CPPC as a positive control for 1 or 2 h. Cells were collected and
homogenized in a buffer (5 mM Hepes, pH 7.4, containing 50 mM sucrose) followed by
10 min incubation on ice. The cell homogenate was centrifuged at 250 x g for 5 min at
4 °C to remove unbroken cells. Reaction was started by addition of C8:0-dihydroceramide
(C8:0-dhCer) as a non-physiological substrate for the DEGS enzyme and NADH as a
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cofactor at 37 °C for an hour. Immediately after the reaction, lipids were extracted and
the products (C8:0-Cer and C8:0-SM) were quantified by LC-MS/MS.
In Situ DEGS assay - HCT-116 cells were pretreated with either a tested
compound or C8-CPPC, and then added 10 μM of C8:0-dhCer as a substrate for the DEGS
enzyme, followed by 1h incubation. The cells were collected and lipids were extracted.
The levels of products (C8:0-Cer and C8:0-SM) were measured by LC-MS/MS.

4.3.8

Statistics

Statistical significance was determined using a Student’s t-test. P < 0.05 was
considered statistically significant.

4.4

4.4.1

Results

Curcumin increased dhCers, dhSph, and C24-Cers, but decreased C16:0-Cer by
DEGS inhibition

We first investigated the effects of curcumin, which is a polyphenolic compound
isolated from a rhizome of the plant Curcuma longa and a promising phytochemical for
cancer chemoprevention and therapy, on sphingolipid metabolism using LC-MS/MS in
human colon HCT-116 cancer cells. HCT-116 cells were treated with 10 μM of curcumin
for 1, 2, and 4 hours. During the treatment times, curcumin caused significant increases
of dhCers including C16:0-, C24:1-, and C24:0-dhCers, and dhSph, compared with controls
(Fig. 4.2B). While C16:0-Cer was significantly decreased as early as 1 h incubation with
curcumin, C24-Cers were increased compared with controls (Fig. 4.2C). Meanwhile, there
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were no apparent changes of SM and dhSM species after 4 h incubation with curcumin
(Fig. 4.2D; Table 4.1). Since treatment of curcumin induced accumulations of dhCers and
dhSph, which are important sphingolipid metabolites in the de novo sphingolipid
biosynthesis pathway (Fig. 4.3A), we used 13C3, 15N-labeled L-serine to only trace the
effect of curcumin on de novo synthesized sphingolipids. Curcumin treatment induced
significant increases in labeled dhCers, but decreases in C16:0-Cer as early as 20 min to 90
min (Figs. 4.3C and D), without affecting the amount of total de novo-syntheized
sphingolipids (Fig. 4.3B; Table 4.2). The increases of de novo dhCers but decreases of de
novo Cers suggest the inhibition of DEGS-catalyzed reaction by curcumin treatment.
Therefore, we next examined the effect of curcumin on the DEGS enzyme activity. In the
in vitro DEGS assay with cell homogenates, 1 h incubation with 10 or 20 μM of
curcumin showed ~76% and ~92% inhibition of DEGS enzyme activity, respectively
(Fig. 4.4A). In another assay, in situ DEGS assay also showed significant inhibition of
DEGS activity with 10 or 20 μM of curcumin after 2-3 hours incubation, though the
inhibitory effects in this assay were much lower than those in the in vitro assay (Fig.
4.4B). In both assays, C8-CPPC, a known competitive inhibitor of DEGS (Triola et al.,
2003), inhibited the enzyme activity by about 85~95%. Interestingly, these all modulation
of sphingolipid metabolism was occurred prior to any signs of cell death determined by
MTT cell viability assay (data not shown).
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Figure 4.2 Effects of curcumin on sphingolipid metabolism in HCT-116 cells. (A) The
anti-proliferative effects of curcumin on human colon HCT-116 cancer cells. Relative
cell viability was measured after treatment with curcumin at the stated concentrations and
time by MTT assay compared with control. The data are mean ± SD for 3 independent
experiments, each performed in duplicate. HCT-116 cells were treated with 10 μM of
curcumin for 1, 2, and 4 hours. The sphingolipid levels including (B) dhCers; C16:0-,
C24:1-, and C24:0-dhCers and dhSph, (C) Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM;
C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were determined by LC-MS/MS.
Results are shown as mean ± SD for 3-4 independent experiments. *p < 0.05 and **p <
0.01 indicate a significant difference between treated and control cells.
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A

De novo synthesis of sphingolipid
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Figure 4.3 Effects of curcumin on de novo sphingolipid biosynthesis in HCT-116 cells.
(A) The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin synthase;
SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM 13C3, 15Nlabeled L-serine alone as control or with a combination of 400 μM 13C3, 15N-labeled Lserine and 10 μM curcumin for 20, 30, 60, and 90 min. The amount of each labeled de
novo sphingolipid including (B) total amounts of all the de novo synthesized
sphingolipids, (C) de novo total dhCer and de novo C16:0-dhCer, (D) de novo total Cers,
de novo C16:0-Cer, and de novo C24:1-Cer were determined by LC-MS/MS. Results are
shown as mean ± SEM for 3-4 independent experiments. *p < 0.05 and **p < 0.01
indicate a significant difference between treated and control cells.
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Figure 4.4 Effects of curcumin on DEGS activity. HCT-116 cells were treated with either
10 or 20 μM curcumin or 1 μM C8-CPPC as a positive control. (A) In vitro DEGS assay:
After 1 h of treatment, cells were collected and homogenized. Using the homogenates,
reaction was started by addition of C8:0-dhCer as a substrate for DEGS with NADH for an
hour in 37 °C. The levels of products which are C8:0-sphingolipids were analyzed by
using LC-MS/MS. The data are mean ± SD of 1-2 independent experiments. (B) In situ
DEGS assay: After 1-2 hours of pretreatment, cells were incubated with 10 μM C8:0dhCer as a substrate for DEGS for additional 1 h. The cells were collected and the levels
of products which are C8:0-sphingolipids were analyzed by using LC-MS/MS. The data
are mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01 indicate a
significant difference between treated and control cells.
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4.4.2

Resveratrol and DTT increased dhCers, dhSph, but decreased C16:0-Cer and C24Cers
We next examined the modulation of sphingolipid using another naturally

occurring, well-recognized cancer chemopreventive polyphenolic compound, resveratrol,
found in grapes and wine. Reseveratrol has been shown to induce autophagy by inhibition
of DEGS activity followed by dhCer accumulation in gastric cancer cells (Signorelli et
al., 2009). Consistently, 50 μM of resveratrol treatment for 2-4 hours significantly
enhanced intracelluar levels of dhCers and dhSph (Fig. 4.5B). Compared with controls,
resveratrol treatment induced decreases in C16:0- and C24:1-Cers (Fig. 4.5C). While C16:0SM was decreased, C16:0-dhSM was increased by 4 h incubation with resveratrol (Fig.
4.5D; Table 4.3).
In addition, we tested the effects of ER stress inducers including DTT and
thapsigargin on sphingolipid metabolism. Since de novo synthesis pathway occurs in the
ER, we hypothesized that disruption of ER environment by ER stress induction may also
induce interruption of sphingolipid metabolism. As we expected, similar to resveratrol, 2
mM of DTT treatment for 2-4 hours elevated dhCers and dhSph, but decreased in C16:0and C24-Cers (Figs. 4.6A and B). DTT treatment also tends to decrease in C16:0-SM but
increase in C16:0-dhSM as compared with controls (Fig. 4.6C; Table 4.4).
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Figure 4.5 Effects of resveratrol on sphingolipid metabolism in HCT-116 cells. (A) The
anti-proliferative effects of resveratrol on human colon HCT-116 cancer cells. Relative
cell viability was measured after treatment with resveratrol at the stated concentrations
and time by MTT assay compared with control. The data are mean ± SD for 1 duplicate
experiment. HCT-116 cells were treated with 50 μM of resveratrol for 2 and 4 hours. The
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C)
Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0-
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and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for
three independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference
between treated and control cells.

Figure 4.6 Effects of DTT on sphingolipid metabolism in HCT-116 cells. HCT-116 cells
were treated with 2 mM of DTT for 2 and 6 hours. The sphingolipid levels including (A)
dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-, C24:1-, and C24:0-Cers,
(C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were determined by
LC-MS/MS. Results are shown as mean ± SD for 1 (6 h) or 2 (2 h) independent
experiments.
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4.4.3

Sulforaphane, quercetin, thapsigargin, doxorubicin and camptothecin increased
Cers and dhCers
We then investigated to see whether sulforaphane also modulates sphingolipid

metabolism as it belongs to a class of organosulfur compounds in phytochemical groups.
Different with phenolic compounds that contain one or more hydroxyl groups attached to
one or more aromatic rings, organosulfur compounds contain sulfur in their structure.
Treatment of cells with 20 μM of sulforaphane for 2-4 hours also modulated sphingolipid
metabolism by increasing the levels of Cers as well as the levels of dhCers compared
with controls (Fig. 4.7; Table 4.5). Another phenolic compound, quercetin modulated the
levels of sphingolipid metabolites as similar way with sulforaphane (Fig. 4.8; Table 4.6).
Since 20 μM of quercetin elevated not only dhCers, but also Cers, we tested the effects of
quercetin on DEGS enzyme activity. In the in situ DEGS assay, incubation of cells with
20 μM of quercetin for 2-3 hours significantly inhibited the DEGS activity by 42% (Fig.
4.8E). Interestingly, thapsigargin, another ER stress inducer, also induced accumulation
of intracellular C16:0-dhCer after 6 h treatment with 1 μM concentration, but different
with DTT, it did not decrease the levels of Cers (Fig. 4.9; Table 4.7).
Furthermore, to evaluate whether cancer chemotherapeutic drugs modulate
sphingolipid metabolism or not, we used two well-known drugs, doxorubicin and
camptothecin. Treatment of cells with 5 μM of doxorubicin or 1 μM of camptothecin
both enhanced C16:0-dhCer and Cers after 24 h incubation (Fig 4.10; Table 4.8).
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Figure 4.7 Effects of sulforaphane on sphingolipid metabolism in HCT-116 cells. HCT116 cells were treated with 20 μM of sulforaphane for 2 and 4 hours. The sphingolipid
levels including (A) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-,
C24:1-, and C24:0-Cers, (C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs
were determined by LC-MS/MS. Results are shown as mean ± SD for two independent
experiments.
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Figure 4.8 Effects of quercetin on sphingolipid metabolism in HCT-116 cells. (A) The
anti-proliferative effects of quercetin on human colon HCT-116 cancer cells. Relative cell
viability was measured after treatment with quercetin at the stated concentrations and
time by MTT assay compared with control. The data are mean ± SD for 1 duplicate
experiment. HCT-116 cells were treated with 20 μM of quercetin for 2 and 4 hours. The
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C)
Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for two
independent experiments. (E) The effect of quercetin on DEGS activity was measured by
in situ assay. HCT-116 cells were preincubated with either 20 μM quercetin or 1 μM C8CPPC for 2-3 hours followed by 10 μM C8:0-dhCer treatment for 1 h. The cells were
collected and the levels of products which are C8:0-sphingolipids were analyzed by using
LC-MS/MS. The data are mean ± SD of three independent experiments. *p < 0.05 and
**p < 0.01 indicate a significant difference between treated and control cells.

174

Figure 4.9 Effects of thapsigargin on sphingolipid metabolism in HCT-116 cells. HCT116 cells were treated with 1 μM of thapsigargin for 6 hours. The sphingolipid levels
including (A) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-, C24:1-,
and C24:0-Cers, (C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were
determined by LC-MS/MS. Results are shown as mean ± SD for two independent
experiments.
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Figure 4.10 Effects of cancer chemotherapeutic drugs (doxorubicin and camptothecin) on
sphingolipid metabolism in HCT-116 cells. (A) The anti-proliferative effects of
doxorubicin on human colon HCT-116 cancer cells. Relative cell viability was measured
after treatment with doxorubicin at the stated concentrations and time by MTT assay
compared with control. The data are mean ± SD for 1 duplicate experiment. HCT-116
cells were treated with 5 μM of doxorubicin or 1 μM of camptothecin for 24 hours. The
sphingolipid levels including (B and E) dhCers; C16:0-, C24:1-, and C24:0-dhCers and
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dhSph, (C and F) Cers; C16:0-, C24:1-, and C24:0-Cers, (D and G) dhSM; C16:0- and C24:0dhSMs, and SMs; C16:0- and C24:1-SMs were determined by LC-MS/MS. Results are
shown as mean ± SD for one independent experiment.

4.4.4

EGCG increased dhCer, but did not affect other sphingolipids

The effects of EGCG, the major polyphenolic compound found in green tea, on
sphingolipid metabolism were investigated in human colon HCT-116 cancer cells.
Treatment of cells with 50 μM of EGCG for 4 h elevated dhCers including C16:0-, C24:1-,
and C24:0-dhCers compared with controls, but not in 2 h incubation with EGCG (Fig.
4.11B). Even in 4 h incubation, EGCG did not change the levels of Cer species (Fig.
4.11C). While EGCG tends to increase C24:1-SM at 2 h, it did not affect SM and dhSM
levels in 4 h incubation (Fig. 4.11D; Table 4.9).
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Figure 4.11 Effects of EGCG on sphingolipid metabolism in HCT-116 cells. (A) The
anti-proliferative effects of EGCG on human colon HCT-116 cancer cells. Relative cell
viability was measured after treatment with EGCG at the stated concentrations and time
by MTT assay compared with control. The data are mean ± SD for 1 duplicate
experiment. HCT-116 cells were treated with 50 μM of EGCG for 2 and 4 hours. The
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C)
Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for
three independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference
between treated and control cells.
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Table 4.1 Effect of curcumin on sphingolipid metabolism in HCT-116 cells. HCT-116
cells were treated with 10 µM curcumin for 1, 2, and 4 h. The amount of each
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 3-4 independent
experiments. *p < 0.05, **p < 0.01, significant difference between control and curcumintreated cells. Cer, ceramide; dhCer, dihydroceramide; Sph, sphingosine; dhSph,
dihydrosphingosine; S1P, sphingosine-1-phosphate; SM, sphingomyelin; dhSM,
dihydrosphingomyelin

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
1
2
4

Control
2.36 ± 0.29
3.29 ± 0.38
3.46 ± 0.42

Cur 10 µM
1.65 ± 0.13**
1.53 ± 0.11**
1.66 ± 0.12**

Control
0.069 ± 0.008
0.083 ± 0.009
0.084 ± 0.019

Cur 10 µM
0.10 ± 0.020
0.093 ± 0.011
0.11 ± 0.022*

Control
0.046 ± 0.009
0.057 ± 0.006
0.058 ± 0.016

Cur 10 µM
0.072 ± 0.013**
0.080 ± 0.008*
0.099 ± 0.026**

Control
0.49 ± 0.11
0.64 ± 0.032
0.58 ± 0.15

Cur 10 µM
0.71 ± 0.13*
0.87 ± 0.092
1.03 ± 0.20**

Control
2.43 ± 0.43
2.39 ± 0.31
1.98 ± 0.33

Cur 10 µM
3.18 ± 0.85*
2.77 ± 0.31**
2.57 ± 0.45*

Control
2.54 ± 0.41
2.61 ± 0.19
2.11 ± 0.34

Cur 10 µM
3.23 ± 0.74*
2.97 ± 0.21**
2.08 ± 0.72

C18:0-Cer
Hours
1
2
4
C20:0-Cer
Hours
1
2
4
C22:0-Cer
Hours
1
2
4
C24:1-Cer
Hours
1
2
4
C24:0-Cer
Hours
1
2
4
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C26:1-Cer
Hours
1
2
4

Control
0.24 ± 0.041
0.24 ± 0.026
0.20 ± 0.029

Cur 10 µM
0.45 ± 0.11**
0.45 ± 0.052**
0.50 ± 0.089**

Control
0.14 ± 0.054
0.19 ± 0.019
0.15 ± 0.024

Cur 10 µM
0.21 ± 0.088**
0.28 ± 0.030**
0.32 ± 0.060**

Control
8.32 ± 0.61
9.51 ± 0.88
8.61 ± 0.96

Cur 10 µM
9.61 ± 1.55
9.05 ± 0.80
8.36 ± 0.94

C26:0-Cer
Hours
1
2
4
Total Cers
Hours
1
2
4

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
1
2
4

Control
0.067 ± 0.009
0.11 ± 0.015
0.11 ± 0.011

Cur 10 µM
0.11 ± 0.011**
0.16 ± 0.023
0.29 ± 0.039**

Control
0.0016 ± 0.0001
0.0020 ± 0.0004
0.0019 ± 0.0004

Cur 10 µM
0.0035 ± 0.0006*
0.0035 ± 0.0006**
0.0071 ± 0.0012**

Control
0.00080 ± 0.0002
0.0011 ± 0.0001
0.0012 ± 0.0002

Cur 10 µM
0.0021 ± 0.0004
0.0017 ± 0.0001**
0.0054 ± 0.0014**

Control
0.0036 ± 0.001
0.0037 ± 0.001
0.0049 ± 0.001

Cur 10 µM
0.009 ± 0.003**
0.011 ± 0.002
0.03 ± 0.007**

C18:0-dhCer
Hours
1
2
4
C20:0-dhCer
Hours
1
2
4
C22:0-dhCer
Hours
1
2
4
C24:1-dhCer
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Hours
1
2
4

Control
0.0055 ± 0.001
0.0055 ± 0.001
0.0069 ± 0.043

Cur 10 µM
0.015 ± 0.003**
0.017 ± 0.003
0.043 ± 0.004**

Control
0.0069 ± 0.001
0.0060 ± 0.0009
0.0081 ± 0.0003

Cur 10 µM
0.014 ± 0.003**
0.016 ± 0.002**
0.046 ± 0.004**

Control
0.00041 ± 0.0002
0.00081 ± 0.0001
0.00085 ± 0.0002

Cur 10 µM
0.0012 ± 0.0007
0.0020 ± 0.0006
0.0060 ± 0.0005**

Control
0.085 ± 0.010
0.13 ± 0.019
0.13 ± 0.010

Cur 10 µM
0.15 ± 0.014**
0.21 ± 0.030
0.42 ± 0.044**

C24:0-dhCer
Hours
1
2
4
C26:1-dhCer
Hours
1
2
4
Total dhCers
Hours
1
2
4

Sphingoid bases (pmol/µg PC)
Sph
Hours
1
2
4

Control
0.94 ± 0.16
1.40 ± 0.15
1.02 ± 0.25

Cur 10 µM
1.25 ± 0.30
1.27 ± 0.17
1.03 ± 0.17

Hours
1
2
4

Control
0.057 ± 0.012
0.082 ± 0.007
0.071 ± 0.011

Cur 10 µM
0.14 ± 0.025**
0.16 ± 0.027*
0.18 ± 0.010*

Hours
1
2
4

Control
0.022 ± 0.006
0.018 ± 0.004
0.017 ± 0.005

Cur 10 µM
0.025 ± 0.013
0.011 ± 0.001
0.0091 ± 0.003

dhSph

S1P

Sphingomyelins (pmol/µg PC)
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C16:0-SM
Hours
1
2
4

Control
54.91 ± 3.13
64.14 ± 4.06
66.1 ± 4.76

Cur 10 µM
59.54 ± 4.97*
56.92 ± 2.24*
65.24 ± 3.01

Control
0.69 ± 0.048
1.06 ± 0.14
0.90 ± 0.075

Cur 10 µM
0.81 ± 0.064*
1.02 ± 0.076
1.42 ± 0.11*

Control
0.57 ± 0.065
1.04 ± 0.24
0.95 ± 0.21

Cur 10 µM
0.70 ± 0.076**
1.12 ± 0.18
1.49 ± 0.18

Control
3.19 ± 0.62
4.77 ± 0.93
4.06 ± 1.15

Cur 10 µM
3.77 ± 0.61*
4.95 ± 0.55
6.49 ± 1.01

Control
14.09 ± 2.57
22.00 ± 5.07
19.56 ± 5.76

Cur 10 µM
16.35 ± 2.76
21.88 ± 2.62
28.11 ± 4.06

Control
0.72 ± 0.15
1.41 ± 0.37
1.23 ± 0.42

Cur 10 µM
0.89 ± 0.17
1.42 ± 0.25
1.78 ± 0.39

Control
74.16 ± 6.26
94.42 ± 10.73
92.81 ± 7.20

Cur 10 µM
82.05 ± 8.59*
87.31 ± 5.17
107.21 ± 5.95*

C18:0-SM
Hours
1
2
4
C20:0-SM
Hours
1
2
4
C22:0-SM
Hours
1
2
4
C24:1-SM
Hours
1
2
4
C26:1-SM
Hours
1
2
4
Total SMs
Hours
1
2
4

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
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Hours
1
2
4

Control
7.14 ± 0.60
13.42 ± 3.22
10.91 ± 1.33

Cur 10 µM
7.63 ± 0.68
11.47 ± 2.39*
12.06 ± 2.32

Control
0.16 ± 0.018
0.38 ± 0.10
0.31 ± 0.033

Cur 10 µM
0.19 ± 0.029
0.37 ± 0.089
0.54 ± 0.083**

Control
0.14 ± 0.012
0.32 ± 0.083
0.25 ± 0.054

Cur 10 µM
0.18 ± 0.033
0.34 ± 0.092
0.46 ± 0.050

Control
0.38 ± 0.047
0.84 ± 0.15
0.78 ± 0.16

Cur 10 µM
0.46 ± 0.057
0.86 ± 0.15
1.37 ± 0.14

Control
0.56 ± 0.094
1.44 ± 0.30
1.24 ± 0.32

Cur 10 µM
0.67 ± 0.11
1.44 ± 0.32
5.63 ± 3.20

Control
0.067 ± 0.006
0.19 ± 0.058
0.14 ± 0.052

Cur 10 µM
0.075 ± 0.010
0.19 ± 0.070
0.17 ± 0.011

Control
8.44 ± 0.71
16.58 ± 3.55
13.63 ± 0.98

Cur 10 µM
9.21 ± 0.83
14.66 ± 2.93
20.23 ± 5.73

C18:0-dhSM
Hours
1
2
4
C20:0-dhSM
Hours
1
2
4
C22:0-dhSM
Hours
1
2
4
C24:0-dhSM
Hours
1
2
4
C26:0-dhSM
Hours
1
2
4
Total dhSMs
Hours
1
2
4

Table 4.2 Effect of curcumin on de novo sphingolipid biosynthesis in HCT-116 cells.
HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as
control or with a combination of 400 µM 13C3, 15N-labeled L-serine and 10 µM curcumin
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for 20, 30, 60, and 90 min. The amount of each labeled de novo sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 3-4 independent experiments. *p <
0.05, **p < 0.01, significant difference between control and curcumin-treated cells.

Ceramides (pmol/µg PC)
De novo C16:0-Cer
Minutes
20
30
60
90

Control
0.045 ± 0.014
0.15 ± 0.035
0.27 ± 0.035
0.38 ± 0.065

Cur 10 µM
0.027 ± 0.008**
0.078 ± 0.022**
0.13 ± 0.023**
0.18 ± 0.031**

Control
0.063 ± 0.032
0.16 ± 0.070
0.25 ± 0.094
0.40 ± 0.15

Cur 10 µM
0.056 ± 0.029
0.18 ± 0.082
0.31 ± 0.11**
0.53 ± 0.21*

Control
0.11 ± 0.046
0.33 ± 0.10
0.55 ± 0.13
0.86 ± 0.22

Cur 10 µM
0.082 ± 0.038*
0.27 ± 0.10*
0.47 ± 0.14
0.79 ± 0.23

De novo C24:1-Cer
Minutes
20
30
60
90
De novo total Cers
Minutes
20
30
60
90

Dihydroceramides (pmol/µg PC)
De novo C16:0-dhCer
Minutes
20
30
60
90

Control
0.0076 ± 0.002
0.018 ± 0.003
0.027 ± 0.005
0.030 ± 0.005

Cur 10 µM
0.0059 ± 0.001
0.019 ± 0.001
0.037 ± 0.010
0.045 ± 0.007**

Sphingomyelins (pmol/µg PC)
De novo C16:0-SM
Minutes
20
30
60

Control
0.26 ± 0.043
0.34 ± 0.025
0.42 ± 0.056

Cur 10 µM
0.27 ± 0.051
0.31 ± 0.040
0.40 ± 0.032
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90

0.64 ± 0.052

0.56 ± 0.033

Control
0.0095 ± 0.007
0.024 ± 0.019
0.018 ± 0.015
0.018 ± 0.009

Cur 10 µM
0.0038 ± 0.002
0.028 ± 0.024
0.045 ± 0.038
0.018 ± 0.009

Control
0.14 ± 0.073
0.15 ± 0.054
0.13 ± 0.048
0.18 ± 0.076

Cur 10 µM
0.13 ± 0.076
0.11 ± 0.052**
0.17 ± 0.058
0.21 ± 0.066

Control
0.41 ± 0.079
0.51 ± 0.043
0.57 ± 0.077
0.83 ± 0.12

Cur 10 µM
0.41 ± 0.061
0.45 ± 0.049
0.62 ± 0.064
0.79 ± 0.070

De novo C18:0-SM
Minutes
20
30
60
90
De novo C24:1-SM
Minutes
20
30
60
90
De novo total SMs
Minutes
20
30
60
90

Dihydrosphingomyelins (pmol/µg PC)
De novo C16:0-dhSM
Minutes
20
30
60
90

Control
0.094 ± 0.019
0.11 ± 0.012
0.094 ± 0.004
0.12 ± 0.005

Cur 10 µM
0.071 ± 0.005
0.088 ± 0.008
0.11 ± 0.010
0.17 ± 0.023

Table 4.3 Effect of resveratrol on sphingolipid metabolism in HCT-116 cells. HCT-116
cells were treated with 50 µM resveratrol for 2 and 4 h. The amount of each sphingolipid
was determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p
< 0.05, **p < 0.01, significant difference between control and resveratrol-treated cells.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
2
4

Control
3.29 ± 0.38
3.78 ± 0.37

Res 50 µM
1.46 ± 0.11**
1.37 ± 0.11**
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C18:0-Cer
Hours
2
4

Control
0.083 ± 0.009
0.098 ± 0.018

Res 50 µM
0.068 ± 0.005**
0.069 ± 0.003*

Control
0.057 ± 0.006
0.069 ± 0.016

Res 50 µM
0.049 ± 0.004
0.049 ± 0.006*

Control
0.64 ± 0.032
0.70 ± 0.13

Res 50 µM
0.64 ± 0.067
0.78 ± 0.046

Control
2.39 ± 0.31
2.18 ± 0.38

Res 50 µM
1.60 ± 0.18**
1.29 ± 0.26**

Control
2.61 ± 0.19
2.31 ± 0.39

Res 50 µM
2.43 ± 0.27
2.62 ± 0.58

Control
0.24 ± 0.026
0.22 ± 0.034

Res 50 µM
0.24 ± 0.036
0.25 ± 0.043

Hours
2
4
Total Cers

Control
0.19 ± 0.019
0.17 ± 0.023

Res 50 µM
0.19 ± 0.023
0.21 ± 0.035*

Hours
2
4

Control
9.51 ± 0.88
9.52 ± 0.44

Res 50 µM
6.66 ± 0.65**
6.64 ± 0.92*

C20:0-Cer
Hours
2
4
C22:0-Cer
Hours
2
4
C24:1-Cer
Hours
2
4
C24:0-Cer
Hours
2
4
C26:1-Cer
Hours
2
4
C26:0-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
2

Control
0.11 ± 0.015

Res 50 µM
1.04 ± 0.090**
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4

0.12 ± 0.011

0.92 ± 0.029**

Control
0.0020 ± 0.0004
0.0021 ± 0.0005

Res 50 µM
0.012 ± 0.0005**
0.011 ± 0.002**

Control
0.0011 ± 0.0001
0.0014 ± 0.0003

Res 50 µM
0.014 ± 0.0003
0.013 ± 0.0035**

Control
0.0037 ± 0.001
0.0055 ± 0.002

Res 50 µM
0.14 ± 0.011**
0.17 ± 0.028**

Control
0.0055 ± 0.0014
0.0069 ± 0.0004

Res 50 µM
0.16 ± 0.016*
0.15 ± 0.0058**

Control
0.0060 ± 0.0009
0.0083 ± 0.0002

Res 50 µM
0.23 ± 0.019**
0.29 ± 0.019**

Control
0.00081 ± 0.0001
0.0010 ± 0.0002

Res 50 µM
0.022 ± 0.0034
0.020 ± 0.0003

Control
0.13 ± 0.019
0.14 ± 0.008

Res 50 µM
1.62 ± 0.12**
1.56 ± 0.007**

C18:0-dhCer
Hours
2
4
C20:0-dhCer
Hours
2
4
C22:0-dhCer
Hours
2
4
C24:1-dhCer
Hours
2
4
C24:0-dhCer
Hours
2
4
C26:1-dhCer
Hours
2
4
Total dhCers
Hours
2
4

Sphingoid bases (pmol/µg PC)
Sph
Hours
2
4

Control
1.40 ± 0.15
1.17 ± 0.27

Res 50 µM
1.24 ± 0.10
0.91 ± 0.17*

Control

Res 50 µM

dhSph
Hours
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2
4

0.082 ± 0.007
0.074 ± 0.016

0.29 ± 0.014**
0.27 ± 0.040**

Hours
2
4

Control
0.018 ± 0.004
0.020 ± 0.006

Res 50 µM
0.018 ± 0.004
0.013 ± 0.002

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
2
4

Control
64.14 ± 4.06
66.68 ± 6.68

Res 50 µM
58.89 ± 5.65*
51.39 ± 5.09*

Control
1.06 ± 0.14
0.92 ± 0.10

Res 50 µM
0.93 ± 0.13
0.83 ± 0.11*

Control
1.04 ± 0.24
0.96 ± 0.30

Res 50 µM
1.05 ± 0.25
1.02 ± 0.19

Control
4.77 ± 0.93
4.01 ± 1.62

Res 50 µM
5.07 ± 1.06*
5.43 ± 0.99

Control
22.00 ± 5.07
19.51 ± 8.14

Res 50 µM
22.84 ± 5.11
22.94 ± 3.91

Control
1.41 ± 0.37
1.30 ± 0.58

Res 50 µM
1.49 ± 0.41
1.57 ± 0.31

Control
94.42 ± 10.73
93.38 ± 10.16

Res 50 µM
90.27 ± 12.59
83.17 ± 10.59**

C18:0-SM
Hours
2
4
C20:0-SM
Hours
2
4
C22:0-SM
Hours
2
4
C24:1-SM
Hours
2
4
C26:1-SM
Hours
2
4
Total SMs
Hours
2
4
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Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
2
4

Control
13.42 ± 3.22
11.70 ± 1.52

Res 50 µM
13.73 ± 1.23
16.18 ± 1.52*

Control
0.38 ± 0.10
0.34 ± 0.019

Res 50 µM
0.45 ± 0.087
0.64 ± 0.023**

Control
0.32 ± 0.083
0.28 ± 0.069

Res 50 µM
0.43 ± 0.11*
0.65 ± 0.076

Control
0.84 ± 0.15
0.79 ± 0.22

Res 50 µM
1.48 ± 0.30**
2.70 ± 0.23

Control
1.44 ± 0.30
1.19 ± 0.44

Res 50 µM
1.79 ± 0.44
3.15 ± 0.33

Control
0.19 ± 0.058
0.15 ± 0.071

Res 50 µM
0.22 ± 0.057*
0.35 ± 0.034

Control
16.58 ± 3.55
14.44 ± 0.77

Res 50 µM
18.11 ± 1.65
23.67 ± 0.91**

C18:0-dhSM
Hours
2
4
C20:0-dhSM
Hours
2
4
C22:0-dhSM
Hours
2
4
C24:0-dhSM
Hours
2
4
C26:0-dhSM
Hours
2
4
Total dhSMs
Hours
2
4

Table 4.4 Effect of DTT on sphingolipid metabolism in HCT-116 cells. HCT-116 cells
were treated with 2 mM DTT for 2 and 6 h. The amount of each sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 1 (6 h) or 2 (2 h) independent
experiments.

Ceramides (pmol/µg PC)
C16:0-Cer
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Hours
2
6

Control
2.59 ± 0.20
1.76

DTT 2 mM
1.75 ± 0.059
1.55

Control
0.055 ± 0.002
0.038

DTT 2 mM
0.043 ± 0.004
0.036

Control
0.034 ± 0.0001
0.029

DTT 2 mM
0.027 ± 0.0007
0.023

Control
0.27 ± 0.002
0.10

DTT 2 mM
0.15 ± 0.007
0.059

Control
2.07 ± 0.90
0.12

DTT 2 mM
1.05 ± 0.51
0.054

Control
1.95 ± 0.94
0.17

DTT 2 mM
1.15 ± 0.49
0.069

Hours
2
6
Total Cers

Control
0.22 ± 0.069
0.019

DTT 2 mM
0.11 ± 0.046
0.0076

Hours
2
6

Control
7.20 ± 2.12
2.23

DTT 2 mM
4.28 ± 1.11
1.80

C18:0-Cer
Hours
2
6
C20:0-Cer
Hours
2
6
C22:0-Cer
Hours
2
6
C24:1-Cer
Hours
2
6
C24:0-Cer
Hours
2
6
C26:1-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
2
6

Control
0.15 ± 0.049
0.16

DTT 2 mM
2.30 ± 0.89
5.95
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C18:0-dhCer
Hours
2
6

Control
0.00066 ± 0.0007
0.0018

DTT 2 mM
0.0052 ± 0.0052
0.028

Control
0.0017
0.0022

DTT 2 mM
0.023
0.096

Control
0.0080 ± 0.006
0.0018

DTT 2 mM
0.27 ± 0.12
0.063

Control
0.015 ± 0.007
0.0040

DTT 2 mM
0.22 ± 0.10
0.070

Control
0.17 ± 0.034
0.17

DTT 2 mM
2.81 ± 0.64
6.23

C22:0-dhCer
Hours
2
6
C24:1-dhCer
Hours
2
6
C24:0-dhCer
Hours
2
6
Total dhCers
Hours
2
6

Sphingoid bases (pmol/µg PC)
Sph
Hours
2
6

Control
0.68 ± 0.059
1.69

DTT 2 mM
0.56 ± 0.068
1.06

Hours
2
6

Control
0.088 ± 0.016
0.19

DTT 2 mM
0.15 ± 0.018
0.62

Hours
2
6

Control
0.042 ± 0.003
0.037

DTT 2 mM
0.035 ± 0.005
0.020

dhSph

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
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Hours
2
6

Control
38.08 ± 4.13
28.09

DTT 2 mM
33.91 ± 3.57
19.89

Control
1.54 ± 0.091
0.53

DTT 2 mM
0.64 ± 0.075
0.40

Control
0.33 ± 0.054
0.64

DTT 2 mM
0.49 ± 0.015
0.44

Control
0.90 ± 0.29
0.77

DTT 2 mM
1.41 ± 0.33
0.55

Control
3.16 ± 0.89
4.29

DTT 2 mM
4.68 ± 1.02
2.99

Control
0.68 ± 0.017
0.43

DTT 2 mM
0.28 ± 0.10
0.33

Control
44.69 ± 5.47
34.75

DTT 2 mM
41.41 ± 5.08
24.59

C18:0-SM
Hours
2
6
C20:0-SM
Hours
2
6
C22:0-SM
Hours
2
6
C24:1-SM
Hours
2
6
C26:1-SM
Hours
2
6
Total SMs
Hours
2
6

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
2
6

Control
10.36 ± 0.79
5.15

DTT 2 mM
10.76 ± 1.18
6.30

Control
0.27 ± 0.005
0.18

DTT 2 mM
0.35 ± 0.022
0.18

C18:0-dhSM
Hours
2
6
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C20:0-dhSM
Hours
2
6

Control
0.11 ± 0.002
0.17

DTT 2 mM
0.30 ± 0.010
0.20

Control
0.19 ± 0.090
0.12

DTT 2 mM
0.37 ± 0.029
0.23

Control
0.20 ± 0.045
0.27

DTT 2 mM
0.41 ± 0.054
0.57

Control
11.13 ± 0.91
5.96

DTT 2 mM
12.20 ± 1.30
7.61

C22:0-dhSM
Hours
2
6
C24:0-dhSM
Hours
2
6
Total dhSMs
Hours
2
6

Table 4.5 Effect of sulforaphane on sphingolipid metabolism in HCT-116 cells. HCT-116
cells were treated with 20 µM sulforaphane for 2 and 4 h. The amount of each
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 2 independent
experiments.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
2
4

Control
2.40 ± 0.18
2.85 ± 0.36

SFN 20 µM
3.13 ± 0.073
3.83 ± 0.010

Control
0.038 ± 0.001
0.042 ± 0.0002

SFN 20 µM
0.054 ± 0.009
0.061 ± 0.006

Control
0.022 ± 0.003
0.025 ± 0.002

SFN 20 µM
0.035 ± 0.006
0.042 ± 0.010

Control
0.19 ± 0.017

SFN 20 µM
0.26 ± 0.024

C18:0-Cer
Hours
2
4
C20:0-Cer
Hours
2
4
C22:0-Cer
Hours
2
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4

0.21 ± 0.0003

0.30 ± 0.025

Control
4.45 ± 0.42
4.76 ± 0.26

SFN 20 µM
5.61 ± 0.35
6.68 ± 0.58

Control
4.41 ± 0.59
4.67 ± 0.67

SFN 20 µM
4.31 ± 0.40
4.41 ± 0.50

Hours
2
4
Total Cers

Control
0.37 ± 0.051
0.43 ± 0.037

SFN 20 µM
0.47 ± 0.017
0.47 ± 0.024

Hours
2
4

Control
11.88 ± 1.23
12.99 ± 1.32

SFN 20 µM
13.87 ± 0.65
15.79 ± 1.04

C24:1-Cer
Hours
2
4
C24:0-Cer
Hours
2
4
C26:1-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
2
4

Control
0.053 ± 0.006
0.072 ± 0.018

SFN 20 µM
0.078 ± 0.007
0.11 ± 0.019

Control
0.0078 ± 0.008
0.0074 ± 0.007

SFN 20 µM
0.012 ± 0.012
0.016 ± 0.016

Control
0.061 ± 0.002
0.079 ± 0.011

SFN 20 µM
0.090 ± 0.004
0.12 ± 0.003

C24:1-dhCer
Hours
2
4
Total dhCers
Hours
2
4

Sphingoid bases (pmol/µg PC)
Sph
Hours
2
4

Control
0.57 ± 0.018
0.53 ± 0.025

SFN 20 µM
0.50 ± 0.013
0.61 ± 0.055
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dhSph
Hours
2
4

Control
0.10 ± 0.011
0.10 ± 0.001

SFN 20 µM
0.081 ± 0.005
0.10 ± 0.006

Hours
2
4

Control
0.013 ± 0.007
0.010 ± 0.002

SFN 20 µM
0.016 ± 0.003
0.014 ± 0.004

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
2
4

Control
83.97 ± 19.12
90.58 ± 20.91

SFN 20 µM
62.22 ± 15.81
67.94 ± 22.24

Control
1.59 ± 0.26
1.61 ± 0.13

SFN 20 µM
0.65 ± 0.17
0.60 ± 0.14

Control
0.37 ± 0.17
0.28 ± 0.084

SFN 20 µM
0.50 ± 0.13
0.50 ± 0.13

Control
1.32 ± 0.63
1.03 ± 0.33

SFN 20 µM
1.77 ± 0.29
1.84 ± 0.47

Control
4.80 ± 2.52
3.86 ± 1.53

SFN 20 µM
5.98 ± 1.14
6.31 ± 1.74

Control
2.12 ± 0.12
2.15 ± 0.048

SFN 20 µM
0.25 ± 0.040
0.27 ± 0.064

Control
94.16 ± 22.83

SFN 20 µM
71.37 ± 17.57

C18:0-SM
Hours
2
4
C20:0-SM
Hours
2
4
C22:0-SM
Hours
2
4
C24:1-SM
Hours
2
4
C26:1-SM
Hours
2
4
Total SMs
Hours
2
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4

99.51 ± 23.04

77.45 ± 24.79

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
2
4

Control
6.22 ± 0.15
5.50 ± 0.42

SFN 20 µM
6.78 ± 0.46
6.24 ± 0.12

Control
0.11 ± 0.019
0.082 ± 0.016

SFN 20 µM
0.16 ± 0.005
0.13 ± 0.008

Control
0.033 ± 0.005
0.025 ± 0.011

SFN 20 µM
0.078 ± 0.016
0.068 ± 0.007

Control
0.081 ± 0.006
0.053 ± 0.026

SFN 20 µM
0.17 ± 0.034
0.15 ± 0.004

Control
0.063 ± 0.010
0.045 ± 0.029

SFN 20 µM
0.12 ± 0.026
0.11 ± 0.012

Control
0.0052 ± 0.001
0.0036 ± 0.002

SFN 20 µM
0.010 ± 0.002
0.011 ± 0.003

Control
6.51 ± 1.16
5.71 ± 0.00002

SFN 20 µM
7.30 ± 0.17
6.71 ± 0.84

C18:0-dhSM
Hours
2
4
C20:0-dhSM
Hours
2
4
C22:0-dhSM
Hours
2
4
C24:0-dhSM
Hours
2
4
C26:0-dhSM
Hours
2
4
Total dhSMs
Hours
2
4

Table 4.6 Effect of quercetin on sphingolipid metabolism in HCT-116 cells. HCT-116
cells were treated with 20 µM quercetin for 2 and 4 h. The amount of each sphingolipid
was determined by LC-MS/MS. Data are mean ± SEM of 2 independent experiments.

Ceramides (pmol/µg PC)
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C16:0-Cer
Hours
2
4

Control
2.59 ± 0.20
3.04 ± 0.32

Quer 20 µM
3.79 ± 0.29
4.10 ± 0.11

Control
0.055 ± 0.002
0.058 ± 0.009

Quer 20 µM
0.082 ± 0.003
0.085 ± 0.004

Control
0.034 ± 0.0001
0.038 ± 0.005

Quer 20 µM
0.052 ± 0.001
0.050 ± 0.003

Control
0.27 ± 0.002
0.25 ± 0.025

Quer 20 µM
0.32 ± 0.022
0.32 ± 0.010

Control
2.07 ± 0.90
2.31 ± 1.07

Quer 20 µM
2.19 ± 1.08
2.10 ± 0.89

Control
1.95 ± 0.94
2.23 ± 1.07

Quer 20 µM
2.28 ± 1.03
2.48 ± 0.98

Hours
2
4
Total Cers

Control
0.22 ± 0.069
0.21 ± 0.085

Quer 20 µM
0.17 ± 0.10
0.16 ± 0.086

Hours
2
4

Control
7.20 ± 2.12
8.14 ± 2.59

Quer 20 µM
8.88 ± 2.52
9.30 ± 2.06

C18:0-Cer
Hours
2
4
C20:0-Cer
Hours
2
4
C22:0-Cer
Hours
2
4
C24:1-Cer
Hours
2
4
C24:0-Cer
Hours
2
4
C26:1-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
2

Control
0.15 ± 0.049

Quer 20 µM
0.34 ± 0.10
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4

0.19 ± 0.055

0.68 ± 0.18

Control
0.0080 ± 0.006
0.025 ± 0.015

Quer 20 µM
0.020 ± 0.008
0.060 ± 0.029

Control
0.015 ± 0.007
0.016 ± 0.009

Quer 20 µM
0.048 ± 0.020
0.12 ± 0.063

Control
0.17 ± 0.034
0.24 ± 0.028

Quer 20 µM
0.42 ± 0.064
0.87 ± 0.081

C24:1-dhCer
Hours
2
4
C24:0-dhCer
Hours
2
4
Total dhCers
Hours
2
4

Sphingoid bases (pmol/µg PC)
Sph
Hours
2
4

Control
0.68 ± 0.059
0.75 ± 0.029

Quer 20 µM
1.13 ± 0.31
0.77 ± 0.017

Hours
2
4

Control
0.088 ± 0.016
0.11 ± 0.021

Quer 20 µM
0.11 ± 0.008
0.14 ± 0.037

Hours
2
4

Control
0.042 ± 0.003
0.033 ± 0.008

Quer 20 µM
0.039 ± 0.001
0.026 ± 0.019

dhSph

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
2
4

Control
38.08 ± 4.13
43.38 ± 5.40

Quer 20 µM
39.18 ± 2.96
35.33 ± 4.79

Control
1.54 ± 0.091
1.69 ± 0.078

Quer 20 µM
0.68 ± 0.021
0.59 ± 0.15

C18:0-SM
Hours
2
4
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C20:0-SM
Hours
2
4

Control
0.33 ± 0.054
0.33 ± 0.092

Quer 20 µM
0.51 ± 0.069
0.60 ± 0.070

Control
0.90 ± 0.29
0.93 ± 0.30

Quer 20 µM
1.55 ± 0.23
1.33 ± 0.40

Control
3.16 ± 0.89
3.25 ± 1.13

Quer 20 µM
5.24 ± 0.92
4.77 ± 1.25

Control
0.68 ± 0.017
0.78 ± 0.099

Quer 20 µM
0.34 ± 0.083
0.30 ± 0.065

Control
44.69 ± 5.47
50.37 ± 7.10

Quer 20 µM
47.51 ± 4.28
42.93 ± 6.72

C22:0-SM
Hours
2
4
C24:1-SM
Hours
2
4
C26:1-SM
Hours
2
4
Total SMs
Hours
2
4

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
2
4

Control
10.36 ± 0.79
10.56 ± 1.01

Quer 20 µM
11.25 ± 0.92
9.13 ± 1.95

Control
0.27 ± 0.005
0.36 ± 0.11

Quer 20 µM
0.40 ± 0.012
0.33 ± 0.072

Control
0.11 ± 0.002
0.087 ± 0.010

Quer 20 µM
0.21 ± 0.054
0.17 ± 0.021

Control
0.19 ± 0.090

Quer 20 µM
0.36 ± 0.048

C18:0-dhSM
Hours
2
4
C20:0-dhSM
Hours
2
4
C22:0-dhSM
Hours
2
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4

0.17 ± 0.046

0.32 ± 0.095

Control
0.20 ± 0.045
0.16 ± 0.004

Quer 20 µM
0.35 ± 0.046
0.38 ± 0.18

Control
11.13 ± 1.72
11.34 ± 1.62

Quer 20 µM
12.56 ± 1.73
10.33 ± 3.30

C24:0-dhSM
Hours
2
4
Total dhSMs
Hours
2
4

Table 4.7 Effect of thapsigargin on sphingolipid metabolism in HCT-116 cells. HCT-116
cells were treated with 1 µM thapsigargin for 6 h. The amount of each sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 2 independent experiments.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
6

Control
2.21 ± 0.45

TG 1 µM
3.43 ± 0.93

Control
0.045 ± 0.007

TG 1 µM
0.088 ± 0.020

Control
0.031 ± 0.003

TG 1 µM
0.059 ± 0.004

Control
0.16 ± 0.059

TG 1 µM
0.31 ± 0.15

Control
0.68 ± 0.56

TG 1 µM
0.81 ± 0.66

Hours
6
Total Cers

Control
0.72 ± 0.55

TG 1 µM
0.90 ± 0.73

Hours
6

Control
3.92 ± 1.68

TG 1 µM
5.71 ± 2.57

C18:0-Cer
Hours
6
C20:0-Cer
Hours
6
C22:0-Cer
Hours
6
C24:1-Cer
Hours
6
C24:0-Cer
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Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
6

Control
0.20 ± 0.035

TG 1 µM
0.67 ± 0.19

Control
0.0059 ± 0.0041

TG 1 µM
0.0094 ± 0.0068

Control
0.0054 ± 0.0015

TG 1 µM
0.017 ± 0.010

Control
0.21 ± 0.038

TG 1 µM
0.71 ± 0.20

C24:1-dhCer
Hours
6
C24:0-dhCer
Hours
6
Total dhCers
Hours
6

Sphingoid bases (pmol/µg PC)
Sph
Hours
6

Control
1.12 ± 0.56

TG 1 µM
1.03 ± 0.27

Hours
6

Control
0.13 ± 0.060

TG 1 µM
0.11 ± 0.048

Hours
6

Control
0.032 ± 0.005

TG 1 µM
0.030 ± 0.003

dhSph

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
6

Control
28.09 ± 1.52

TG 1 µM
31.20 ± 3.89

Control
1.60 ± 0.023

TG 1 µM
0.63 ± 0.085

Control
0.35 ± 0.12

TG 1 µM
0.58 ± 0.10

C18:0-SM
Hours
6
C20:0-SM
Hours
6
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C22:0-SM
Hours
6

Control
0.40 ± 0.12

TG 1 µM
1.03 ± 0.25

Control
2.25 ± 0.25

TG 1 µM
4.32 ± 0.17

Hours
6
Total SMs

Control
0.85 ± 0.089

TG 1 µM
0.41 ± 0.10

Hours
6

Control
33.54 ± 1.16

TG 1 µM
38.18 ± 3.85

C24:1-SM
Hours
6
C26:1-SM

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
6

Control
5.15 ± 0.97

TG 1 µM
7.23 ± 1.63

Control
0.20 ± 0.021

TG 1 µM
0.24 ± 0.070

Control
0.17 ± 0.003

TG 1 µM
0.19 ± 0.014

Control
0.12 ± 0.059

TG 1 µM
0.19 ± 0.059

Control
0.14 ± 0.038

TG 1 µM
0.29 ± 0.045

Control
5.86 ± 0.98

TG 1 µM
8.21 ± 1.78

C18:0-dhSM
Hours
6
C20:0-dhSM
Hours
6
C22:0-dhSM
Hours
6
C24:0-dhSM
Hours
6
Total dhSMs
Hours
6

Table 4.8 Effect of cancer chemotherapeutic drugs (doxorubicin and camptothecin) on
sphingolipid metabolism in HCT-116 cells. HCT-116 cells were treated with 5 µM
doxorubicin or 1 µM camptothecin for 24 h. The amount of each sphingolipid was
determined by LC-MS/MS. Data are results of 1 experiment.
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Ceramides (pmol/µg PC)
C16:0-Cer
Hours
24

Control
2.03

Dox 5 µM
3.93

CPT 1 µM
6.04

Control
0.025

Dox 5 µM
0.064

CPT 1 µM
0.094

Control
0.022

Dox 5 µM
0.039

CPT 1 µM
0.062

Control
0.16

Dox 5 µM
0.24

CPT 1 µM
0.27

Control
1.18

Dox 5 µM
2.03

CPT 1 µM
2.08

Control
1.87

Dox 5 µM
1.51

CPT 1 µM
1.75

Control
0.16

Dox 5 µM
0.11

CPT 1 µM
0.22

Hours
24
Total Cers

Control
0.15

Dox 5 µM
0.11

CPT 1 µM
0.24

Hours
24

Control
5.60

Dox 5 µM
8.03

CPT 1 µM
10.77

C18:0-Cer
Hours
24
C20:0-Cer
Hours
24
C22:0-Cer
Hours
24
C24:1-Cer
Hours
24
C24:0-Cer
Hours
24
C26:1-Cer
Hours
24
C26:0-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
24

Control
0.26

Dox 5 µM
0.57

CPT 1 µM
0.38

Control

Dox 5 µM

CPT 1 µM

C24:1-dhCer
Hours
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0.024

0.088

0.021

Control
0.28

Dox 5 µM
0.66

CPT 1 µM
0.40

Total dhCers
Hours
24

Sphingoid bases (pmol/µg PC)
Sph
Hours
24

Control
0.88

Dox 5 µM
0.96

CPT 1 µM
2.10

Hours
24

Control
0.08

Dox 5 µM
0.10

CPT 1 µM
0.16

Hours
24

Control
0.011

Dox 5 µM
0.029

CPT 1 µM
0.034

dhSph

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
24

Control
62.19

Dox 5 µM
66.74

CPT 1 µM
68.25

Control
0.51

Dox 5 µM
0.65

CPT 1 µM
0.68

Control
0.45

Dox 5 µM
0.55

CPT 1 µM
0.55

Control
1.58

Dox 5 µM
1.99

CPT 1 µM
1.94

Control
7.02

Dox 5 µM
9.60

CPT 1 µM
8.38

Control
0.37

Dox 5 µM
0.57

CPT 1 µM
0.48

C18:0-SM
Hours
24
C20:0-SM
Hours
24
C22:0-SM
Hours
24
C24:1-SM
Hours
24
C26:1-SM
Hours
24
Total SMs
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Hours
24

Control
72.12

Dox 5 µM
80.11

CPT 1 µM
80.28

Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
24

Control
10.19

Dox 5 µM
13.65

CPT 1 µM
12.52

Control
0.23

TG 1 µM
0.38

CPT 1 µM
0.38

Control
0.15

TG 1 µM
0.26

CPT 1 µM
0.24

Control
0.26

TG 1 µM
0.42

CPT 1 µM
0.38

Control
0.31

TG 1 µM
0.50

CPT 1 µM
0.38

Control
0.03

TG 1 µM
0.06

CPT 1 µM
0.06

Control
11.17

TG 1 µM
15.26

CPT 1 µM
13.96

C18:0-dhSM
Hours
24
C20:0-dhSM
Hours
24
C22:0-dhSM
Hours
24
C24:0-dhSM
Hours
24
C26:0-dhSM
Hours
24
Total dhSMs
Hours
24

Table 4.9 Effect of EGCG on sphingolipid metabolism in HCT-116 cells. HCT-116 cells
were treated with 50 µM EGCG for 2 and 4 h. The amount of each sphingolipid was
determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p <
0.05, **p < 0.01, significant difference between control and EGCG-treated cells.

Ceramides (pmol/µg PC)
C16:0-Cer
Hours
2
4

Control
3.29 ± 0.38
3.78 ± 0.37

EGCG 50 µM
3.80 ± 0.10
4.22 ± 0.40
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C18:0-Cer
Hours
2
4

Control
0.083 ± 0.009
0.098 ± 0.018

EGCG 50 µM
0.080 ± 0.008
0.085 ± 0.009

Control
0.057 ± 0.006
0.069 ± 0.016

EGCG 50 µM
0.058 ± 0.006
0.064 ± 0.008

Control
0.64 ± 0.032
0.70 ± 0.13

EGCG 50 µM
0.63 ± 0.069
0.59 ± 0.031

Control
2.39 ± 0.31
2.18 ± 0.38

EGCG 50 µM
2.47 ± 0.28
1.76 ± 0.38

Control
2.61 ± 0.19
2.31 ± 0.39

EGCG 50 µM
2.76 ± 0.35
2.21 ± 0.42

Control
0.24 ± 0.026
0.22 ± 0.034

EGCG 50 µM
0.22 ± 0.036
0.16 ± 0.028*

Hours
2
4
Total Cers

Control
0.19 ± 0.019
0.17 ± 0.023

EGCG 50 µM
0.17 ± 0.026
0.15 ± 0.022

Hours
2
4

Control
9.51 ± 0.88
9.52 ± 0.44

EGCG 50 µM
10.18 ± 0.86
9.24 ± 0.87

C20:0-Cer
Hours
2
4
C22:0-Cer
Hours
2
4
C24:1-Cer
Hours
2
4
C24:0-Cer
Hours
2
4
C26:1-Cer
Hours
2
4
C26:0-Cer

Dihydroceramides (pmol/µg PC)
C16:0-dhCer
Hours
2

Control
0.11 ± 0.015

EGCG 50 µM
0.11 ± 0.002
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4

0.12 ± 0.011

0.24 ± 0.037*

Control
0.0020 ± 0.0004
0.0021 ± 0.0005

EGCG 50 µM
0.0019 ± 0.0002
0.0037 ± 0.0004*

Control
0.0011 ± 0.0001
0.0014 ± 0.0003

EGCG 50 µM
0.00092 ± 0.0001
0.0019 ± 0.0002

Control
0.0037 ± 0.0006
0.0055 ± 0.0019

EGCG 50 µM
0.0034 ± 0.0007
0.012 ± 0.0027*

Control
0.0055 ± 0.0014
0.0069 ± 0.0004

EGCG 50 µM
0.0058 ± 0.0002
0.013 ± 0.0011**

Control
0.0060 ± 0.0009
0.0083 ± 0.0002

EGCG 50 µM
0.0056 ± 0.0010
0.020 ± 0.0025**

Control
0.00081 ± 0.0001
0.0010 ± 0.0002

EGCG 50 µM
0.0009 ± 0.0001
0.0015 ± 0.0002

Control
0.13 ± 0.019
0.14 ± 0.008

EGCG 50 µM
0.13 ± 0.003
0.29 ± 0.041*

C18:0-dhCer
Hours
2
4
C20:0-dhCer
Hours
2
4
C22:0-dhCer
Hours
2
4
C24:1-dhCer
Hours
2
4
C24:0-dhCer
Hours
2
4
C26:1-dhCer
Hours
2
4
Total dhCers
Hours
2
4

Sphingoid bases (pmol/µg PC)
Sph
Hours
2
4

Control
1.40 ± 0.15
1.17 ± 0.27

EGCG 50 µM
1.24 ± 0.16
0.96 ± 0.20*

Control

EGCG 50 µM

dhSph
Hours
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2
4

0.082 ± 0.007
0.074 ± 0.016

0.067 ± 0.003
0.045 ± 0.019

Hours
2
4

Control
0.018 ± 0.004
0.020 ± 0.006

EGCG 50 µM
0.022 ± 0.003
0.017 ± 0.004

S1P

Sphingomyelins (pmol/µg PC)
C16:0-SM
Hours
2
4

Control
64.14 ± 4.06
66.68 ± 6.68

EGCG 50 µM
66.62 ± 9.12
55.12 ± 1.34

Control
1.06 ± 0.14
0.92 ± 0.10

EGCG 50 µM
1.34 ± 0.25
0.99 ± 0.088*

Control
1.04 ± 0.24
0.96 ± 0.30

EGCG 50 µM
1.30 ± 0.37
1.05 ± 0.12

Control
4.77 ± 0.93
4.01 ± 1.62

EGCG 50 µM
5.90 ± 1.51
4.99 ± 0.55

Control
22.00 ± 5.07
19.51 ± 8.14

EGCG 50 µM
25.67 ± 6.43**
23.25 ± 2.37

Control
1.41 ± 0.37
1.30 ± 0.58

EGCG 50 µM
1.65 ± 0.47**
1.53 ± 0.15

Control
94.42 ± 10.73
93.38 ± 10.16

EGCG 50 µM
102.48 ± 17.82
86.92 ± 4.56

C18:0-SM
Hours
2
4
C20:0-SM
Hours
2
4
C22:0-SM
Hours
2
4
C24:1-SM
Hours
2
4
C26:1-SM
Hours
2
4
Total SMs
Hours
2
4
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Dihydrosphingomyelins (pmol/µg PC)
C16:0-dhSM
Hours
2
4

Control
13.42 ± 3.22
11.70 ± 1.52

EGCG 50 µM
12.75 ± 1.58
10.46 ± 2.02

Control
0.38 ± 0.10
0.34 ± 0.019

EGCG 50 µM
0.44 ± 0.10
0.40 ± 0.044

Control
0.32 ± 0.083
0.28 ± 0.069

EGCG 50 µM
0.40 ± 0.11
0.35 ± 0.031

Control
0.84 ± 0.15
0.79 ± 0.22

EGCG 50 µM
1.08 ± 0.22**
1.08 ± 0.12

Control
1.44 ± 0.30
1.19 ± 0.44

EGCG 50 µM
1.62 ± 0.34
1.65 ± 0.16

Control
0.19 ± 0.058
0.15 ± 0.071

EGCG 50 µM
0.22 ± 0.059*
0.27 ± 0.059

Control
16.58 ± 3.55
14.44 ± 0.77

EGCG 50 µM
16.51 ± 2.07
14.21 ± 2.25

C18:0-dhSM
Hours
2
4
C20:0-dhSM
Hours
2
4
C22:0-dhSM
Hours
2
4
C24:0-dhSM
Hours
2
4
C26:0-dhSM
Hours
2
4
Total dhSMs
Hours
2
4
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4.5

Discussion

We show that various anticancer compounds including representative
chemopreventive phytochemicals against cancer (phenolics: curcumin, resveratrol,
quercetin, EGCG; organosulfur compound: sulforaphane), ER stress inducers (DTT,
thapsigargin), and cancer chemotherapeutic drugs (doxorubicin, camptothecin), all
modulated sphingolipid metabolism in human colon HCT-116 cancer cells. Specifically,
while the effects of individual compounds on Cer species with specific fatty acid chain
lengths were different, all tested compounds increased the levels of dhCers compared
with controls. For instance, curcumin increased C24-Cers, but decreased C16:0-Cer, and
resveratrol and DTT decreased the levels of all different species of Cers. On the other
hand, while sulforaphane, quercentin, thapsigargin, doxorubicin and camptothecin
increased all Cers, EGCG did not affect on the Cer levels during our tested treatment
times. Moreover, we found that curcumin and quercetin significantly inhibited DEGS
enzyme activities. Interestingly, these changes of sphingolipid by the tested compounds
occurred quickly and took place prior to any manifestation of cell death. These data
demonstrated that modulation of sphingolipid metabolism might be a general mechanism
for the anticancer effects of chemopreventive compounds against cancer, and inhibition
of DEGS enzyme might be the initial primary target of their anticancer actions.
We suggests DEGS in the de novo sphingolipid biosynthesis pathway as an initial
inhibitory target of various cancer chemopreventive compounds based on the quick
increase of intracellular dhCers after treatment of all the tested compounds in human
colon HCT-116 cancer cells. DEGS is a key enzyme, which is responsible for addition of
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a double bond in dhCer, thus regulating the levels of dhCer as well as Cer in the cell. As
well as the elevation of dhCers, various compounds seem to have different effects on the
regulation of individual Cer species. Recent studies have shown that individual Cers with
specific fatty acid chain lengths have distinct roles in cell proliferation and death
(Hannun and Obeid, 2011; Ryland et al., 2011). For instance, C18:0-Cer generated by
CerS1 has been found to induce apoptosis (Senkal et al., 2010) or lethal autophagy
(Sentelle et al., 2012). The roles of C16:0-Cer generated by CerS5/6 are still debatable as it
has shown anti- or pro-apoptotic properties (Mullen et al., 2011; Schiffmann et al.,
2009b; Senkal et al., 2010; White-Gilbertson et al., 2009). In this study, in contrast to
dhCer, the effects of various cancer chemopreventive or chemotherapeutic compounds on
Cer varied with treatment time and specific Cer species. Therefore, further studies are
needed to verify their specific effects on CerS enzymes and the roles of individual Cers in
the regulation of cell fate.
Plant-derived phytochemicals were thought to act as only antioxidants to exhibit
their chemopreventive effects against cancer. However, interestingly, these compounds
have been found to show dual roles as pro-oxidants as well as antioxidants depending on
various environmental factors. They can generate reactive oxygen species and cause
oxidative stress (Babich et al., 2011; Fujisawa et al., 2004; Galati et al., 2002). Recently,
DEGS activity was found to be inhibited by hydrogen peroxide (Idkowiak-Baldys et al.,
2010). The mechanism whether the inhibition of DEGS and modulation of sphingolipid
metabolism by our tested compounds are caused by their pro-oxidant effects is not
understood, which warrants further investigation. In addition, the concentrations of
several compounds that we used in this study are not physiological as their low
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bioavailability due to rapid metabolism and excretion. Although many studies reported
anticancer effects of phytochemicals in vitro and in vivo, the effects of phytochemicals in
humans will need to be assessed in the future studies.
The current results also showed that ER stress inducers, DTT and thapsigargin,
modulated sphingolipid metabolism in cancer cells. The ER is an important organelle that
plays roles in the folding and maturation of newly synthesized transmembrane and
secretory proteins. Disruption of ER function causes an accumulation of unfolded and
misfolded proteins in the ER lumen, a condition termed ER stress, which then activates
unfolded protein response (UPR) to recover the condition. However, the excessive and
unresolvable ER stress induces apoptosis of the cell (Sano and Reed, 2013). DTT is an
ER stress inducer as it is a strong reducing compound and blocks disulfide-bond
formation. Thapsigargin is another well-known ER stress inducer and it acts as a specific
inhibitor of the sarcoplasmic/ER Ca2+-ATPase (SERCA), resulting in a decrease in
calcium levels in the ER. The decreased calcium levels in the ER lead to the
accumulation of unfolded protein followed by ER stress induction due to the loss of
activities of calcium-dependent ER chaperones (Oslowski and Urano, 2011). Since the de
novo sphingolipid biosynthesis pathway occurs in the ER, we hypothesized that ER stress
inducers may interrupt this sphingolipid metabolism. We found that both ER stress
inducers, DTT and thapsigargin enhanced dhCers and modulated sphingolipid
metabolism. Their mechanism of actions on sphingolipid metabolism is not completely
identified yet, but DTT has been shown to strongly inhibit DEGS activity, probably by
elevating cellular thiol contents or/and interfering with disulfide bonds in enzyme,
leading to impaired protein stability and catalytic activity (Michel et al., 1997).

212
In summary, we have shown that various compounds with cancer preventive or
therapeutic properties all induced accumulation of dhCers and modulation of sphingolipid
metabolism in human colon HCT-116 cancer cells. Our results indicate that these
compounds initially target DEGS and induce subsequent increase of dhCer species as
these responses took place very quickly and prior to any signs of cell death. Although
further studies to identify the clear mechanisms and the different effects of
chemopreventive compounds on individual CerSs are needed, we have demonstrated that
sphingolipid metabolism is the initial primary target of anticancer effects of various
compounds.
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CHAPTER 5. SUMMARY AND FUTURE DIRECTION

5.1

Effects and Mechanisms of γTE on Sphingolipid Metabolism

Sphingolipids are structural components of cell membranes and play important
roles in cellular signal transduction. Using sphingolipidomic approach by LC-MS/MS,
we demonstrated that γTE, a vitamin E form abundant in palm oil, modulated
sphingolipid metabolism as an initial primary target and led to induction of apoptosis,
autophagy and death of cancer cells. Specifically, γTE induced accumulation of
intracellular dhCers and dhSph, which are important sphingolipid intermediates in the de
novo biosynthesis pathway and appear to mediate cell death, but decreased in total Cers
during the initial phase. In the study with 13C3, 15N-labeled L-serine for tracing newlysynthesized sphingolipids, γTE caused rapid increase of dhCers, but decreases of Cers,
suggesting that DEGS-catalyzed reaction is likely inhibited by γTE. Consistently, we
found the inhibition of DEGS activity by γTE, but not the expression. In addition, γTE
treatment caused increases of endogenous Cer levels with still lower levels of de novo
Cers during prolonged incubation, suggesting hydrolysis of SM via SMases activation by
γTE treatment. Blocking the γTE-induced increases of dhCers/dhSph or Cers from SM by
using myriocin (a specific inhibitor of the first enzyme in the de novo sphingolipid
pathway) or desipramine (an inhibitor of acid SMase), repectively, partially but
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significantly reversed the γTE-induced cancer cell death. Overall, our results indicate that
γTE modulated enzyme activities in sphingolipid metabolism, specifically by inhibition
of DEGS as an initial target and activation of SM hydrolysis, and this modulation of
sphingolipid plays an important role in γTE-induced cancer cell death.
We showed that γTE also modulated Cer levels, although the effects of γTE on
individual Cers were varied in cancer cells. For instance, γTE treatment led to significant
decrease in C16:0-Cer during the initial phase, but increase in the longer time treatment.
While γTE caused an increase in C18:0-Cer, it led to continuous decreases in C24:1- and
C24:0-Cers. Interestingly, emerging results suggest that endogenous Cers with different
fatty acyl-chain lengths appear to have distinct bioactivities. C18:0-Cer generated by
CerS1 has been found to induce apoptosis and lethal autophagy (Senkal et al., 2010;
Sentelle et al., 2012). However, the roles of C16:0-Cer and C24-Cers in the regulation of
cell death are still debatable. C16:0-Cer generated by CerS5/6 have been proposed to have
antiapoptotic roles (Senkal et al., 2010), but several other studies found that this Cer also
plays important roles in apoptotic cell death (Mullen et al., 2011; Schiffmann et al.,
2009b; White-Gilbertson et al., 2009). Therefore, further investigation should be
conducted to determine the role of individual Cer species and to characterize the effects
of γTE on individual CerSs and Cers.
Although our study provided a mechanistic explanation of anticancer activity of
γTE, the underlying mechanisms by which γTE modulates sphingolipid metabolism are
not completely understood. Since sphingolipid metabolism is a dynamic and complex
process, we need to consider many possible aspects that control this process. Specifically,
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it remains to be investigated regarding how γTE inhibits DEGS enzyme activity and
activates acid SMase. In addition, whether this mechanistic study can be translated in
preclinical models also warrants further investigation.

5.2

Anticancer Effects and Mechanisms of 13’-carboxychromanols, Long-chain
Metabolites of Vitamin E

Cancer is one of the leading causes of death worldwide. Natural forms of vitamin E
are potentially good chemoprevention agents as they are known to be safe and specific
forms of vitamin E have been shown to have cancer prevention effects. Among them, αT,
which is the predominant vitamin E form in tissues, is the most extensively studied in
relation to prevention of cancer. However, the human clinical studies as well as numerous
animal studies of αT in cancer prevention resulted in inconsistent and disappointing
outcomes. On the other hand, recent mechanistic and preclinical studies using preclinical
animal models have demonstrated that other forms of vitamin E appear to have different
and stronger biological properties for cancer prevention and therapy compared with αT.
Despite these exciting findings, the anticancer effects may not directly be rooted in nonαT form of vitamin E per se because most vitamin E forms are readily metabolized in
vivo. Recently, long-chain carboxychromanols are found at high levels in feces from mice
fed diet supplemented with γT or δT, and 13’-carboxychromanols (13’-COOHs) were
major fecal excreted carboxychromanols (Bardowell et al., 2012a; Bardowell et al.,
2012b; Jiang et al., 2007; Jiang et al., 2013). Interestingly, 13’-COOHs appear to have
superior anti-inflammatory properties over their vitamin E precursor by showing dual
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inhibitory effects toward COXs and LOX activities (Jiang et al., 2008; Jiang et al., 2011).
Since chronic inflammation has been recognized to be an important risk factor in cancer
development, 13’-COOHs could be potential cancer preventive agents due to their strong
anti-inflammatory properties. Birringer et al. recently found that 13’-COOHs
metabolized from αT or δT induced apoptosis in human liver cells, but the underlying
mechanism was not completely understood (Birringer et al., 2010).
We showed that 13’-COOHs derived from δT or δTE inhibited the growth and
induced apoptosis and autophagy in human colon, breast, and pancreatic cancer cells. In
these activities, 13’-COOHs were much stronger than natural forms of vitamin E. Using
LC-MS/MS method, we found that δT-13’-COOH increased intracellular dhSph and
dhCers but decreased C16:0-Cer within 2 h treatment. During longer treatment, δT-13’COOH enhanced all sphingoid bases including Cers while decreased SMs. Modulation of
sphingolipids by 13’-COOHs was observed prior to or coinciding with biochemical
manifestation of cell death including PARP cleavage and LC3-II increase. The
importance of sphingolipid modulation was supported by the observation that
pharmaceutically blocking the increase of these sphingolipids partially counteracted 13’COOH-induced cell death. Further mechanistic studies indicated that 13’-COOH
inhibited DEGS without affecting its protein expression and may activate SM hydrolysis
to enhance Cers. In agreement with these cell-based studies, δTE-13’-COOH
significantly decreased colon tumor multiplicity induced by AOM with two cycles of
1.5% DSS without any apparent toxicity even when the dietary supplementation was
started after AOM injection. Our study demonstrates that 13’-COOHs have potent
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anticancer effects by modulating enzyme activities in sphingolipid metabolism in cancer
cells.
Current study demonstrated that 13’-COOHs have potent anticancer effects in
various human cancer cells, even stronger than their unmetabolized vitamin E forms.
However, as 13’-COOHs are relatively newly found compounds, studies to investigate
the effects and mechanisms of 13’-COOHs are scarce. Therefore, many further studies
are needed to understand the properties of these compounds using cell culture studies,
animal models and human studies. First of all, although our study provides mechanistic
insight into 13’-COOHs-mediated anticancer effects, underlying mechanisms by which
13’-COOHs modulate enzyme activities in sphingolipid metabolism and exert anticancer
effects are not completely understood. Moreover, investigation and comparison of the
anticancer effects of other 13’-COOHs would be interesting. Second, in our AOM-DSS
colon cancer animal study, supplementation of δTE-13’-COOH significantly attenuated
DSS-caused colon inflammation and decreased the number of large-sized tumors. To
better understand the underlying mechanisms of the anticancer effects of 13’-COOHs, we
can analyze other cancer biomarkers such as β-catenin and Ki67 as a proliferation marker
as well as inflammatory markers such as PGE2 and LTB4 from plasma. Further
measurement of the levels of 13’-COOHs in plasma, feces, and other tissues also needed
to be conducted. In addition, further researches are needed to investigate bioavailability
of 13’-COOHs in animals and humans. Although we know that relative high levels of
13’-COOHs can be found in feces after vitamin E supplementation and we can speculate
that 13’-COOHs may exert their anticancer effects when they pass through the colon
tissue, the bioavailability information of these metabolites in other tissues is lacking.
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Therefore, future studies are needed to investigate their anticancer effects and underlying
mechanisms as well as bioavailability in other cancer tissues.

5.3

Phytochemicals as Chemopreventive Agents

Carcinogenesis is generally recognized as a multistep process including tumor
initiation, promotion and progression, and cancer cell growth is driven by multiple altered
signaling pathways to gain unlimited growth potential. Therefore, blocking only one
signaling transduction pathway might not be sufficient to suppress the growth of cancer
cells.
Dietary phytochemicals have been used for the prevention as well as treatment of
cancer for a long time due to their safety and general availability. Chemopreventive
phytochemicals can block or reverse the multistep carcinogenesis by targeting multiple
signaling pathways and proteins. Despite their beneficial properties against cancers, the
underlying mechanisms are not completely understood. Although many studies have
shown the multiple targets of chemopreventive phytochemicals, if we can find the initial
primary target of their anticancer effects, it would be more useful information to
understand their mechanism.
We demonstrate that various representative phytochemicals including curcumin,
resveratrol, EGCG, quercetin and sulforaphane show anticancer effects by modulation of
sphingolipid metabolism using LC-MS/MS technology. Specifically, while the effects of
individual compounds on different Cer species with distinct chain-length of fatty acylCoA were different, all the tested compounds increased the levels of dhCers compared
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with controls. Interestingly, these changes of sphingolipids by the tested phytochemicals
occurred quickly and took place prior to any signs of cell death. These data demonstrated
that modulation of sphingolipid metabolism might be a general mechanism for the
anticancer effects of various chemopreventive compounds against cancer, and inhibition
of DEGS enzyme might be the initial primary target of their anticancer actions.
Although several phytochemicals have been extensively studied and have
exhibited potent anticancer activities through alteration of various mechanisms, and our
study demonstrates the modulation of sphingolipid metabolism as an initial and primary
target for anticancer activity of them, there are still a number of key weaknesses and
further researches to be conducted. First weakness of the current researches of
phytochemicals is that most studies have been conducted in vitro and little is known
about the bioavailability of the compounds. Although numerous cell-culture studies have
evaluated and defined the anticancer effects and mechanisms of several phytochemicals,
most in vitro studies used supraphysiological concentrations, which might not be
achievable when the phytochemicals are administered as a diet. In addition,
phytochemicals generally show very low bioavailability as the small proportion of these
compounds is absorbed and it further has extensive metabolism before going to target
organs. Moreover, their bioavailability might become further lower as they are present as
glycosides or converted to other conjugated forms after absorption. Finally, although
many reports have suggested health benefits and molecular targets of dietary
phytochemicals in cell culture and animal models, the effects of phytochemicals in
humans will need to be assessed. In order to apply phytochemicals as cancer preventive
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agents in humans, further investigations of pharmacokinetics and bioavailability, and the
anticancer effects and mechanisms of the compounds should be conducted carefully.

5.4

Dietary Vitamin E in Colon Cancer Prevention

Colon cancer is one of the leading causes of cancer-related deaths in the US (Siegel
et al., 2015). Because advanced colon cancer is a devastating disease for patients,
intervening before the development of tumor can prevent cancer-associated deaths. Early
detection of dysplasia and prevention of colon cancer progression in high-risk population
as secondary prevention, which is the treatment for patients who already have developed
risk factors or disease, will be a key strategy to reduce its incidence. Given that chronic
inflammation has been directly associated with the malignant transformation and
development of colon cancer, patients with long-standing inflammatory bowel disease
(IBD), which can be divided into two major disorders such as ulcerative colitis and
Chrohn’s disease, have an increased risk of developing colon cancer and have been
known to be a high-risk population for colon cancer. Although IBD-associated colon
cancer accounts for only about 1~2% of all cases of colon cancer, patients with IBD are
six times more likely to develop colon cancer than the general population (Lennard-Jones
et al., 1983). Thus, secondary prevention must be considered in this population to prevent
the risk.
The ideal chemopreventive agent would be safe, inexpensive, and effective. In this
regard, natural forms of vitamin E are considered as potentially promising
chemopreventive agents. Recent studies by others and us have shown that vitamin E
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forms such as γT and γTE, and δT-13’-COOH, a long-chain metabolite of δT exert antiinflammatory activities (Jiang, 2014; Jiang et al., 2000; Wang and Jiang, 2013; Wang et
al., 2015). In addition, results from previous studies in our lab and this study have
demonstrated that supplementation of vitamin E forms (Jiang et al., 2013) or its longchain metabolite results in a significant reduction of carcinogen-induced colon tumor
incidence or the fecal scores in AOM-DSS colon cancer model and DSS colitis model in
mice, respectively, suggesting that vitamin E may play important roles in preventing
colon tumorigenesis.
Although the doses of vitamin E used in the current study had no adverse effects in
mice, more researches are needed to translate the dose of vitamin E and the timing to
begin vitamin E supplementation in animal studies into clinical trials in humans. Overall,
our data from the in vivo studies as well as in vitro studies support that dietary vitamin E
reduces the risk of colon tumorigenesis and may contribute to the establishment of
dietary recommendation for vitamin E to prevent colon cancer.
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